MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q |
x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to |
Delaware | 43-1878297 |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
800 North Lindbergh Blvd., | 63167 |
St. Louis, MO | (Zip Code) |
(Address of principal executive offices) |
Large accelerated filer | x | Accelerated filer | o | |
Non-accelerated filer | o (Do not check if a smaller reporting company) | Smaller reporting company | o | |
Emerging growth company | o |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q |
CAUTION REGARDING FORWARD-LOOKING STATEMENTS |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q |
TABLE OF CONTENTS |
Page | ||
Item 1. | ||
Item 2. | ||
Item 3. | ||
Item 4. | ||
Item 1. | ||
Item 1A. | ||
Item 2. | ||
Item 5. | ||
Item 6. | ||
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q |
PART I—FINANCIAL INFORMATION |
ITEM 1. | FINANCIAL STATEMENTS |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q |
Unaudited (Dollars in millions, except per share amounts) | Three Months Ended | Nine Months Ended | ||||||||||
May 31, 2017 | May 31, 2016 | May 31, 2017 | May 31, 2016 | |||||||||
Net Sales | $ | 4,230 | $ | 4,189 | $ | 11,954 | $ | 10,940 | ||||
Cost of goods sold | 1,844 | 1,809 | 5,357 | 5,061 | ||||||||
Gross Profit | 2,386 | 2,380 | 6,597 | 5,879 | ||||||||
Operating Expenses: | ||||||||||||
Selling, general and administrative expenses | 789 | 729 | 2,031 | 1,858 | ||||||||
Research and development expenses | 417 | 387 | 1,168 | 1,091 | ||||||||
Restructuring charges | (17 | ) | 15 | (30 | ) | 290 | ||||||
Pending Bayer transaction related costs | 33 | — | 153 | — | ||||||||
Total Operating Expenses | 1,222 | 1,131 | 3,322 | 3,239 | ||||||||
Income from Operations | 1,164 | 1,249 | 3,275 | 2,640 | ||||||||
Interest expense | 100 | 100 | 338 | 332 | ||||||||
Interest income | (17 | ) | (14 | ) | (53 | ) | (51 | ) | ||||
Other expense (income), net | 4 | (35 | ) | (41 | ) | 160 | ||||||
Income from Continuing Operations Before Income Taxes | 1,077 | 1,198 | 3,031 | 2,199 | ||||||||
Income tax provision | 230 | 483 | 796 | 696 | ||||||||
Income from Continuing Operations Including Portion Attributable to Noncontrolling Interest | $ | 847 | $ | 715 | $ | 2,235 | $ | 1,503 | ||||
Discontinued Operations: | ||||||||||||
Income from operations of discontinued business | — | — | 21 | 24 | ||||||||
Income tax provision | — | — | 8 | 9 | ||||||||
Income from Discontinued Operations | — | — | 13 | 15 | ||||||||
Net Income | $ | 847 | $ | 715 | $ | 2,248 | $ | 1,518 | ||||
Less: Net income (loss) attributable to noncontrolling interest | 4 | (2 | ) | 8 | (9 | ) | ||||||
Net Income Attributable to Monsanto Company | $ | 843 | $ | 717 | $ | 2,240 | $ | 1,527 | ||||
Amounts Attributable to Monsanto Company: | ||||||||||||
Income from continuing operations | $ | 843 | $ | 717 | $ | 2,227 | $ | 1,512 | ||||
Income from discontinued operations | — | — | 13 | 15 | ||||||||
Net Income Attributable to Monsanto Company | $ | 843 | $ | 717 | $ | 2,240 | $ | 1,527 | ||||
Basic Earnings per Share Attributable to Monsanto Company: | ||||||||||||
Income from continuing operations | $ | 1.92 | $ | 1.64 | $ | 5.08 | $ | 3.40 | ||||
Income from discontinued operations | — | — | 0.03 | 0.03 | ||||||||
Net Income Attributable to Monsanto Company | $ | 1.92 | $ | 1.64 | $ | 5.11 | $ | 3.43 | ||||
Diluted Earnings per Share Attributable to Monsanto Company: | ||||||||||||
Income from continuing operations | $ | 1.90 | $ | 1.63 | $ | 5.03 | $ | 3.37 | ||||
Income from discontinued operations | — | — | 0.03 | 0.03 | ||||||||
Net Income Attributable to Monsanto Company | $ | 1.90 | $ | 1.63 | $ | 5.06 | $ | 3.40 | ||||
Weighted Average Shares Outstanding: | ||||||||||||
Basic | 439.1 | 437.1 | 438.6 | 444.2 | ||||||||
Diluted | 443.4 | 440.3 | 443.0 | 448.2 | ||||||||
Dividends Declared per Share | $ | — | $ | — | $ | 1.08 | $ | 1.08 |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q |
Unaudited (Dollars in millions) | Three Months Ended | Nine Months Ended | ||||||||||
May 31, 2017 | May 31, 2016 | May 31, 2017 | May 31, 2016 | |||||||||
Comprehensive Income Attributable to Monsanto Company | ||||||||||||
Net Income Attributable to Monsanto Company | $ | 843 | $ | 717 | $ | 2,240 | $ | 1,527 | ||||
Other Comprehensive Income (Loss), Net of Tax: | ||||||||||||
Foreign currency translation, net of tax of $0, $3, $0 and $2, respectively | 83 | 139 | (15 | ) | (127 | ) | ||||||
Postretirement benefit plan activity, net of tax of $4, $3, $16 and $12, respectively | 9 | 8 | 32 | 24 | ||||||||
Unrealized net losses on investment holdings, net of tax of $0, $0, $(1) and $(1), respectively | — | — | (2 | ) | (2 | ) | ||||||
Realized net losses on investment holdings, net of tax of $0, $0, $1 and $0, respectively | — | — | 1 | — | ||||||||
Unrealized net derivative (losses) gains, net of tax of $(7), $18, $14 and $(3), respectively | (12 | ) | 30 | 26 | (1 | ) | ||||||
Realized net derivative losses, net of tax of $2, $13, $21 and $39, respectively | 2 | 15 | 31 | 48 | ||||||||
Total Other Comprehensive Income (Loss), Net of Tax | 82 | 192 | 73 | (58 | ) | |||||||
Comprehensive Income Attributable to Monsanto Company | $ | 925 | $ | 909 | $ | 2,313 | $ | 1,469 | ||||
Comprehensive Income (Loss) Attributable to Noncontrolling Interests | ||||||||||||
Net Income (Loss) Attributable to Noncontrolling Interests | 4 | (2 | ) | 8 | (9 | ) | ||||||
Other Comprehensive Income (Loss) | ||||||||||||
Foreign currency translation | 1 | 1 | 1 | (1 | ) | |||||||
Total Other Comprehensive Income (Loss) | 1 | 1 | 1 | (1 | ) | |||||||
Comprehensive Income (Loss) Attributable to Noncontrolling Interests | $ | 5 | $ | (1 | ) | $ | 9 | $ | (10 | ) | ||
Total Comprehensive Income | $ | 930 | $ | 908 | $ | 2,322 | $ | 1,459 |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q |
Unaudited (Dollars in millions, except share amounts) | As of | |||||
May 31, 2017 | Aug. 31, 2016 | |||||
Assets | ||||||
Current Assets: | ||||||
Cash and cash equivalents (variable interest entity restricted - 2017: $58 and 2016: $122) | $ | 1,614 | $ | 1,676 | ||
Short-term investments | 6 | 60 | ||||
Trade receivables, net (variable interest entity restricted - 2017: $56 and 2016: $7) | 3,913 | 1,926 | ||||
Miscellaneous receivables | 763 | 755 | ||||
Inventory, net | 3,189 | 3,241 | ||||
Assets held for sale | 302 | 272 | ||||
Other current assets | 231 | 227 | ||||
Total Current Assets | 10,018 | 8,157 | ||||
Total property, plant and equipment | 11,664 | 11,116 | ||||
Less accumulated depreciation | 6,164 | 5,885 | ||||
Property, Plant and Equipment, net | 5,500 | 5,231 | ||||
Goodwill | 4,032 | 4,020 | ||||
Other Intangible Assets, Net | 1,045 | 1,125 | ||||
Noncurrent Deferred Tax Assets | 534 | 613 | ||||
Long-Term Receivables, Net | 117 | 101 | ||||
Other Assets | 512 | 489 | ||||
Total Assets | $ | 21,758 | $ | 19,736 | ||
Liabilities and Shareowners’ Equity | ||||||
Current Liabilities: | ||||||
Short-term debt, including current portion of long-term debt (variable interest entity restricted - 2017: $0 and 2016: $113) | $ | 2,611 | $ | 1,587 | ||
Accounts payable | 753 | 1,006 | ||||
Income taxes payable | 243 | 41 | ||||
Accrued compensation and benefits | 366 | 239 | ||||
Accrued marketing programs | 1,455 | 1,650 | ||||
Deferred revenue | 545 | 568 | ||||
Grower production accruals | 68 | 47 | ||||
Dividends payable | — | 237 | ||||
Customer payable | 37 | 123 | ||||
Restructuring reserves | 67 | 227 | ||||
Miscellaneous short-term accruals | 813 | 1,004 | ||||
Total Current Liabilities | 6,958 | 6,729 | ||||
Long-Term Debt (variable interest entity restricted - 2017: $98 and 2016: $0) | 7,246 | 7,453 | ||||
Postretirement Liabilities | 316 | 371 | ||||
Long-Term Deferred Revenue | 24 | 35 | ||||
Noncurrent Deferred Tax Liabilities | 122 | 68 | ||||
Long-Term Portion of Environmental and Litigation Liabilities | 213 | 200 | ||||
Long-Term Restructuring Reserves | 10 | 17 | ||||
Other Liabilities | 321 | 318 | ||||
Shareowners’ Equity: | ||||||
Common stock (authorized: 1,500,000,000 shares, par value $0.01) | ||||||
Issued 612,881,253 and 611,435,047 shares, respectively | ||||||
Outstanding 439,240,373 and 437,795,024 shares, respectively | 6 | 6 | ||||
Treasury stock 173,640,880 and 173,640,023 shares, respectively, at cost | (15,053 | ) | (15,053 | ) | ||
Additional contributed capital | 11,787 | 11,626 | ||||
Retained earnings | 12,527 | 10,763 | ||||
Accumulated other comprehensive loss | (2,735 | ) | (2,808 | ) | ||
Total Monsanto Company Shareowners’ Equity | 6,532 | 4,534 | ||||
Noncontrolling Interest | 16 | 11 | ||||
Total Shareowners’ Equity | 6,548 | 4,545 | ||||
Total Liabilities and Shareowners’ Equity | $ | 21,758 | $ | 19,736 |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q |
Unaudited (Dollars in millions) | Nine Months Ended | |||||
May 31, 2017 | May 31, 2016 | |||||
Operating Activities: | ||||||
Net Income | $ | 2,248 | $ | 1,518 | ||
Adjustments to reconcile cash provided by operating activities: | ||||||
Items that did not require (provide) cash: | ||||||
Depreciation and amortization | 549 | 542 | ||||
Bad-debt expense | 61 | 81 | ||||
Stock-based compensation expense | 94 | 88 | ||||
Excess tax benefits from stock-based compensation | (6 | ) | (13 | ) | ||
Deferred income taxes | 83 | 168 | ||||
Restructuring impairments | 40 | 119 | ||||
Equity affiliate expense, net | 6 | 6 | ||||
Net gain on sale of a business or other assets | (88 | ) | (31 | ) | ||
Other items | 80 | 141 | ||||
Changes in assets and liabilities that (required) provided cash, net of acquisitions: | ||||||
Trade receivables, net | (2,062 | ) | (1,755 | ) | ||
Inventory, net | 14 | (6 | ) | |||
Deferred revenue | (35 | ) | 61 | |||
Accounts payable and other accrued liabilities | (129 | ) | (588 | ) | ||
Restructuring, net | (165 | ) | 90 | |||
Pension contributions | (31 | ) | (47 | ) | ||
Other items, net | 31 | 41 | ||||
Net Cash Provided by Operating Activities | 690 | 415 | ||||
Cash Flows Provided (Required) by Investing Activities: | ||||||
Maturities of short-term investments | 52 | 35 | ||||
Capital expenditures | (848 | ) | (666 | ) | ||
Acquisition of businesses, net of cash acquired | (11 | ) | (2 | ) | ||
Technology and other investments | (46 | ) | (43 | ) | ||
Other investments and property disposal proceeds | 101 | 37 | ||||
Net Cash Required by Investing Activities | (752 | ) | (639 | ) | ||
Cash Flows Provided (Required) by Financing Activities: | ||||||
Net change in financing with less than 90-day maturities | 514 | 1,942 | ||||
Short-term debt proceeds | 63 | 46 | ||||
Short-term debt reductions | (12 | ) | (252 | ) | ||
Long-term debt proceeds | 600 | 9 | ||||
Long-term debt reductions | (517 | ) | (305 | ) | ||
Debt issuance costs | (2 | ) | — | |||
Treasury stock purchases | — | (3,001 | ) | |||
Stock option exercises | 78 | 66 | ||||
Excess tax benefits from stock-based compensation | 6 | 13 | ||||
Tax withholding on restricted stock and restricted stock units | (18 | ) | (22 | ) | ||
Dividend payments | (712 | ) | (727 | ) | ||
Payments to noncontrolling interests | (4 | ) | (2 | ) | ||
Net Cash Required by Financing Activities | (4 | ) | (2,233 | ) | ||
Effect of Exchange Rate Changes on Cash and Cash Equivalents | 4 | (39 | ) | |||
Net Decrease in Cash and Cash Equivalents | (62 | ) | (2,496 | ) | ||
Cash and Cash Equivalents at Beginning of Period | 1,676 | 3,701 | ||||
Cash and Cash Equivalents at End of Period | $ | 1,614 | $ | 1,205 |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q |
Monsanto Shareowners | |||||||||||||||||||||
Unaudited (Dollars in millions, except per share data) | Common Stock | Treasury Stock | Additional Contributed Capital | Retained Earnings | Accumulated Other Comprehensive (Loss)(1) | Non-Controlling Interest | Total | ||||||||||||||
Balance as of Aug. 31, 2015 | $ | 6 | $ | (12,053 | ) | $ | 11,464 | $ | 10,374 | $ | (2,801 | ) | $ | 15 | $ | 7,005 | |||||
Net Income (Loss) | — | — | — | 1,336 | — | (23 | ) | 1,313 | |||||||||||||
Other Comprehensive Loss for 2016 | — | — | — | — | (7 | ) | (1 | ) | (8 | ) | |||||||||||
Treasury Stock Purchases | — | (3,000 | ) | (1 | ) | — | — | — | (3,001 | ) | |||||||||||
Restricted Stock and Restricted Stock Unit Tax Withholding | — | — | (24 | ) | — | — | — | (24 | ) | ||||||||||||
Issuance of Shares Under Employee Stock Plans | — | — | 81 | — | — | — | 81 | ||||||||||||||
Net Excess Tax Benefits from Stock-based Compensation | — | — | 11 | — | — | — | 11 | ||||||||||||||
Stock-based Compensation Expense | — | — | 111 | — | — | — | 111 | ||||||||||||||
Cash Dividends of $2.16 per Common Share | — | — | — | (947 | ) | — | — | (947 | ) | ||||||||||||
Acquisition of Noncontrolling Interest | — | — | (16 | ) | — | — | 26 | 10 | |||||||||||||
Payments to Noncontrolling Interest | — | — | — | — | — | (6 | ) | (6 | ) | ||||||||||||
Balance as of Aug. 31, 2016 | $ | 6 | $ | (15,053 | ) | $ | 11,626 | $ | 10,763 | $ | (2,808 | ) | $ | 11 | $ | 4,545 | |||||
Net Income | — | — | — | 2,240 | — | 8 | 2,248 | ||||||||||||||
Other Comprehensive Income for 2017 | — | — | — | — | 73 | 1 | 74 | ||||||||||||||
Stock Option Exercises | — | — | 78 | — | — | — | 78 | ||||||||||||||
Restricted Stock and Restricted Stock Unit Tax Withholding | — | — | (17 | ) | — | — | — | (17 | ) | ||||||||||||
Net Excess Tax Benefits from Stock-based Compensation | — | — | 6 | — | — | — | 6 | ||||||||||||||
Stock-based Compensation Expense | — | — | 94 | — | — | — | 94 | ||||||||||||||
Cash Dividends of $1.08 per Common Share | — | — | — | (476 | ) | — | — | (476 | ) | ||||||||||||
Payments to Noncontrolling Interest | — | — | — | — | — | (4 | ) | (4 | ) | ||||||||||||
Balance as of May 31, 2017 | $ | 6 | $ | (15,053 | ) | $ | 11,787 | $ | 12,527 | $ | (2,735 | ) | $ | 16 | $ | 6,548 |
(1) | See Note 15 — Accumulated Other Comprehensive Loss — for further details of the components of accumulated other comprehensive loss. |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q | |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED |
NOTE 1. | BACKGROUND AND BASIS OF PRESENTATION |
NOTE 2. | NEW ACCOUNTING STANDARDS |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q | |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued) |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q | |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued) |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q | |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued) |
NOTE 3. | RESTRUCTURING |
Three Months Ended | Nine Months Ended | |||||||||||
(Dollars in millions) | May 31, 2017 | May 31, 2016 | May 31, 2017 | May 31, 2016 | ||||||||
Cost of Goods Sold(1) | $ | (14 | ) | $ | (1 | ) | $ | (21 | ) | $ | (53 | ) |
Restructuring Charges(2) | 17 | (15 | ) | 30 | (290 | ) | ||||||
Income from Continuing Operations Before Income Taxes | $ | 3 | $ | (16 | ) | $ | 9 | $ | (343 | ) | ||
Income Tax Provision | (3 | ) | 7 | 2 | 118 | |||||||
Net Income | $ | — | $ | (9 | ) | $ | 11 | $ | (225 | ) |
(1) | For the three months ended May 31, 2017, and May 31, 2016, $14 million and $1 million of restructuring charges in cost of goods sold were recorded to the Seeds and Genomics segment, respectively. For the nine months ended May 31, 2017, $21 million of restructuring charges in cost of goods sold was split by segment as follows: $20 million in Seeds and Genomics and $1 million in Agricultural Productivity. For the nine months ended May 31, 2016, $53 million of restructuring charges in cost of goods sold was recorded to the Seeds and Genomics segment. |
(2) | For the three months ended May 31, 2017, the net reversal of previously recognized expense of $17 million was split by segment as follows: $15 million in Seeds and Genomics and $2 million in Agricultural Productivity. For the three months ended May 31, 2016, $15 million of restructuring charges was split by segment as follows: $13 million in Seeds and Genomics and $2 million in Agricultural Productivity. For the nine months ended May 31, 2017, the net reversal of previously recognized expense of $30 million was split by segment as follows: $27 million in Seeds and Genomics and $3 million in Agricultural Productivity. For the nine months ended May 31, 2016, $290 million of restructuring charges was split by segment as follows: $259 million in Seeds and Genomics and $31 million in Agricultural Productivity. |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q | |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued) |
Three months ended May 31, 2017 | Three months ended May 31, 2016 | |||||||||||||||||
(Dollars in millions) | Seeds and Genomics | Agricultural Productivity | Total | Seeds and Genomics | Agricultural Productivity | Total | ||||||||||||
Work Force Reductions | $ | (24 | ) | $ | (2 | ) | $ | (26 | ) | $ | (4 | ) | $ | — | $ | (4 | ) | |
Facility Closures/Exit Costs | 3 | — | 3 | 5 | — | 5 | ||||||||||||
Asset Impairments and Write-offs: | ||||||||||||||||||
Property, plant and equipment | 6 | — | 6 | 9 | 2 | 11 | ||||||||||||
Inventory | 10 | — | 10 | 1 | — | 1 | ||||||||||||
Goodwill and other assets | 4 | — | 4 | 3 | — | 3 | ||||||||||||
Total Restructuring Charges, Net | $ | (1 | ) | $ | (2 | ) | $ | (3 | ) | $ | 14 | $ | 2 | $ | 16 |
Nine months ended May 31, 2017 | Nine months ended May 31, 2016 | Cumulative Amount through May 31, 2017 | |||||||||||||||||||||||||
(Dollars in millions) | Seeds and Genomics | Agricultural Productivity | Total | Seeds and Genomics | Agricultural Productivity | Total | Seeds and Genomics | Agricultural Productivity | Total | ||||||||||||||||||
Work Force Reductions | $ | (58 | ) | $ | (4 | ) | $ | (62 | ) | $ | 204 | $ | 9 | $ | 213 | $ | 325 | $ | 19 | $ | 344 | ||||||
Facility Closures/Exit Costs | 13 | 1 | 14 | 11 | — | 11 | 36 | 6 | 42 | ||||||||||||||||||
Asset Impairments and Write-offs: | |||||||||||||||||||||||||||
Property, plant and equipment | 25 | 1 | 26 | 38 | 2 | 40 | 147 | 3 | 150 | ||||||||||||||||||
Inventory | 10 | — | 10 | 38 | — | 38 | 103 | — | 103 | ||||||||||||||||||
Goodwill and other assets | 3 | — | 3 | 21 | 20 | 41 | 189 | 20 | 209 | ||||||||||||||||||
Total Restructuring Charges, Net | $ | (7 | ) | $ | (2 | ) | $ | (9 | ) | $ | 312 | $ | 31 | $ | 343 | $ | 800 | $ | 48 | $ | 848 |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q | |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued) |
(Dollars in millions) | Work Force Reductions(1) | Facility Closures/Exit Costs(2) | Asset Impairments and Write-offs | Total | ||||||||
Balance as of Aug. 31, 2015 | $ | 217 | $ | — | $ | — | $ | 217 | ||||
Net restructuring charges recognized in fiscal year 2016 | 189 | 28 | 147 | 364 | ||||||||
Cash payments | (164 | ) | (28 | ) | — | (192 | ) | |||||
Asset impairments and write-offs | — | — | (147 | ) | (147 | ) | ||||||
Foreign currency impact | 2 | — | — | 2 | ||||||||
Balance as of Aug. 31, 2016 | $ | 244 | $ | — | $ | — | $ | 244 | ||||
Net restructuring charges recognized in first nine months of fiscal year 2017 | (62 | ) | 14 | 39 | (9 | ) | ||||||
Cash payments | (105 | ) | (11 | ) | — | (116 | ) | |||||
Asset impairments and write-offs | — | — | (39 | ) | (39 | ) | ||||||
Foreign currency impact | (2 | ) | — | — | (2 | ) | ||||||
Balance as of May 31, 2017 | $ | 75 | $ | 3 | $ | — | $ | 78 |
(1) | The restructuring liability balance included $10 million and $17 million that were recorded in long-term restructuring reserves in the Statements of Consolidated Financial Position as of May 31, 2017, and Aug. 31, 2016, respectively. |
NOTE 4. | CUSTOMER FINANCING PROGRAMS |
As of | ||||||
(Dollars in millions) | May 31, 2017 | Aug. 31, 2016 | ||||
Transactions that Qualify for Sales Treatment | ||||||
U.S. agreement to sell trade receivables(1) | ||||||
Outstanding balance | $ | 171 | $ | 511 | ||
Maximum future payout under recourse provisions | 9 | 19 | ||||
European and Latin American agreements to sell trade receivables(2) | ||||||
Outstanding balance | $ | 9 | $ | 60 | ||
Maximum future payout under recourse provisions | 3 | 35 | ||||
Agreements with Lenders(3) | ||||||
Outstanding balance | $ | 95 | $ | 73 | ||
Maximum future payout under the guarantee | 64 | 57 |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q | |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued) |
Gross Amounts of Receivables Sold | ||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||
(Dollars in millions) | May 31, 2017 | May 31, 2016 | May 31, 2017 | May 31, 2016 | ||||||||
Transactions that Qualify for Sales Treatment | ||||||||||||
U.S. agreement to sell trade receivables(1) | $ | 151 | $ | 151 | $ | 266 | $ | 167 | ||||
European and Latin American agreements to sell trade receivables(2) | 1 | 6 | 12 | 38 |
(1) | Monsanto has agreements in the United States to sell trade receivables, both with and without recourse, up to a maximum outstanding balance of $1.5 billion and to service such accounts. These receivables qualify for sales treatment under the Transfers and Servicing topic of the ASC and, accordingly, the proceeds are included in net cash provided by operating activities in the Statements of Consolidated Cash Flows. The liability for the guarantees for sales with recourse is recorded at an amount that approximates fair value, based upon the company’s historical collection experience and a current assessment of credit exposure. |
(2) | Monsanto has various agreements in European and Latin American countries to sell trade receivables, both with and without recourse. These receivables qualify for sales treatment under the Transfers and Servicing topic of the ASC and, accordingly, the proceeds are included in net cash provided by operating activities in the Statements of Consolidated Cash Flows. The liability for the guarantees for sales with recourse is recorded at an amount that approximates fair value, based upon the company’s historical collection experience and a current assessment of credit exposure. |
(3) | Monsanto has additional agreements with lenders to establish programs that provide financing for select customers in the United States, Latin America and Europe. Monsanto provides various levels of recourse through guarantees of the accounts in the event of customer default. The term of the guarantee is equivalent to the term of the customer loans. The liability for the guarantees is recorded at an amount that approximates fair value, based on the company’s historical collection experience with customers that participate in the program and a current assessment of credit exposure. If performance is required under the guarantee, Monsanto may retain amounts that are subsequently collected from customers. |
NOTE 5. | VARIABLE INTEREST ENTITIES AND INVESTMENTS |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q | |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued) |
As of | ||||||
(Dollars in millions) | May 31, 2017 | Aug. 31, 2016 | ||||
Equity Method Investments | $ | 146 | $ | 152 | ||
Cost Basis Investments | 100 | 94 | ||||
Total | $ | 246 | $ | 246 |
NOTE 6. | RECEIVABLES |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q | |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued) |
(Dollars in millions) | |||
Balance as of Aug. 31, 2015 | $ | 120 | |
Incremental Provision | 78 | ||
Recoveries | (2 | ) | |
Write-offs | (4 | ) | |
Other(1) | 36 | ||
Balance as of Aug. 31, 2016 | $ | 228 | |
Incremental Provision | 17 | ||
Recoveries | (31 | ) | |
Write-offs | (1 | ) | |
Other(1) | 21 | ||
Balance as of May 31, 2017 | $ | 234 |
NOTE 7. | INVENTORY |
As of | ||||||
(Dollars in millions) | May 31, 2017 | Aug. 31, 2016 | ||||
Finished Goods | $ | 1,564 | $ | 1,404 | ||
Goods In Process | 1,316 | 1,489 | ||||
Raw Materials and Supplies | 466 | 498 | ||||
Inventory at FIFO Cost | 3,346 | 3,391 | ||||
Excess of FIFO over LIFO Cost | (157 | ) | (150 | ) | ||
Total | $ | 3,189 | $ | 3,241 |
NOTE 8. | GOODWILL AND OTHER INTANGIBLE ASSETS |
(Dollars in millions) | Seeds and Genomics | Agricultural Productivity | Total | ||||||
Balance as of Aug. 31, 2016 | $ | 3,967 | $ | 53 | $ | 4,020 | |||
Effect of foreign currency translation and other adjustments | 14 | (2 | ) | 12 | |||||
Balance as of May 31, 2017 | $ | 3,981 | $ | 51 | $ | 4,032 |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q | |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued) |
As of May 31, 2017 | As of Aug. 31, 2016 | |||||||||||||||||
(Dollars in millions) | Carrying Amount | Accumulated Amortization | Net | Carrying Amount | Accumulated Amortization | Net | ||||||||||||
Acquired Germplasm | $ | 1,070 | $ | (801 | ) | $ | 269 | $ | 1,070 | $ | (778 | ) | $ | 292 | ||||
Acquired Intellectual Property | 1,073 | (654 | ) | 419 | 1,042 | (593 | ) | 449 | ||||||||||
Trademarks | 334 | (165 | ) | 169 | 334 | (152 | ) | 182 | ||||||||||
Customer Relationships | 286 | (220 | ) | 66 | 301 | (223 | ) | 78 | ||||||||||
Other | 68 | (38 | ) | 30 | 65 | (33 | ) | 32 | ||||||||||
Total Other Intangible Assets, Finite Lives | $ | 2,831 | $ | (1,878 | ) | $ | 953 | $ | 2,812 | $ | (1,779 | ) | $ | 1,033 | ||||
In Process Research & Development, Indefinite Lives | 92 | — | 92 | 92 | — | 92 | ||||||||||||
Total Other Intangible Assets | $ | 2,923 | $ | (1,878 | ) | $ | 1,045 | $ | 2,904 | $ | (1,779 | ) | $ | 1,125 |
(Dollars in millions) | Amount | ||
2017 | $ | 147 | |
2018 | 120 | ||
2019 | 111 | ||
2020 | 108 | ||
2021 | 106 |
NOTE 9. | INCOME TAXES |
NOTE 10. | DEBT AND OTHER CREDIT ARRANGEMENTS |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q | |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued) |
NOTE 11. | FAIR VALUE MEASUREMENTS |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q | |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued) |
Fair Value Measurements at May 31, 2017, Using | ||||||||||||
(Dollars in millions) | Level 1 | Level 2 | Level 3 | Net Balance | ||||||||
Assets at Fair Value: | ||||||||||||
Cash equivalents | $ | 1,243 | $ | — | $ | — | $ | 1,243 | ||||
Short-term investments | 6 | — | — | 6 | ||||||||
Equity securities | 10 | — | — | 10 | ||||||||
Derivative assets related to: | ||||||||||||
Foreign currency contracts | — | 23 | — | 23 | ||||||||
Commodity contracts | 27 | 4 | — | 31 | ||||||||
Total Assets at Fair Value | $ | 1,286 | $ | 27 | $ | — | $ | 1,313 | ||||
Liabilities at Fair Value: | ||||||||||||
Short-term debt instruments(1) | $ | — | $ | 2,621 | $ | — | $ | 2,621 | ||||
Long-term debt instruments(1) | — | 7,385 | 98 | 7,483 | ||||||||
Derivative liabilities related to: | ||||||||||||
Foreign currency contracts | — | 9 | — | 9 | ||||||||
Commodity contracts | 10 | 6 | — | 16 | ||||||||
Total Liabilities at Fair Value | $ | 10 | $ | 10,021 | $ | 98 | $ | 10,129 |
(1) | Debt instruments, excluding mandatorily redeemable shares, are not recorded at fair value on a recurring basis; however, they are measured at fair value for disclosure purposes, as required by the Fair Value Measurements and Disclosures topic of the ASC. |
Fair Value Measurements at Aug. 31, 2016, Using | ||||||||||||
(Dollars in millions) | Level 1 | Level 2 | Level 3 | Net Balance | ||||||||
Assets at Fair Value: | ||||||||||||
Cash equivalents | $ | 1,081 | $ | — | $ | — | $ | 1,081 | ||||
Short-term investments | 60 | — | — | 60 | ||||||||
Equity securities | 13 | — | — | 13 | ||||||||
Derivative assets related to: | ||||||||||||
Foreign currency contracts | — | 10 | — | 10 | ||||||||
Commodity contracts | 9 | 9 | — | 18 | ||||||||
Total Assets at Fair Value | $ | 1,163 | $ | 19 | $ | — | $ | 1,182 | ||||
Liabilities at Fair Value: | ||||||||||||
Short-term debt instruments(1) | $ | — | $ | 1,476 | $ | 113 | $ | 1,589 | ||||
Long-term debt instruments(1) | — | 7,834 | — | 7,834 | ||||||||
Derivative liabilities related to: | ||||||||||||
Foreign currency contracts | — | 15 | — | 15 | ||||||||
Commodity contracts | 32 | 20 | — | 52 | ||||||||
Interest rate contracts | — | 41 | — | 41 | ||||||||
Total Liabilities at Fair Value | $ | 32 | $ | 9,386 | $ | 113 | $ | 9,531 |
(1) | Debt instruments, excluding mandatorily redeemable shares, are not recorded at fair value on a recurring basis; however, they are measured at fair value for disclosure purposes, as required by the Fair Value Measurements and Disclosures topic of the ASC. |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q | |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued) |
(Dollars in millions) | |||
Balance Aug. 31, 2016 | $ | — | |
Issuance of mandatorily redeemable shares | 93 | ||
Accretion expense | 6 | ||
Payments | (5 | ) | |
Effect of foreign currency translation adjustments | 4 | ||
Balance May 31, 2017(1) | $ | 98 |
(1) | Includes 315,000 mandatorily redeemable shares outstanding with a par value of 1,000 Brazilian reais (approximately $308) as of May 31, 2017. |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q | |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued) |
(Dollars in millions) | |||
Balance Aug. 31, 2016(1) | $ | 113 | |
Redemption of mandatorily redeemable shares | (103 | ) | |
Accretion expense | 2 | ||
Payments | (7 | ) | |
Effect of foreign currency translation adjustments | (5 | ) | |
Balance May 31, 2017 | $ | — |
(1) | Includes 350,000 mandatorily redeemable shares outstanding with a par value of 1,000 Brazilian reais (approximately $309) as of Aug. 31, 2016. |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q | |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued) |
NOTE 12. | FINANCIAL INSTRUMENTS |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q | |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued) |
As of | ||||||
(Dollars in millions) | May 31, 2017 | Aug. 31, 2016 | ||||
Derivatives Designated as Hedges: | ||||||
Foreign exchange contracts | $ | 218 | $ | 388 | ||
Commodity contracts | 653 | 484 | ||||
Interest rate contracts | — | 150 | ||||
Total Derivatives Designated as Hedges | $ | 871 | $ | 1,022 | ||
Derivatives Not Designated as Hedges: | ||||||
Foreign exchange contracts | $ | 1,547 | $ | 1,096 | ||
Commodity contracts | 280 | 223 | ||||
Interest rate contracts | 21 | 116 | ||||
Total Derivatives Not Designated as Hedges | $ | 1,848 | $ | 1,435 |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q | |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued) |
As of May 31, 2017 | |||||||||||||||||||||||
(Dollars in millions) | Gross Amounts Recognized | Gross Amounts Offset in the Statement of Consolidated Financial Position | Net Amounts Included in the Statement of Consolidated Financial Position | Collateral Pledged | Net Amounts Reported in the Statement of Consolidated Financial Position | Other Items Included in the Statement of Consolidated Financial Position | Statement of Consolidated Financial Position Balance | ||||||||||||||||
Asset Derivatives: | |||||||||||||||||||||||
Other current assets | |||||||||||||||||||||||
Derivatives designated as hedges: | |||||||||||||||||||||||
Commodity contracts(1) | $ | 26 | $ | (9 | ) | $ | 17 | $ | — | $ | 17 | ||||||||||||
Foreign exchange contracts | 2 | — | 2 | — | 2 | ||||||||||||||||||
Derivatives not designated as hedges: | |||||||||||||||||||||||
Commodity contracts | 5 | — | 5 | — | 5 | ||||||||||||||||||
Foreign exchange contracts | 21 | — | 21 | — | 21 | ||||||||||||||||||
Total other current assets | 54 | (9 | ) | 45 | — | 45 | $ | 186 | $ | 231 | |||||||||||||
Other assets | |||||||||||||||||||||||
Derivatives designated as hedges: | |||||||||||||||||||||||
Commodity contracts(1) | — | (1 | ) | (1 | ) | 1 | — | ||||||||||||||||
Total other assets | — | (1 | ) | (1 | ) | 1 | — | 512 | 512 | ||||||||||||||
Total Asset Derivatives | $ | 54 | $ | (10 | ) | $ | 44 | $ | 1 | $ | 45 | ||||||||||||
Liability Derivatives: | |||||||||||||||||||||||
Other current assets | |||||||||||||||||||||||
Derivatives designated as hedges: | |||||||||||||||||||||||
Commodity contracts(1) | $ | 9 | $ | (9 | ) | $ | — | $ | — | $ | — | ||||||||||||
Total other current assets | 9 | (9 | ) | — | — | — | |||||||||||||||||
Other assets | |||||||||||||||||||||||
Derivatives designated as hedges: | |||||||||||||||||||||||
Commodity contracts(1) | 1 | (1 | ) | — | — | — | |||||||||||||||||
Total other assets | 1 | (1 | ) | — | — | — | |||||||||||||||||
Miscellaneous short-term accruals | |||||||||||||||||||||||
Derivatives designated as hedges: | |||||||||||||||||||||||
Commodity contracts | 5 | — | 5 | — | 5 | ||||||||||||||||||
Derivatives not designated as hedges: | |||||||||||||||||||||||
Commodity contracts | 1 | — | 1 | — | 1 | ||||||||||||||||||
Foreign exchange contracts | 9 | — | 9 | — | 9 | ||||||||||||||||||
Total miscellaneous short-term accruals | 15 | — | 15 | — | 15 | $ | 798 | $ | 813 | ||||||||||||||
Total Liability Derivatives | $ | 25 | $ | (10 | ) | $ | 15 | $ | — | $ | 15 |
(1) | As allowed by the Derivatives and Hedging topic of the ASC, derivative assets and liabilities have been offset by collateral subject to an enforceable master netting arrangement or similar arrangement. Therefore, contracts that are in an asset or liability position are included in asset accounts within the Statements of Consolidated Financial Position. |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q | |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued) |
As of Aug. 31, 2016 | |||||||||||||||||||||||
(Dollars in millions) | Gross Amounts Recognized | Gross Amounts Offset in the Statement of Consolidated Financial Position | Net Amounts Included in the Statement of Consolidated Financial Position | Collateral Pledged | Net Amounts Reported in the Statement of Consolidated Financial Position | Other Items Included in the Statement of Consolidated Financial Position | Statement of Consolidated Financial Position Balance | ||||||||||||||||
Asset Derivatives: | |||||||||||||||||||||||
Other current assets | |||||||||||||||||||||||
Derivatives designated as hedges: | |||||||||||||||||||||||
Commodity contracts(1) | $ | 9 | $ | (29 | ) | $ | (20 | ) | $ | 20 | $ | — | |||||||||||
Foreign exchange contracts | 4 | — | 4 | — | 4 | ||||||||||||||||||
Derivatives not designated as hedges: | |||||||||||||||||||||||
Commodity contracts(1) | 9 | (6 | ) | 3 | — | 3 | |||||||||||||||||
Foreign exchange contracts | 6 | — | 6 | — | 6 | ||||||||||||||||||
Total other current assets | 28 | (35 | ) | (7 | ) | 20 | 13 | $ | 214 | $ | 227 | ||||||||||||
Other assets | |||||||||||||||||||||||
Derivatives designated as hedges | |||||||||||||||||||||||
Commodity contracts(1) | — | (4 | ) | (4 | ) | 4 | — | ||||||||||||||||
Total other assets | — | (4 | ) | (4 | ) | 4 | — | 489 | 489 | ||||||||||||||
Total Asset Derivatives | $ | 28 | $ | (39 | ) | $ | (11 | ) | $ | 24 | $ | 13 | |||||||||||
Liability Derivatives: | |||||||||||||||||||||||
Other current assets | |||||||||||||||||||||||
Derivatives designated as hedges: | |||||||||||||||||||||||
Commodity contracts(1) | $ | 29 | $ | (29 | ) | $ | — | $ | — | $ | — | ||||||||||||
Derivatives not designated as hedges: | |||||||||||||||||||||||
Commodity contracts(1) | 6 | (6 | ) | — | — | — | |||||||||||||||||
Total other current assets | 35 | (35 | ) | — | — | — | |||||||||||||||||
Other assets | |||||||||||||||||||||||
Derivatives designated as hedges: | |||||||||||||||||||||||
Commodity contracts(1) | 4 | (4 | ) | — | — | — | |||||||||||||||||
Total other assets | 4 | (4 | ) | — | — | — | |||||||||||||||||
Miscellaneous short-term accruals | |||||||||||||||||||||||
Derivatives designated as hedges: | |||||||||||||||||||||||
Commodity contracts | 11 | — | 11 | — | 11 | ||||||||||||||||||
Foreign currency contracts | 8 | — | 8 | — | 8 | ||||||||||||||||||
Interest rate contracts | 41 | — | 41 | — | 41 | ||||||||||||||||||
Derivatives not designated as hedges: | |||||||||||||||||||||||
Foreign exchange contracts | 7 | — | 7 | — | 7 | ||||||||||||||||||
Total miscellaneous short-term accruals | 67 | — | 67 | — | 67 | $ | 937 | $ | 1,004 | ||||||||||||||
Other liabilities | |||||||||||||||||||||||
Derivatives designated as hedges: | |||||||||||||||||||||||
Commodity contracts | 2 | — | 2 | — | 2 | ||||||||||||||||||
Total other liabilities | 2 | — | 2 | — | 2 | 316 | 318 | ||||||||||||||||
Total Liability Derivatives | $ | 108 | $ | (39 | ) | $ | 69 | $ | — | $ | 69 |
(1) | As allowed by the Derivatives and Hedging topic of the ASC, commodity derivative assets and liabilities have been offset by collateral subject to an enforceable master netting arrangement or similar arrangement. Therefore, these commodity contracts that are in an asset or liability position are included in asset accounts within the Statements of Consolidated Financial Position. |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q | |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued) |
Amount of Gain (Loss) Recognized in AOCL(1) (Effective Portion) | Amount of Gain (Loss) Recognized in Income(2)(3) | ||||||||||||
Three Months Ended | Three Months Ended | Statements of Consolidated Operations Classification | |||||||||||
(Dollars in millions) | May 31, 2017 | May 31, 2016 | May 31, 2017 | May 31, 2016 | |||||||||
Derivatives Designated as Hedges: | |||||||||||||
Fair value hedges: | |||||||||||||
Commodity contracts | $ | 28 | $ | (20 | ) | Cost of goods sold | |||||||
Commodity contract | — | (1 | ) | Other expense (income), net | |||||||||
Cash flow hedges: | |||||||||||||
Foreign currency contracts | $ | — | $ | (9 | ) | (2 | ) | 3 | Net sales | ||||
Foreign currency contracts | (2 | ) | (1 | ) | 3 | 6 | Cost of goods sold | ||||||
Commodity contracts | (17 | ) | 57 | (2 | ) | (34 | ) | Cost of goods sold | |||||
Interest rate contracts | — | 1 | (3 | ) | (3 | ) | Interest expense | ||||||
Total Derivatives Designated as Hedges | (19 | ) | 48 | 24 | (49 | ) | |||||||
Derivatives Not Designated as Hedges: | |||||||||||||
Foreign currency contracts(4) | 20 | (8 | ) | Other expense (income), net | |||||||||
Commodity contracts | 1 | 7 | Net sales | ||||||||||
Commodity contracts | 1 | — | Cost of goods sold | ||||||||||
Total Derivatives Not Designated as Hedges | 22 | (1 | ) | ||||||||||
Total Derivatives | $ | (19 | ) | $ | 48 | $ | 46 | $ | (50 | ) |
(1) | Accumulated other comprehensive loss (AOCL) |
(2) | For derivatives designated as cash flow hedges under the Derivatives and Hedging topic of the ASC, this represents the effective portion of the gain (loss) reclassified from AOCL into income during the period. |
(3) | The gain or loss on derivatives designated as hedges from ineffectiveness is not significant during the three months ended May 31, 2017, and May 31, 2016. No gains or losses were excluded from the assessment of hedge effectiveness during the three months ended May 31, 2017, and May 31, 2016. |
(4) | Gain or loss on foreign currency contracts not designated as hedges was offset by a foreign currency transaction loss of $31 million and a gain of $19 million during the three months ended May 31, 2017, and May 31, 2016, respectively. |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q | |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued) |
Amount of Gain (Loss) Recognized in AOCL(1) (Effective Portion) | Amount of Gain (Loss) Recognized in Income(2)(3) | ||||||||||||
Nine Months Ended | Nine Months Ended | Statements of Consolidated Operations Classification | |||||||||||
(Dollars in millions) | May 31, 2017 | May 31, 2016 | May 31, 2017 | May 31, 2016 | |||||||||
Derivatives Designated as Hedges: | |||||||||||||
Fair value hedges: | |||||||||||||
Commodity contracts | $ | 18 | $ | (19 | ) | Cost of goods sold | |||||||
Commodity contracts | — | (1 | ) | Other expense (income), net | |||||||||
Cash flow hedges: | |||||||||||||
Foreign currency contracts | $ | 20 | $ | (4 | ) | 8 | 11 | Net sales | |||||
Foreign currency contracts | 5 | 3 | 5 | 19 | Cost of goods sold | ||||||||
Commodity contracts | 12 | 20 | (17 | ) | (106 | ) | Cost of goods sold | ||||||
Interest rate contracts | — | — | (37 | ) | — | Other expense (income), net | |||||||
Interest rate contracts | 3 | (23 | ) | (11 | ) | (11 | ) | Interest expense | |||||
Total Derivatives Designated as Hedges | 40 | (4 | ) | (34 | ) | (107 | ) | ||||||
Derivatives Not Designated as Hedges: | |||||||||||||
Foreign currency contracts(4) | 1 | (32 | ) | Other expense (income), net | |||||||||
Commodity contracts | 1 | 8 | Net sales | ||||||||||
Commodity contracts | — | 1 | Cost of goods sold | ||||||||||
Total Derivatives Not Designated as Hedges | 2 | (23 | ) | ||||||||||
Total Derivatives | $ | 40 | $ | (4 | ) | $ | (32 | ) | $ | (130 | ) |
(1) | Accumulated other comprehensive loss (AOCL) |
(2) | For derivatives designated as cash flow hedges under the Derivatives and Hedging topic of the ASC, this represents the effective portion of the gain (loss) reclassified from AOCL into income during the period. |
(3) | The gain or loss on derivatives designated as hedges from ineffectiveness is not significant during the nine months ended May 31, 2017, and May 31, 2016. No gains or losses were excluded from the assessment of hedge effectiveness during the nine months ended May 31, 2017, and May 31, 2016. |
(4) | Gain or loss on foreign currency contracts not designated as hedges was offset by a foreign currency transaction loss of $13 million and $169 million during the nine months ended May 31, 2017, and May 31, 2016, respectively. |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q | |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued) |
NOTE 13. | POSTRETIREMENT BENEFITS — PENSIONS, HEALTH CARE AND OTHER |
Pension Benefits | Three Months Ended May 31, 2017 | Three Months Ended May 31, 2016 | ||||||||||||||||
(Dollars in millions) | U.S. | Outside the U.S. | Total | U.S. | Outside the U.S. | Total | ||||||||||||
Service Cost for Benefits Earned During the Period | $ | 16 | $ | 3 | $ | 19 | $ | 19 | $ | 3 | $ | 22 | ||||||
Interest Cost on Benefit Obligation | 20 | 1 | 21 | 28 | 2 | 30 | ||||||||||||
Assumed Return on Plan Assets | (43 | ) | (2 | ) | (45 | ) | (46 | ) | (2 | ) | (48 | ) | ||||||
Amortization of Unrecognized Net Loss | 12 | 1 | 13 | 13 | 1 | 14 | ||||||||||||
Curtailment and Settlement Charges | — | 1 | 1 | — | — | — | ||||||||||||
Total Net Periodic Benefit Cost | $ | 5 | $ | 4 | $ | 9 | $ | 14 | $ | 4 | $ | 18 |
Pension Benefits | Nine Months Ended May 31, 2017 | Nine Months Ended May 31, 2016 | ||||||||||||||||
(Dollars in millions) | U.S. | Outside the U.S. | Total | U.S. | Outside the U.S. | Total | ||||||||||||
Service Cost for Benefits Earned During the Period | $ | 46 | $ | 9 | $ | 55 | $ | 51 | $ | 9 | $ | 60 | ||||||
Interest Cost on Benefit Obligation | 61 | 4 | 65 | 77 | 5 | 82 | ||||||||||||
Assumed Return on Plan Assets | (128 | ) | (6 | ) | (134 | ) | (125 | ) | (6 | ) | (131 | ) | ||||||
Amortization of Unrecognized Net Loss | 35 | 3 | 38 | 39 | 3 | 42 | ||||||||||||
Restructuring Charges | — | 2 | 2 | — | 1 | 1 | ||||||||||||
Curtailment and Settlement Charges | — | 1 | 1 | — | — | — | ||||||||||||
Total Net Periodic Benefit Cost | $ | 14 | $ | 13 | $ | 27 | $ | 42 | $ | 12 | $ | 54 |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q | |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued) |
Health Care and Other Postretirement Benefits | Three Months Ended | |||||
(Dollars in millions) | May 31, 2017 | May 31, 2016 | ||||
Service Cost for Benefits Earned During the Period | $ | 3 | $ | 2 | ||
Interest Cost on Benefit Obligation | 1 | 1 | ||||
Amortization of Unrecognized Net Loss/(Gain) | 1 | (1 | ) | |||
Total Net Periodic Benefit Cost | $ | 5 | $ | 2 |
Health Care and Other Postretirement Benefits | Nine Months Ended | |||||
(Dollars in millions) | May 31, 2017 | May 31, 2016 | ||||
Service Cost for Benefits Earned During the Period | $ | 5 | $ | 5 | ||
Interest Cost on Benefit Obligation | 4 | 5 | ||||
Amortization of Unrecognized Net Loss/(Gain) | 4 | (4 | ) | |||
Restructuring Charges | 2 | — | ||||
Total Net Periodic Benefit Cost | $ | 15 | $ | 6 |
NOTE 14. | STOCK-BASED COMPENSATION PLANS |
Three Months Ended | ||||||
(Dollars in millions) | May 31, 2017 | May 31, 2016 | ||||
Cost of Goods Sold | $ | 3 | $ | 4 | ||
Selling, General and Administrative Expenses | 19 | 11 | ||||
Research and Development Expenses | 6 | 6 | ||||
Restructuring Charges | — | 2 | ||||
Pre-Tax Stock-Based Compensation Expense | 28 | 23 | ||||
Income Tax Benefit | (9 | ) | (7 | ) | ||
Net Stock-Based Compensation Expense | $ | 19 | $ | 16 |
Nine Months Ended | ||||||
(Dollars in millions) | May 31, 2017 | May 31, 2016 | ||||
Cost of Goods Sold | $ | 10 | $ | 11 | ||
Selling, General and Administrative Expenses | 64 | 57 | ||||
Research and Development Expenses | 19 | 22 | ||||
Restructuring Charges | 1 | 2 | ||||
Pre-Tax Stock-Based Compensation Expense | 94 | 92 | ||||
Income Tax Benefit | (32 | ) | (30 | ) | ||
Net Stock-Based Compensation Expense | $ | 62 | $ | 62 |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q | |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued) |
NOTE 15. | ACCUMULATED OTHER COMPREHENSIVE LOSS |
(Dollars in millions) | Foreign Currency Translation Adjustments | Postretirement Benefit Items | Net Unrealized Gain (Loss) on Available-for-Sale Securities | Cash Flow Hedges | Total Accumulated Other Comprehensive (Loss) Income | ||||||||||
Balance as of Aug. 31, 2015 | $ | (2,327 | ) | $ | (286 | ) | $ | 2 | $ | (190 | ) | $ | (2,801 | ) | |
Other comprehensive income (loss) before reclassifications | 35 | (83 | ) | (2 | ) | (42 | ) | (92 | ) | ||||||
Amounts reclassified from accumulated other comprehensive loss | — | 29 | 1 | 55 | 85 | ||||||||||
Net current-period other comprehensive income (loss) | 35 | (54 | ) | (1 | ) | 13 | (7 | ) | |||||||
Balance as of Aug. 31, 2016 | $ | (2,292 | ) | $ | (340 | ) | $ | 1 | $ | (177 | ) | $ | (2,808 | ) | |
Other comprehensive (loss) income before reclassifications | (15 | ) | — | (2 | ) | 26 | 9 | ||||||||
Amounts reclassified from accumulated other comprehensive loss | — | 32 | 1 | 31 | 64 | ||||||||||
Net current-period other comprehensive (loss) income | (15 | ) | 32 | (1 | ) | 57 | 73 | ||||||||
Balance as of May 31, 2017 | $ | (2,307 | ) | $ | (308 | ) | $ | — | $ | (120 | ) | $ | (2,735 | ) |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q | |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued) |
Three Months Ended | Nine Months Ended | ||||||||||||
(Dollars in millions) | May 31, 2017 | May 31, 2016 | May 31, 2017 | May 31, 2016 | Affected Line Item in the Statements of Consolidated Operations | ||||||||
Available for Sale Securities: | |||||||||||||
Loss on Equity Security | $ | — | $ | — | $ | 2 | $ | — | Other expense (income), net | ||||
— | — | 2 | — | Total before income taxes | |||||||||
— | — | (1 | ) | — | Income tax provision | ||||||||
$ | — | $ | — | $ | 1 | $ | — | Net of tax | |||||
Cash Flow Hedges: | |||||||||||||
Foreign Exchange Contracts | $ | 2 | $ | (3 | ) | $ | (8 | ) | $ | (11 | ) | Net sales | |
Foreign Exchange Contracts | (3 | ) | (6 | ) | (5 | ) | (19 | ) | Cost of goods sold | ||||
Commodity Contracts | 2 | 34 | 17 | 106 | Cost of goods sold | ||||||||
Interest Rate Contracts | — | — | 37 | — | Other expense (income), net | ||||||||
Interest Rate Contracts | 3 | 3 | 11 | 11 | Interest expense | ||||||||
4 | 28 | 52 | 87 | Total before income taxes | |||||||||
(2 | ) | (13 | ) | (21 | ) | (39 | ) | Income tax provision | |||||
$ | 2 | $ | 15 | $ | 31 | $ | 48 | Net of tax | |||||
Postretirement Benefit Items: | |||||||||||||
Amortization of Unrecognized Net Loss | $ | 5 | $ | 4 | $ | 15 | $ | 12 | Inventory/Cost of goods sold(1) | ||||
Amortization of Unrecognized Net Loss | 9 | 7 | 29 | 24 | Selling, general and administrative expenses | ||||||||
Amortization of Unrecognized Net Loss | — | — | 4 | — | Restructuring charges | ||||||||
14 | 11 | 48 | 36 | Total before income taxes | |||||||||
(5 | ) | (3 | ) | (16 | ) | (12 | ) | Income tax provision | |||||
$ | 9 | $ | 8 | $ | 32 | $ | 24 | Net of tax | |||||
Total Reclassifications For The Period | $ | 11 | $ | 23 | $ | 64 | $ | 72 | Net of tax |
(1) | The amortization of unrecognized net loss is recorded to net periodic benefit cost, which is allocated to selling, general and administrative expenses and to inventory, which is recognized through cost of goods sold. The company recorded $5 million and $4 million of net periodic benefit cost to inventory, of which approximately $3 million and $2 million was recognized in cost of goods sold during the three months ended May 31, 2017, and May 31, 2016, respectively. The company recorded $15 million and $12 million of net periodic benefit cost to inventory, of which approximately $14 million and $12 million was recognized in cost of goods sold during the nine months ended May 31, 2017, and May 31, 2016, respectively. See Note 13 — Postretirement Benefits - Pensions, Health Care and Other — for additional information. |
NOTE 16. | EARNINGS PER SHARE |
Three Months Ended | Nine Months Ended | |||||||
(Shares in millions) | May 31, 2017 | May 31, 2016 | May 31, 2017 | May 31, 2016 | ||||
Weighted-Average Number of Common Shares | 439.1 | 437.1 | 438.6 | 444.2 | ||||
Dilutive Potential Common Shares | 4.3 | 3.2 | 4.4 | 4.0 | ||||
Antidilutive Potential Common Shares | 0.3 | 5.3 | 2.1 | 4.9 | ||||
Shares Excluded From Computation of Dilutive Potential Shares with Exercise Prices Greater than the Average Market Price of Common Shares for the Period | 0.3 | 3.2 | 1.7 | 3.2 |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q | |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued) |
NOTE 17. | SUPPLEMENTAL CASH FLOW INFORMATION |
Nine Months Ended | ||||||
(Dollars in millions) | May 31, 2017 | May 31, 2016 | ||||
Interest | $ | 287 | $ | 256 | ||
Taxes | 475 | 704 |
• | During the nine months ended May 31, 2017, and May 31, 2016, the company recognized noncash transactions related to restructuring. See Note 3 — Restructuring. |
• | As of May 31, 2017, and May 31, 2016, the company recognized noncash capital expenditures of $136 million and $84 million, respectively, in accounts payable in the Statements of Consolidated Financial Position. |
• | During the nine months ended May 31, 2017, and May 31, 2016, the company recognized noncash transactions related to stock-based compensation. See Note 14 — Stock-Based Compensation Plans. |
NOTE 18. | COMMITMENTS AND CONTINGENCIES |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q | |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued) |
NOTE 19. | SEGMENT INFORMATION |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q | |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued) |
Three Months Ended | Nine Months Ended | |||||||||||
(Dollars in millions) | May 31, 2017 | May 31, 2016 | May 31, 2017 | May 31, 2016 | ||||||||
Net Sales(1) | ||||||||||||
Corn seed and traits | $ | 1,491 | $ | 1,592 | $ | 5,342 | $ | 5,024 | ||||
Soybean seed and traits | 896 | 693 | 2,358 | 1,913 | ||||||||
Cotton seed and traits | 338 | 285 | 562 | 370 | ||||||||
Vegetable seeds | 199 | 196 | 523 | 526 | ||||||||
All other crops seeds and traits | 208 | 441 | 381 | 590 | ||||||||
Total Seeds and Genomics | $ | 3,132 | $ | 3,207 | $ | 9,166 | $ | 8,423 | ||||
Agricultural productivity | 1,098 | 982 | $ | 2,788 | $ | 2,517 | ||||||
Total Agricultural Productivity | $ | 1,098 | $ | 982 | $ | 2,788 | $ | 2,517 | ||||
Total | $ | 4,230 | $ | 4,189 | $ | 11,954 | $ | 10,940 |
Gross Profit | ||||||||||||
Corn seed and traits | $ | 922 | $ | 976 | $ | 3,389 | $ | 3,063 | ||||
Soybean seed and traits | 588 | 391 | 1,667 | 1,220 | ||||||||
Cotton seed and traits | 268 | 205 | 418 | 248 | ||||||||
Vegetable seeds | 99 | 108 | 267 | 244 | ||||||||
All other crops seeds and traits | 138 | 369 | 191 | 430 | ||||||||
Total Seeds and Genomics | $ | 2,015 | $ | 2,049 | $ | 5,932 | $ | 5,205 | ||||
Agricultural productivity | 371 | 331 | $ | 665 | $ | 674 | ||||||
Total Agricultural Productivity | $ | 371 | $ | 331 | $ | 665 | $ | 674 | ||||
Total | $ | 2,386 | $ | 2,380 | $ | 6,597 | $ | 5,879 |
EBIT(2)(3)(4) | ||||||||||||
Seeds and Genomics | $ | 995 | $ | 1,094 | $ | 3,033 | $ | 2,258 | ||||
Agricultural Productivity | 160 | 187 | 292 | 253 | ||||||||
Total | $ | 1,155 | $ | 1,281 | $ | 3,325 | $ | 2,511 |
Depreciation and Amortization Expense | ||||||||||||
Seeds and Genomics | $ | 137 | $ | 144 | $ | 422 | $ | 444 | ||||
Agricultural Productivity | 40 | 34 | 127 | 98 | ||||||||
Total | $ | 177 | $ | 178 | $ | 549 | $ | 542 |
(1) | Represents net sales from continuing operations. |
(2) | EBIT is defined as earnings (loss) before interest and taxes; see the following table for reconciliation. Earnings (loss) is intended to mean net income (loss) attributable to Monsanto Company as presented in the Statements of Consolidated Operations under U.S. GAAP. EBIT is an operating performance measure for the two reportable segments. |
(3) | Agricultural Productivity EBIT includes income from operations of discontinued businesses of $21 million and $24 million for the nine months ended May 31, 2017, and May 31, 2016, respectively. |
(4) | Seeds and Genomics EBIT includes losses from operations of noncontrolling interests of $5 million and $11 million for the three and nine months ended May 31, 2017. Seeds and Genomics EBIT includes a loss from operations of noncontrolling interests of $2 million for the three months ended May 31, 2016, and income from operations of noncontrolling interests of $10 million for the nine months ended May 31, 2016. For the three and nine months ended May 31, 2017, and May 31, 2016, Agricultural Productivity EBIT includes losses from operations of noncontrolling interests of $1 million, respectively. |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q | |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued) |
Three Months Ended | Nine Months Ended | |||||||||||
(Dollars in millions) | May 31, 2017 | May 31, 2016 | May 31, 2017 | May 31, 2016 | ||||||||
EBIT(1) | $ | 1,155 | $ | 1,281 | $ | 3,325 | $ | 2,511 | ||||
Interest Expense — Net | 83 | 86 | 285 | 281 | ||||||||
Income Tax Provision(2) | 229 | 478 | 800 | 703 | ||||||||
Net Income Attributable to Monsanto Company | $ | 843 | $ | 717 | $ | 2,240 | $ | 1,527 |
(1) | Includes the income from operations of discontinued businesses and the (loss) income from operations of noncontrolling interests. |
(2) | Includes the income tax provision on discontinued operations and the income tax (benefit) expense of noncontrolling interest. |
NOTE 20. | SUBSEQUENT EVENT |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q |
ITEM 2. | MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
OVERVIEW |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q |
RESULTS OF OPERATIONS |
Three Months Ended | Nine Months Ended | |||||||||||||||
(Dollars in millions, except per share amounts) | May 31, 2017 | May 31, 2016 | Increase/ (Decrease) | May 31, 2017 | May 31, 2016 | Increase/ (Decrease) | ||||||||||
Net Sales | $ | 4,230 | $ | 4,189 | 1 | % | $ | 11,954 | $ | 10,940 | 9 | % | ||||
Cost of goods sold | 1,844 | 1,809 | 2 | % | 5,357 | 5,061 | 6 | % | ||||||||
Gross Profit | 2,386 | 2,380 | — | % | 6,597 | 5,879 | 12 | % | ||||||||
Operating Expenses: | ||||||||||||||||
Selling, general and administrative expenses | 789 | 729 | 8 | % | 2,031 | 1,858 | 9 | % | ||||||||
Research and development expenses | 417 | 387 | 8 | % | 1,168 | 1,091 | 7 | % | ||||||||
Restructuring charges | (17 | ) | 15 | NM | (30 | ) | 290 | NM | ||||||||
Pending Bayer transaction related costs | 33 | — | NM | 153 | — | NM | ||||||||||
Total Operating Expenses | 1,222 | 1,131 | 8 | % | 3,322 | 3,239 | 3 | % | ||||||||
Income from Operations | 1,164 | 1,249 | (7 | )% | 3,275 | 2,640 | 24 | % | ||||||||
Interest expense | 100 | 100 | — | % | 338 | 332 | 2 | % | ||||||||
Interest income | (17 | ) | (14 | ) | 21 | % | (53 | ) | (51 | ) | 4 | % | ||||
Other expense (income), net | 4 | (35 | ) | NM | (41 | ) | 160 | NM | ||||||||
Income from Continuing Operations Before Income Taxes | 1,077 | 1,198 | (10 | )% | 3,031 | 2,199 | 38 | % | ||||||||
Income tax provision | 230 | 483 | (52 | )% | 796 | 696 | 14 | % | ||||||||
Income from Continuing Operations Including Portion Attributable to Noncontrolling Interest | 847 | 715 | 18 | % | 2,235 | 1,503 | 49 | % | ||||||||
Discontinued Operations: | ||||||||||||||||
Income from operations of discontinued business | — | — | — | % | 21 | 24 | (13 | )% | ||||||||
Income tax provision | — | — | — | % | 8 | 9 | (11 | )% | ||||||||
Income from Discontinued Operations | — | — | — | % | 13 | 15 | (13 | )% | ||||||||
Net Income | $ | 847 | $ | 715 | 18 | % | $ | 2,248 | $ | 1,518 | 48 | % | ||||
Less: Net income (loss) attributable to noncontrolling interest | 4 | (2 | ) | NM | 8 | (9 | ) | NM | ||||||||
Net Income Attributable to Monsanto Company | $ | 843 | $ | 717 | 18 | % | $ | 2,240 | $ | 1,527 | 47 | % | ||||
Diluted Earnings per Share Attributable to Monsanto Company: | ||||||||||||||||
Income from continuing operations | $ | 1.90 | $ | 1.63 | 17 | % | $ | 5.03 | $ | 3.37 | 49 | % | ||||
Income from discontinued operations | — | — | — | % | 0.03 | 0.03 | — | % | ||||||||
Net Income Attributable to Monsanto Company | $ | 1.90 | $ | 1.63 | 17 | % | $ | 5.06 | $ | 3.40 | 49 | % | ||||
NM = Not Meaningful | ||||||||||||||||
Effective Tax Rate | 21 | % | 40 | % | 26 | % | 32 | % | ||||||||
Comparison as a Percent of Net Sales: | ||||||||||||||||
Cost of goods sold | 44 | % | 43 | % | 45 | % | 46 | % | ||||||||
Gross profit | 56 | % | 57 | % | 55 | % | 54 | % | ||||||||
Selling, general and administrative expenses | 19 | % | 17 | % | 17 | % | 17 | % | ||||||||
Research and development expenses | 10 | % | 9 | % | 10 | % | 10 | % | ||||||||
Total operating expenses | 29 | % | 27 | % | 28 | % | 30 | % | ||||||||
Income from continuing operations before income taxes | 25 | % | 29 | % | 25 | % | 20 | % | ||||||||
Net income attributable to Monsanto Company | 20 | % | 17 | % | 19 | % | 14 | % |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q |
Third Quarter 2017 Percentage Change in Net Sales vs. Third Quarter 2016 | ||||
Volume | Price | Currency | Total | |
Seeds and Genomics Segment | (4)% | 3% | (1)% | (2)% |
Agricultural Productivity Segment | 8% | 4% | —% | 12% |
Total Monsanto Company | (1)% | 3% | (1)% | 1% |
Third Quarter 2017 Percentage Change in Cost of Goods Sold vs. Third Quarter 2016 | ||||
Volume | Costs(1) | Currency | Total | |
Seeds and Genomics Segment | 5% | (7)% | (2)% | (4)% |
Agricultural Productivity Segment | 10% | 1% | 1% | 12% |
Total Monsanto Company | 7% | (4)% | (1)% | 2% |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q |
First Nine Months 2017 Percentage Change in Net Sales vs. First Nine Months 2016 | ||||
Volume | Price | Currency | Total | |
Seeds and Genomics Segment | 3% | 5% | 1% | 9% |
Agricultural Productivity Segment | 16% | (7)% | 2% | 11% |
Total Monsanto Company | 6% | 2% | 1% | 9% |
First Nine Months 2017 Percentage Change in Cost of Goods Sold vs. First Nine Months 2016 | ||||
Volume | Costs(1) | Currency | Total | |
Seeds and Genomics Segment | 7% | (7)% | 1% | 1% |
Agricultural Productivity Segment | 17% | (4)% | 2% | 15% |
Total Monsanto Company | 11% | (6)% | 1% | 6% |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q |
SEEDS AND GENOMICS SEGMENT |
Three Months Ended | Nine Months Ended | |||||||||||||||
(Dollars in millions) | May 31, 2017 | May 31, 2016 | Increase/ (Decrease) | May 31, 2017 | May 31, 2016 | Increase/ (Decrease) | ||||||||||
Net Sales | ||||||||||||||||
Corn seed and traits | $ | 1,491 | $ | 1,592 | (6 | )% | $ | 5,342 | $ | 5,024 | 6 | % | ||||
Soybean seed and traits | 896 | 693 | 29 | % | 2,358 | 1,913 | 23 | % | ||||||||
Cotton seed and traits | 338 | 285 | 19 | % | 562 | 370 | 52 | % | ||||||||
Vegetable seeds | 199 | 196 | 2 | % | 523 | 526 | (1 | )% | ||||||||
All other crops seeds and traits | 208 | 441 | (53 | )% | 381 | 590 | (35 | )% | ||||||||
Total Net Sales | $ | 3,132 | $ | 3,207 | (2 | )% | $ | 9,166 | $ | 8,423 | 9 | % | ||||
Gross Profit | ||||||||||||||||
Corn seed and traits | $ | 922 | $ | 976 | (6 | )% | $ | 3,389 | $ | 3,063 | 11 | % | ||||
Soybean seed and traits | 588 | 391 | 50 | % | 1,667 | 1,220 | 37 | % | ||||||||
Cotton seed and traits | 268 | 205 | 31 | % | 418 | 248 | 69 | % | ||||||||
Vegetable seeds | 99 | 108 | (8 | )% | 267 | 244 | 9 | % | ||||||||
All other crops seeds and traits | 138 | 369 | (63 | )% | 191 | 430 | (56 | )% | ||||||||
Total Gross Profit | $ | 2,015 | $ | 2,049 | (2 | )% | $ | 5,932 | $ | 5,205 | 14 | % | ||||
EBIT(1) | $ | 995 | $ | 1,094 | (9 | )% | $ | 3,033 | $ | 2,258 | 34 | % |
(1) | EBIT is defined as earnings (loss) before interest and taxes. Interest and taxes are recorded on a total company basis. We do not record these items at the segment level. See Item 1 — Financial Statements —Note 19 — Segment Information and the “Overview — Non-GAAP Financial Measures” section of MD&A for further details. |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q |
AGRICULTURAL PRODUCTIVITY SEGMENT |
Three Months Ended | Nine Months Ended | |||||||||||||||
(Dollars in millions) | May 31, 2017 | May 31, 2016 | Increase/(Decrease) | May 31, 2017 | May 31, 2016 | Increase/ (Decrease) | ||||||||||
Net Sales | ||||||||||||||||
Agricultural productivity | $ | 1,098 | $ | 982 | 12 | % | $ | 2,788 | $ | 2,517 | 11 | % | ||||
Total Net Sales | $ | 1,098 | $ | 982 | 12 | % | $ | 2,788 | $ | 2,517 | 11 | % | ||||
Gross Profit | ||||||||||||||||
Agricultural productivity | $ | 371 | $ | 331 | 12 | % | $ | 665 | $ | 674 | (1 | )% | ||||
Total Gross Profit | $ | 371 | $ | 331 | 12 | % | $ | 665 | $ | 674 | (1 | )% | ||||
EBIT(1) | $ | 160 | $ | 187 | (14 | )% | $ | 292 | $ | 253 | 15 | % |
(1) | EBIT is defined as earnings (loss) before interest and taxes. Interest and taxes are recorded on a total company basis. We do not record these items at the segment level. See Item 1 — Financial Statements — Note 19 — Segment Information — and the “Overview — Non-GAAP Financial Measures” section of MD&A for further details. |
RESTRUCTURING |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q |
FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES |
Working Capital and Financial Condition | |||||||||
As of | |||||||||
(Dollars in millions, except current ratio) | May 31, 2017 | May 31, 2016 | Aug. 31, 2016 | ||||||
Cash and Cash Equivalents(1) | $ | 1,614 | $ | 1,205 | $ | 1,676 | |||
Trade Receivables, Net(1) | 3,913 | 3,168 | 1,926 | ||||||
Inventory, Net | 3,189 | 3,370 | 3,241 | ||||||
Other Current Assets(2) | 1,302 | 1,312 | 1,314 | ||||||
Total Current Assets | $ | 10,018 | $ | 9,055 | $ | 8,157 | |||
Short-Term Debt, Including Current Portion of Long-Term Debt(1) | $ | 2,611 | $ | 2,557 | $ | 1,587 | |||
Accounts Payable | 753 | 620 | 1,006 | ||||||
Accrued Liabilities(1)(3) | 3,594 | 3,003 | 4,136 | ||||||
Total Current Liabilities | $ | 6,958 | $ | 6,180 | $ | 6,729 | |||
Working Capital(4) | $ | 3,060 | $ | 2,875 | $ | 1,428 | |||
Current Ratio(4) | 1.44:1 | 1.47:1 | 1.21:1 |
(1) | May include restrictions as a result of variable interest entities. See the Statements of Consolidated Financial Position and Item 1 — Financial Statements — Note 5 — Variable Interest Entities and Investments — for more information. |
(2) | Includes short-term investments, miscellaneous receivables, assets held for sale and other current assets. |
(3) | Includes income taxes payable, accrued compensation and benefits, accrued marketing programs, deferred revenues, grower production accruals, dividends payable, customer payable, restructuring reserves and miscellaneous short-term accruals. |
(4) | Working capital is total current assets less total current liabilities; current ratio represents total current assets divided by total current liabilities. |
• | Trade receivables, net increased $1,987 million between the respective periods primarily due to the seasonality of our business and timing of collections. |
• | Accounts payable decreased $253 million between the respective periods primarily due to timing of payments. |
• | Accrued liabilities decreased $542 million between the respective periods primarily due to the following fluctuations: |
◦ | Accrued marketing programs decreased $195 million between the respective periods primarily due to fiscal 2017 payments made on fiscal 2016 programs, partially offset by increased accruals in the United States and higher Brazil accruals due to higher Intacta RR2 PRO soybean revenues. |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q |
◦ | Dividends payable decreased $237 million due to the timing of dividend declaration and payments. |
◦ | Customer payable decreased $86 million due to North American customer refunds paid in the first nine months of fiscal 2017. |
◦ | Restructuring reserves decreased $160 million as a result of payments made under the 2015 Restructuring Plan and changes in estimates related to work force reductions. |
◦ | Miscellaneous short-term accruals decreased $191 million primarily due to a payment related to the PCB settlement of $280 million as described in Item 1 — Financial Statements — Note 18 — Commitments and Contingencies, partially offset by increased interest accruals. |
◦ | Income taxes payable increased $202 million primarily due the seasonality of our U.S. business and the timing of tax payments. |
◦ | Accrued compensation and benefits increased $127 million primarily due to increased current year incentive accruals. |
• | Cash and cash equivalents decreased $62 million between the respective periods primarily due to cash from operating and investing activities coupled with debt proceeds, offset by capital expenditures, payments of dividends and repayment of debt. |
• | Inventory decreased $52 million between the respective periods primarily due to decreased Agricultural Productivity inventory, specifically Roundup inventory, resulting from higher sales. |
• | Short term debt, including the current portion of long-term debt, increased $1,024 million between the respective periods primarily due to increased commercial paper borrowings of $712 million, proceeds received from the delayed draw term loan facility of $500 million and the reclassification of Senior Notes from long-term to short-term of approximately $300 million. These increases were partially offset by the repayment of Senior Notes and mandatorily redeemable shares of the Brazil VIE totaling approximately $513 million. |
• | Cash and cash equivalents increased $409 million between the respective periods primarily due to cash from operating and investing activities coupled with debt proceeds. These increases were partially offset by repayment of debt and dividend payments. |
• | Trade receivables, net increased $745 million between the respective periods primarily due to increased revenues globally. |
• | Inventory decreased $181 million between the respective periods primarily due to reductions in seed and genomics and agricultural productivity production plans coupled with increased sales in the current year, partially offset by build up of dicamba-based herbicide inventory. |
• | Short-term debt, including the current portion of long-term debt, increased $54 million between the respective periods primarily due to proceeds received from the delayed draw term loan facility of $500 million and the reclassification of Senior Notes from long-term to short-term of approximately $300 million, offset by decreased commercial paper borrowings of $714 million. |
• | Accounts payable increased $133 million between the respective periods primarily due to timing of payments. |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q |
• | Accrued liabilities increased $591 million between the respective periods primarily due to the following: |
◦ | Accrued compensation and benefits increased $164 million primarily due to increased current year incentive accruals. |
◦ | Accrued marketing programs increased $362 million primarily due to increased revenues in the United States and higher Brazil accruals due to higher Intacta RR2 PRO soybean revenues. |
Nine Months Ended | ||||||
(Dollars in millions) | May 31, 2017 | May 31, 2016 | ||||
Net Cash Provided by Operating Activities | $ | 690 | $ | 415 | ||
Net Cash Required by Investing Activities | (752 | ) | (639 | ) | ||
Net Cash Required by Financing Activities | (4 | ) | (2,233 | ) | ||
Effect of Exchange Rate Changes on Cash and Cash Equivalents | 4 | (39 | ) | |||
Net Decrease in Cash and Cash Equivalents | (62 | ) | (2,496 | ) |
Nine Months Ended | ||||||
(Dollars in millions) | May 31, 2017 | May 31, 2016 | ||||
Net Cash Provided by Operating Activities | $ | 690 | $ | 415 | ||
Capital Expenditures | (848 | ) | (666 | ) | ||
Free Cash Flow(1) | (158 | ) | (251 | ) |
(1) | Free cash flow represents the total of net cash provided or required by operating activities less capital expenditures (see the “Overview - Non-GAAP Financial Measures” section of MD&A for a further discussion). |
• | Increased net income compared to prior year, and |
• | An increase in taxes payable, an increase in employee incentives and an increase in market funding offset by cash payments related to the PCB settlement described in Item 1 — Financial Statements — Note 18 — Commitments and Contingencies. |
• | An increase in trade receivables, net resulting primarily from increased revenues, |
• | A decrease in deferred revenue due to timing and recognition of prepayments, and |
• | A decrease in the restructuring reserves due to timing of expense recognition related to workforce reductions and changes in related estimates resulting from the 2015 Restructuring Plan. |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q |
As of | As of | ||||||||
(Dollars in millions, except debt-to-capital ratio) | May 31, 2017 | May 31, 2016 | Aug. 31, 2016 | ||||||
Short-Term Debt | $ | 2,611 | $ | 2,557 | $ | 1,587 | |||
Long-Term Debt | 7,246 | 7,948 | 7,453 | ||||||
Total Monsanto Company Shareowners’ Equity | 6,532 | 5,110 | 4,534 | ||||||
Debt-to-Capital Ratio(1) | 60 | % | 67 | % | 67 | % |
(1) | Debt-to-Capital ratio represents short-term and long-term debt divided by total Monsanto Company shareowners’ equity, short-term and long-term debt. |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q |
Quarter Ending | Declaration Date | Dividend | Payment Date | To Shareowners of Record as of: |
Aug. 31, 2017 | Jun. 6, 2017 | 54 cents | Jul. 28, 2017 | Jul. 7, 2017 |
Feb. 29, 2017 | Jan. 27, 2017 | 54 cents | Apr. 28, 2017 | Apr. 7, 2017 |
Feb. 29, 2017 | Dec. 5, 2016 | 54 cents | Jan. 27, 2017 | Jan. 6, 2017 |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q |
OUTLOOK |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q |
CRITICAL ACCOUNTING POLICIES AND ESTIMATES |
ITEM 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q |
ITEM 4. | CONTROLS AND PROCEDURES |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q |
PART II—OTHER INFORMATION |
ITEM 1. | LEGAL PROCEEDINGS |
ITEM 1A. | RISK FACTORS |
ITEM 2. | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS |
Period | (a) Total Number of Shares Purchased | (b) Average Price Paid per Share(1) | (c) Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | (d) Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs | |||||||||
March 2017: | |||||||||||||
Mar. 1, 2017, through Mar. 31, 2017 | 30 | (2) | $ | 113.20 | — | $ | — | ||||||
April 2017: | |||||||||||||
Apr. 1, 2017, through Apr. 30, 2017 | 30 | (2) | $ | 116.60 | — | $ | — | ||||||
May 2017: | |||||||||||||
May 1, 2017, through May 31, 2017 | 617 | (2) | $ | 116.81 | — | $ | — | ||||||
Total | 677 | $ | 116.64 | — | $ | — |
(1) | The average price paid per share is calculated on a trade date basis and excludes commission. |
(2) | Shares withheld for taxes on restricted stock. |
ITEM 5. | OTHER INFORMATION |
ITEM 6. | EXHIBITS |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q |
SIGNATURE |
MONSANTO COMPANY | |
(Registrant) | |
By: | /s/ NICOLE M. RINGENBERG |
Nicole M. Ringenberg | |
Vice President and Controller | |
(On behalf of the Registrant and as Principal Accounting Officer) |
MONSANTO COMPANY | THIRD QUARTER 2017 FORM 10-Q |
EXHIBIT INDEX |
Exhibit No. | Description |
2 | Omitted |
3 | Omitted |
4 | Omitted |
11 | Omitted — see Note 16 of Notes to Consolidated Financial Statements — Earnings Per Share. |
12 | Computation of Ratio of Earnings to Fixed Charges. |
15 | Omitted |
18 | Omitted |
19 | Omitted |
22 | Omitted |
23 | Omitted |
24 | Omitted |
31.1 | Rule 13a-14(a) Certifications (pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, executed by the Chief Executive Officer). |
31.2 | Rule 13a-14(a) Certifications (pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, executed by the Chief Financial Officer). |
32 | Rule 13a-14(b) Certifications (pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, executed by the Chief Executive Officer and the Chief Financial Officer). |
101.INS | XBRL Instance Document. |
101.SCH | XBRL Taxonomy Extension Schema Document. |
101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document. |
101.DEF | XBRL Taxonomy Extension Definition Linkbase Document. |
101.LAB | XBRL Taxonomy Extension Label Linkbase Document. |
101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document. |
Nine Months Ended May 31, | Year Ended Aug. 31, | |||||||||||||||||||||
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||||||||||||||||
EARNINGS: | ||||||||||||||||||||||
Income from Continuing Operations Before Income Taxes | $ | 3,031 | $ | 1,991 | $ | 3,161 | $ | 3,827 | $ | 3,429 | $ | 2,988 | ||||||||||
Add: | ||||||||||||||||||||||
Fixed charges | 405 | 515 | 509 | 327 | 246 | 257 | ||||||||||||||||
Equity affiliate loss (income) - net | 5 | 12 | 13 | 8 | (15 | ) | (10 | ) | ||||||||||||||
Amortization of capitalized interest | 15 | 20 | 18 | 17 | 16 | 15 | ||||||||||||||||
Less: | ||||||||||||||||||||||
Capitalized interest | (32 | ) | (32 | ) | (26 | ) | (28 | ) | (23 | ) | (21 | ) | ||||||||||
Earnings available for fixed charges | $ | 3,424 | $ | 2,506 | $ | 3,675 | $ | 4,151 | $ | 3,653 | $ | 3,229 | ||||||||||
FIXED CHARGES: | ||||||||||||||||||||||
Interest expense(3) | $ | 338 | $ | 437 | $ | 434 | $ | 250 | $ | 176 | $ | 191 | ||||||||||
Capitalized interest | 32 | 32 | 26 | 28 | 23 | 21 | ||||||||||||||||
Portion of rents representative of interest factor | 35 | 46 | 49 | 49 | 47 | 45 | ||||||||||||||||
Total fixed charges | $ | 405 | $ | 515 | $ | 509 | $ | 327 | $ | 246 | $ | 257 | ||||||||||
Ratio of Earnings to Fixed Charges | 8.45 | 4.87 | 7.22 | 12.69 | 14.85 | 12.56 |
(1) | Monsanto has not paid any preference security dividends and, therefore, has not included the ratio of combined fixed charges and preference security dividends to earnings for the relevant periods. |
(2) | The operating results of the Dairy business have been conformed to discontinued operations presentation for all relevant fiscal years presented. |
(3) | Includes amortization of deferred debt issuance costs and the interest component of the income tax provision. |
1. | I have reviewed this report on Form 10-Q of Monsanto Company; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c) | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d) | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
5. | The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
/s/ Hugh Grant |
Hugh Grant |
Chairman and Chief Executive Officer |
1. | I have reviewed this report on Form 10-Q of Monsanto Company; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c) | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d) | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
5. | The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
/s/ Pierre Courduroux |
Pierre Courduroux |
Senior Vice President and Chief Financial Officer |
(1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
/s/ Hugh Grant |
Hugh Grant |
Chairman and Chief Executive Officer |
/s/ Pierre Courduroux |
Pierre Courduroux |
Senior Vice President and Chief Financial Officer |
Document and Entity Information - shares |
9 Months Ended | |
---|---|---|
May 31, 2017 |
Jun. 26, 2017 |
|
Document and Entity Information [Abstract] | ||
Document type | 10-Q | |
Document period end date | May 31, 2017 | |
Amendment flag | false | |
Document Fiscal Year Focus | 2017 | |
Document Fiscal Period Focus | Q3 | |
Entity Registrant Name | MONSANTO CO /NEW/ | |
Entity Central Index Key | 0001110783 | |
Current Fiscal Year End Date | --08-31 | |
Entity Filer Category | Large Accelerated Filer | |
Entity common stock shares outstanding | 439,323,033 |
Statements of Consolidated Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
May 31, 2017 |
May 31, 2016 |
May 31, 2017 |
May 31, 2016 |
|
Statement of Comprehensive Income [Abstract] | ||||
Net Income | $ 847 | $ 715 | $ 2,248 | $ 1,518 |
Comprehensive Income Attributable to Monsanto Company | ||||
Net Income Attributable to Monsanto Company | 843 | 717 | 2,240 | 1,527 |
Other Comprehensive Income (Loss), Net of Tax: | ||||
Foreign currency translation, net of tax of $0, $3, $0 and $2, respectively | 83 | 139 | (15) | (127) |
Postretirement benefit plan activity, net of tax of $4, $3, $16 and $12, respectively | 9 | 8 | 32 | 24 |
Unrealized net losses on investment holdings, net of tax of $0, $0, $(1) and $(1), respectively | 0 | 0 | (2) | (2) |
Realized net losses on investment holdings, net of tax of $0, $0, $1 and $0, respectively | 0 | 0 | 1 | 0 |
Unrealized net derivative (losses) gains, net of tax of $(7), $18, $14 and $(3), respectively | (12) | 30 | 26 | (1) |
Realized net derivative losses, net of tax of $2, $13, $21 and $39, respectively | 2 | 15 | 31 | 48 |
Total Other Comprehensive Income (Loss), Net of Tax | 82 | 192 | 73 | (58) |
Comprehensive Income Attributable to Monsanto Company | 925 | 909 | 2,313 | 1,469 |
Comprehensive Income (Loss) Attributable to Noncontrolling Interests | ||||
Net loss attributable to noncontrolling interest | 4 | (2) | 8 | (9) |
Other Comprehensive Income (Loss) | ||||
Foreign currency translation | 1 | 1 | 1 | (1) |
Total Other Comprehensive Income (Loss) | 1 | 1 | 1 | (1) |
Comprehensive Income (Loss) Attributable to Noncontrolling Interests | 5 | (1) | 9 | (10) |
Total Comprehensive Income | $ 930 | $ 908 | $ 2,322 | $ 1,459 |
Statements of Consolidated Comprehensive Income (Loss) (Unaudited) (Parenthetical) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
May 31, 2017 |
May 31, 2016 |
May 31, 2017 |
May 31, 2016 |
|
Other Comprehensive Income (Loss), Tax, Parenthetical Disclosures [Abstract] | ||||
Foreign currency translation, tax expense (benefit) | $ 0 | $ 3 | $ 0 | $ 2 |
Postretirement benefit plan activity, tax benefit | 4 | 3 | 16 | 12 |
Unrealized net gains on investment holdings, tax (expense) benefit | 0 | 0 | (1) | (1) |
Realized net gains on investment holdings, tax (expense) benefit | 0 | 0 | 1 | 0 |
Unrealized net derivative gains (losses), tax (expense) benefit | (7) | 18 | 14 | (3) |
Realized net derivative (gains) losses, tax (expense) benefit | $ 2 | $ 13 | $ 21 | $ 39 |
Statements of Consolidated Financial Position (Unaudited) - USD ($) $ in Millions |
May 31, 2017 |
Aug. 31, 2016 |
---|---|---|
Current Assets: | ||
Cash and cash equivalents (variable interest entity restricted - 2017: $58 and 2016: $122) | $ 1,614 | $ 1,676 |
Short-term investments | 6 | 60 |
Trade receivables, net (variable interest entity restricted - 2017: $56 and 2016: $7) | 3,913 | 1,926 |
Miscellaneous receivables | 763 | 755 |
Inventory, net | 3,189 | 3,241 |
Assets held for sale | 302 | 272 |
Other current assets | 231 | 227 |
Total Current Assets | 10,018 | 8,157 |
Total property, plant and equipment | 11,664 | 11,116 |
Less accumulated depreciation | 6,164 | 5,885 |
Property, Plant and Equipment, net | 5,500 | 5,231 |
Goodwill | 4,032 | 4,020 |
Other Intangible Assets, Net | 1,045 | 1,125 |
Noncurrent Deferred Tax Assets | 534 | 613 |
Long-Term Receivables, Net | 117 | 101 |
Other Assets | 512 | 489 |
Total Assets | 21,758 | 19,736 |
Current Liabilities: | ||
Short-term debt, including current portion of long-term debt (variable interest entity restricted - 2017: $0 and 2016: $113) | 2,611 | 1,587 |
Accounts payable | 753 | 1,006 |
Income taxes payable | 243 | 41 |
Accrued compensation and benefits | 366 | 239 |
Accrued marketing programs | 1,455 | 1,650 |
Deferred revenue | 545 | 568 |
Grower production accruals | 68 | 47 |
Dividends payable | 0 | 237 |
Customer payable | 37 | 123 |
Restructuring reserves | 67 | 227 |
Miscellaneous short-term accruals | 813 | 1,004 |
Total Current Liabilities | 6,958 | 6,729 |
Long-Term Debt (variable interest entity restricted - 2017: $98 and 2016: $0) | 7,246 | 7,453 |
Postretirement Liabilities | 316 | 371 |
Long-Term Deferred Revenue | 24 | 35 |
Noncurrent Deferred Tax Liabilities | 122 | 68 |
Long-Term Portion of Environmental and Litigation Liabilities | 213 | 200 |
Long-Term Restructuring Reserves | 10 | 17 |
Other Liabilities | 321 | 318 |
Shareowners’ Equity: | ||
Common stock (authorized: 1,500,000,000 shares, par value $0.01) Issued 609,152,562 and 606,457,369 shares, respectively; Outstanding 468,579,556 and 485,261,017 shares, respectively | 6 | 6 |
Treasury stock 173,640,880 and 173,640,023 shares, respectively, at cost | (15,053) | (15,053) |
Additional contributed capital | 11,787 | 11,626 |
Retained earnings | 12,527 | 10,763 |
Accumulated other comprehensive loss | (2,735) | (2,808) |
Total Monsanto Company Shareowners’ Equity | 6,532 | 4,534 |
Noncontrolling Interest | 16 | 11 |
Total Shareowners’ Equity | 6,548 | 4,545 |
Total Liabilities and Shareowners’ Equity | $ 21,758 | $ 19,736 |
Statements of Consolidated Financial Position (Parenthetical) (Unaudited) - USD ($) $ in Millions |
May 31, 2017 |
Aug. 31, 2016 |
---|---|---|
Current Assets: | ||
Cash and cash equivalents (variable interest entity restricted) | $ 58 | $ 122 |
Trade receivables, net (variable interest entity restricted) | 56 | 7 |
Short Term Debt Restricted To Consolidated Variable Interest Entities | 0 | 113 |
Long Term Debt Restricted To Consolidated Variable Interest Entities | 98 | 0 |
Variable Interest Entity Carrying Amount Of Other Current Assets | 0 | 0 |
Variable Interest Entity Carrying Amount Of Property, Plant and Equipment | $ 0 | $ 0 |
Shareowners’ Equity: | ||
Common Stock, Authorized | 1,500,000,000 | 1,500,000,000 |
Common Stock, Par Value | $ 0.01 | $ 0.01 |
Common Stock, Issued | 612,881,253 | 611,435,047 |
Common Stock, Outstanding | 439,240,373 | 437,795,024 |
Treasury Stock, at Cost | 173,640,880 | 173,640,023 |
Variable Interest Entity Carrying Amount Of Accounts Payable | $ 0 | $ 0 |
Variable Interest Entity Carrying Amount Of Accrued Compensation and Benefits | $ 0 | $ 0 |
Statements of Consolidated Cash Flows (Unaudited) - USD ($) $ in Millions |
9 Months Ended | |
---|---|---|
May 31, 2017 |
May 31, 2016 |
|
Operating Activities: | ||
Net Income | $ 2,248 | $ 1,518 |
Items that did not require (provide) cash: | ||
Depreciation and amortization | 549 | 542 |
Bad-debt expense | 61 | 81 |
Stock-based compensation expense | 94 | 88 |
Excess tax benefits from stock-based compensation | (6) | (13) |
Deferred income taxes | 83 | 168 |
Restructuring impairments | 40 | 119 |
Equity affiliate expense, net | 6 | 6 |
Net gain on sale of a business or other assets | (88) | (31) |
Other items | 80 | 141 |
Changes in assets and liabilities that (required) provided cash, net of acquisitions: | ||
Trade receivables, net | (2,062) | (1,755) |
Inventory, net | 14 | (6) |
Deferred revenue | (35) | 61 |
Accounts payable and other accrued liabilities | (129) | (588) |
Restructuring, net | (165) | 90 |
Pension contributions | (31) | (47) |
Other items, net | 31 | 41 |
Net Cash Provided by Operating Activities | 690 | 415 |
Cash Flows Provided (Required) by Investing Activities: | ||
Maturities of short-term investments | 52 | 35 |
Capital expenditures | (848) | (666) |
Acquisition of businesses, net of cash acquired | (11) | (2) |
Technology and other investments | (46) | (43) |
Other investments and property disposal proceeds | 101 | 37 |
Net Cash Required by Investing Activities | (752) | (639) |
Cash Flows Provided (Required) by Financing Activities: | ||
Net change in financing with less than 90-day maturities | 514 | 1,942 |
Short-term debt proceeds | 63 | 46 |
Short-term debt reductions | (12) | (252) |
Long-term debt proceeds | 600 | 9 |
Long-term debt reductions | (517) | (305) |
Debt issuance costs | (2) | 0 |
Treasury stock purchases | 0 | (3,001) |
Stock option exercises | 78 | 66 |
Excess tax benefits from stock-based compensation | 6 | 13 |
Tax withholding on restricted stock and restricted stock units | (18) | (22) |
Dividend payments | (712) | (727) |
Payments to noncontrolling interests | (4) | (2) |
Net Cash Required by Financing Activities | (4) | (2,233) |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | 4 | (39) |
Net Decrease in Cash and Cash Equivalents | (62) | (2,496) |
Cash and Cash Equivalents at Beginning of Period | 1,676 | 3,701 |
Cash and Cash Equivalents at End of Period | $ 1,614 | $ 1,205 |
Statements of Consolidated Shareholders Equity (Unaudited) - USD ($) $ in Millions |
Total |
Common Stock |
Treasury Stock |
Additional Contributed Capital |
Retained Earnings [Member] |
Accumulated Other Comprehensive (Loss) |
NonControlling Interests |
|||
---|---|---|---|---|---|---|---|---|---|---|
Beginning Balance at Aug. 31, 2015 | $ 7,005 | $ 6 | $ (12,053) | $ 11,464 | $ 10,374 | $ (2,801) | [1] | $ 15 | ||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||||
Net Income | 1,313 | 1,336 | (23) | |||||||
Other comprehensive income (loss) | (8) | (7) | [1] | (1) | ||||||
Treasury Stock Purchases | (3,001) | (3,000) | (1) | |||||||
Restricted Stock and Restricted Stock Unit Tax Withholding | (24) | (24) | ||||||||
Issuance of Shares Under Employee Stock Plans | 81 | 81 | ||||||||
Net Excess Tax Benefits from Stock-based Compensation | 11 | 11 | ||||||||
Stock-based Compensation Expense | 111 | 111 | ||||||||
Cash dividends per common share ($1.78 for 2014 and $0.98 for 2015) | (947) | (947) | ||||||||
Acquisition of Noncontrolling Interest | 10 | (16) | 26 | |||||||
Payments to Noncontrolling Interest | (6) | (6) | ||||||||
Ending Balance at Aug. 31, 2016 | 4,545 | 6 | (15,053) | 11,626 | 10,763 | (2,808) | [1] | 11 | ||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||||
Net Income | 2,248 | 2,240 | 8 | |||||||
Other comprehensive income (loss) | 74 | 73 | 1 | |||||||
Issuance of Shares Under Employee Stock Plans | 78 | 78 | ||||||||
Restricted Stock and Restricted Stock Unit Tax Withholding | (17) | (17) | ||||||||
Net Excess Tax Benefits from Stock-based Compensation | 6 | 6 | ||||||||
Stock-based Compensation Expense | 94 | 94 | ||||||||
Cash dividends per common share ($1.78 for 2014 and $0.98 for 2015) | (476) | (476) | ||||||||
Payments to Noncontrolling Interest | (4) | (4) | ||||||||
Ending Balance at May. 31, 2017 | $ 6,548 | $ 6 | $ (15,053) | $ 11,787 | $ 12,527 | $ (2,735) | [1] | $ 16 | ||
|
Statements of Consolidated Shareholders Equity (Parenthetical) (Unaudited) - $ / shares |
3 Months Ended | 9 Months Ended | 12 Months Ended | ||
---|---|---|---|---|---|
May 31, 2017 |
May 31, 2016 |
May 31, 2017 |
May 31, 2016 |
Aug. 31, 2016 |
|
Statement of Stockholders' Equity [Abstract] | |||||
Cash dividends per common share | $ 0 | $ 0 | $ 1.08 | $ 1.08 | $ 2.16 |
BACKGROUND AND BASIS OF PRESENTATION |
9 Months Ended |
---|---|
May 31, 2017 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
BACKGROUND AND BASIS OF PRESENTATION | BACKGROUND AND BASIS OF PRESENTATION Monsanto Company, along with its subsidiaries, is a leading global provider of agricultural products for farmers. Monsanto’s seeds, biotechnology trait products, herbicides and digital agriculture products provide farmers with solutions that help improve productivity, reduce the costs of farming and produce better food for consumers and better feed for animals. Monsanto manages its business in two reportable segments: Seeds and Genomics and Agricultural Productivity. Through the Seeds and Genomics segment, Monsanto produces leading seed brands, including DEKALB, Asgrow, Deltapine, Seminis and De Ruiter, and Monsanto develops biotechnology traits that assist farmers in controlling insects and weeds and digital agriculture products to assist farmers in decision making. Monsanto also provides other seed companies with genetic material and biotechnology traits for their seed brands. Through the Agricultural Productivity segment, the company manufactures Roundup and Harness brand herbicides and other herbicides. See Note 19 — Segment Information — for further details. In the fourth quarter of 2008, the company announced plans to divest its animal agricultural products business, which focused on dairy cow productivity and was previously reported as part of the Agricultural Productivity segment. This transaction was consummated on Oct. 1, 2008, and included a 10-year earn-out with potential annual payments being earned by Monsanto if certain revenue levels are exceeded. As a result, financial data for this business has been presented as discontinued operations. On Nov. 2, 2015, the company signed a definitive agreement with Deere & Company (“Deere”) to sell the Precision Planting equipment business which is included in the Seed and Genomics segment for approximately $190 million in cash, subject to customary working capital adjustments. In August 2016, the U.S. Department of Justice filed a lawsuit to block Deere’s acquisition of the Precision Planting equipment business. In May 2017, the company terminated its agreement with Deere to sell the Precision Planting equipment business. The company continues to intend to sell the Precision Planting equipment business during this fiscal year and is actively marketing the business to third parties. As of May 31, 2017, and Aug. 31, 2016, Monsanto had $171 million and $172 million of assets held for sale, respectively, and $9 million and $12 million of liabilities held for sale classified within miscellaneous short-term accruals, respectively, on the Statements of Consolidated Financial Position related to this transaction. The assets were primarily related to inventory, net; trade receivables, net; property, plant, and equipment, net; goodwill; and other intangible assets, net, and the liabilities were primarily related to accrued marketing programs and accounts payable. During the nine months ended May 31, 2017, the company divested its European-based silthiofam seed-treatment chemical business previously reported as part of the Agricultural Productivity segment for approximately $140 million in cash, subject to customary working capital adjustments. Approximately $85 million, less the carrying amount of assets sold of approximately $2 million, was recognized within other expense (income), net in the Statements of Consolidated Operations for the nine months ended May 31, 2017. The recognition of the remaining $55 million is contingent on silthiofam re-registration within the European Union. The accompanying consolidated financial statements have not been audited but have been prepared in conformity with accounting principles generally accepted in the United States for interim financial information and with instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, these unaudited consolidated financial statements contain all necessary adjustments which are normal and recurring to present fairly the financial position, results of operations and cash flows for the interim periods reported. This Report on Form 10-Q should be read in conjunction with Monsanto’s Report on Form 10-K for the fiscal year ended Aug. 31, 2016. Financial information for the third quarter and first nine months of fiscal year 2017 should not be annualized because of the seasonality of the company’s business. |
NEW ACCOUNTING STANDARDS |
9 Months Ended |
---|---|
May 31, 2017 | |
NEW ACCOUNTING STANDARDS [Abstract] | |
NEW ACCOUNTING STANDARDS | NEW ACCOUNTING STANDARDS In May 2017, the Financial Accounting Standards Board (“FASB”) issued accounting guidance, “Scope of Modification Accounting” which clarifies modification accounting for share-based payment awards should not be applied if the fair value, vesting conditions, and classification of the modified award are the same before and immediately after the modification. This standard is effective for fiscal years, and interim periods within those fiscal years, beginning after Dec. 15, 2017. Adoption will be applied prospectively to awards modified on or after the adoption date. Accordingly, Monsanto is required to adopt this standard in the first quarter of fiscal year 2019. The company is currently evaluating the impact this guidance will have on the consolidated financial statements and related disclosures. In February 2017, the FASB issued accounting guidance, “Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost” which requires the disaggregation of the service cost component from other components of net periodic benefit cost, clarifies how to present the service cost component and other components of net benefit costs in the Statements of Consolidated Operations and allows only the service cost component of net benefit costs to be eligible for capitalization. This standard is effective for fiscal years, and interim periods within those fiscal years, beginning after Dec. 15, 2017, with early adoption permitted as of the beginning of a fiscal year for which interim or annual statements have not been issued. Adoption will be applied on a retrospective basis for the presentation of all components of net periodic benefit costs and on a prospective basis for the capitalization of the service cost component of net periodic pension cost and net periodic postretirement benefit in assets. Accordingly, Monsanto is required to adopt this standard in the first quarter of fiscal year 2019. The company is currently evaluating the impact this guidance will have on the consolidated financial statements and related disclosures. In February 2017, the FASB issued accounting guidance, “Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sale of Nonfinancial Assets” which clarifies the scope of transactions that are accounted for in accordance with the Other Income topic of the Accounting Standards Codification (“ASC”) as well when these assets would be derecognized. The Other Income topic of the ASC applies to a sale or transfer to a non-customer of nonfinancial assets or financial assets in a contract with substantially all of the fair value concentrated in nonfinancial assets. This standard is effective for fiscal years, and interim periods within those fiscal years, beginning after Dec. 15, 2017, with an early adoption of one-year permitted. This guidance is required to be adopted at the same time “Revenue from Contracts with Customers” is adopted. Entities have the option to apply the new guidance under a retrospective approach to each prior reporting period presented or a modified retrospective approach with the cumulative effect of initially applying the new guidance recognized at the date of initial application within the Statement of Consolidated Financial Position. The method of adoption elected may be different than the method of adoption for “Revenue from Contracts with Customers.” Monsanto is required to adopt this standard in the first quarter of fiscal year 2019. The company is currently evaluating the impact this guidance will have on the consolidated financial statements and related disclosures. In January 2017, the FASB issued accounting guidance, “Simplifying the Test for Goodwill Impairment” which would eliminate the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge. Instead, the amount of an impairment charge would be recognized if the carrying amount of a reporting unit is greater than its fair value. This standard is effective for annual or any interim goodwill impairments tests in fiscal years beginning after Dec. 15, 2019, with early adoption permitted. Adoption will be applied on a prospective basis. Monsanto is required to adopt this standard in the first quarter of fiscal year 2021. The company is currently evaluating the impact this guidance will have on the consolidated financial statements and related disclosures. In January 2017, the FASB issued accounting guidance, “Clarifying the Definition of a Business” which requires an evaluation of whether substantially all fair value of the assets acquired or disposed of is concentrated in a single identifiable asset or a group of similar identifiable assets. If this threshold is met, the set of transferred assets and activities is not a business. The guidance also requires a business to include at least one substantive process. Transactions that meet the definition of a business are expected to decrease as a result of the adoption of this guidance. This standard is effective for fiscal years, and interim periods within those fiscal years, beginning after Dec. 15, 2017, with early adoption permitted. Adoption will be applied on a prospective basis. Monsanto is required to adopt this standard in the first quarter of fiscal year 2019. The company is currently evaluating the impact this guidance will have on the consolidated financial statements and related disclosures. In November 2016, the FASB issued accounting guidance, “Statement of Cash Flows: Restricted Cash” which requires restricted cash and restricted cash equivalents to be classified in the Statements of Cash Flows as cash and cash equivalents. This standard is effective for fiscal years, and interim periods within those fiscal years, beginning after Dec. 15, 2017, with early adoption permitted. Adoption will be applied on a retrospective basis to all periods presented. Monsanto is required to adopt this standard in the first quarter of fiscal year 2019. The company is currently evaluating the impact this guidance will have on the consolidated financial statements and related disclosures. In October 2016, the FASB issued accounting guidance, “Income Taxes: Intra-Entity Transfers of Assets Other than Inventory” which will require the income tax effects of intra-entity transfers of assets other than inventory to be recognized when the transfer occurs. This standard is effective for fiscal years, and interim periods within those fiscal years, beginning after Dec. 15, 2017, with early adoption permitted as of the beginning of an annual period. Adoption will be applied on a modified retrospective basis. Monsanto is required to adopt the standard in the first quarter of fiscal year 2019. The company is currently evaluating the impact this guidance will have on the consolidated financial statements and related disclosures. In August 2016, the FASB issued accounting guidance, “Classification of Certain Cash Receipts and Cash Payments” which clarifies the classification of the activity in the Statements of Consolidated Cash Flows and how the predominant principle should be applied when cash receipts and cash payments have more than one class of cash flows. This standard is effective for fiscal years, and interim periods within those fiscal years, beginning after Dec. 15, 2017, with early adoption permitted. Adoption will be applied retrospectively. Monsanto is required to adopt the standard in the first quarter of fiscal year 2019. The company is currently evaluating the impact this guidance will have on the consolidated financial statements and related disclosures. In June 2016, the FASB issued accounting guidance, “Measurement of Credit Losses on Financial Instruments” which replaces the incurred loss methodology to record credit losses with a methodology that reflects the expected credit losses for financial assets not accounted for at fair value with gains and losses recognized through net income. This standard is effective for fiscal years, and interim periods within those fiscal years, beginning after Dec. 15, 2019, with early adoption permitted for fiscal years, and interim periods within those fiscal years, beginning after Dec. 15, 2018. This standard will be adopted on a modified retrospective basis. Monsanto is required to adopt this standard in the first quarter of fiscal year 2021, with early adoption permitted in the first quarter of fiscal year 2020. The company is currently evaluating the impact this guidance will have on the consolidated financial statements and related disclosures. In March 2016, the FASB issued accounting guidance, “Improvements to Employee Share-Based Payment Accounting” which will simplify the income tax consequences, accounting for forfeitures and classification on the Statements of Consolidated Cash Flows. This standard is effective for fiscal years, and interim periods within those fiscal years, beginning after Dec. 15, 2016, with early adoption permitted. Monsanto is required to adopt the standard in the first quarter of fiscal year 2018. The company has performed a preliminary impact assessment of the guidance and does not expect there to be a material impact on the consolidated financial statements and related disclosures upon adoption. In February 2016, the FASB issued accounting guidance, “Leases” which will supersede the existing lease guidance and will require all leases with a term greater than 12 months to be recognized in the Statements of Financial Position and eliminate current real estate-specific lease guidance, while maintaining substantially similar classification criteria for distinguishing between finance leases and operating leases. This standard is effective for fiscal years, and interim periods within those fiscal years, beginning after Dec. 15, 2018, with early adoption permitted. This standard will be adopted on a modified retrospective basis. Monsanto is required to adopt the standard in the first quarter of fiscal year 2020. The company is currently evaluating the impact this guidance will have on the consolidated financial statements and related disclosures. In January 2016, the FASB issued accounting guidance, “Recognition and Measurement of Financial Assets and Financial Liabilities” which would require equity investments not accounted for as an equity method investment or that result in consolidation to be recorded at their fair value with changes in fair value recognized in the Statements of Consolidated Operations. Those equity investments that do not have a readily determinable fair value may be measured at cost less impairment, if any, plus or minus changes resulting from observable price changes. This standard is effective for fiscal years, and interim periods within those fiscal years, beginning after Dec. 15, 2017, with early adoption prohibited. Monsanto is required to adopt the standard in the first quarter of fiscal year 2019. The company is currently evaluating the impact this guidance will have on the consolidated financial statements and related disclosures. In February 2015, the FASB issued accounting guidance, “Amendments to the Consolidation Analysis” which changes the guidance with respect to the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. All legal entities are subject to reevaluation under the revised consolidation model. The new guidance affects the following areas: (1) limited partnerships and similar legal entities, (2) evaluating fees paid to a decision maker or a service provider as a variable interest, (3) the effect of fee arrangements on the primary beneficiary determination, (4) the effect of related parties on the primary beneficiary determination and (5) certain investment funds. This standard is effective for fiscal years, and for interim periods within those fiscal years, beginning after Dec. 15, 2015. Accordingly, Monsanto adopted this standard in the first quarter of fiscal year 2017. The adoption of this guidance did not have an impact on the consolidated financial statements or related disclosures. In May 2014, the FASB issued accounting guidance, “Revenue from Contracts with Customers” which has been further clarified and amended. The core principle of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (that is, payment) to which the company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively (for example, service revenue and contract modifications) and clarify guidance for multiple-element arrangements. Entities have the option to apply the new guidance under a retrospective approach to each prior reporting period presented or a modified retrospective approach with the cumulative effect of initially applying the new guidance recognized at the date of initial application within the Statement of Consolidated Financial Position. In August 2015, the FASB amended the guidance to allow for the deferral of the effective date of this standard. The standard is effective for fiscal years, and interim periods within those years, beginning after Dec. 15, 2017. Accordingly, Monsanto is required to adopt this standard in the first quarter of fiscal year 2019. One-year early adoption is permitted. The initial analysis identifying areas that will be impacted by the new guidance is substantially complete, and the company is currently analyzing the potential impacts to the consolidated financial statements and related disclosures. The company believes the most significant impact relates to its accounting for biotechnology trait license revenue with fixed payments. Specifically, under the new standard, revenue for biotechnology trait license with fixed payments are expected to be recognized upon commencement of the license term rather than over the contract period. Due to complexities of certain biotechnology trait license agreements, the actual revenue recognition treatment under the standard will be dependent upon contract-specific terms and may vary in some instances from recognition upon commencement of the license term. Revenue from seed sales, agricultural chemical products and biotechnology trait licenses recognized as third-party seed companies sell seed is expected to remain substantially unchanged. The company has not made a decision on the method of adoption. |
RESTRUCTURING |
21 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring and Related Activities [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RESTRUCTURING |
Restructuring charges were recorded in the Statements of Consolidated Operations as follows:
On Oct. 6, 2015, the company approved actions to realign resources to increase productivity, enhance competitiveness by delivering cost improvements and support long-term growth. On Jan. 5, 2016, the company approved additional actions which, together with the Oct. 6, 2015 actions, comprise the 2015 Restructuring Plan. Actions include streamlining and reprioritizing some commercial, enabling, supply chain and research and development efforts. Cumulative pretax charges related to the 2015 Restructuring Plan are estimated to be in the range of $925 million to $1 billion. Implementation of the 2015 Restructuring Plan is expected to be completed by the end of fiscal year 2018, and substantially all of the cash payments are expected to be made by the end of fiscal year 2018. These pretax charges are currently estimated to be comprised of the following categories: $350 million to $370 million in work force reductions, including severance and related benefits; $95 million to $115 million in facility closures/exit costs, including contract termination costs; $480 million to $515 million in asset impairments and write-offs related to property, plant and equipment, inventory and goodwill and other assets. These pretax charges are currently estimated to be incurred primarily by the Seeds and Genomics segment. The following tables display the pretax charges incurred by segment under the 2015 Restructuring Plan.
The company’s written human resource policies are indicative of an ongoing benefit arrangement with respect to severance packages. Benefits paid pursuant to an ongoing benefit arrangement are specifically excluded from the Exit or Disposal Cost Obligations topic of the ASC; therefore, severance charges incurred in connection with the 2015 Restructuring Plan are accounted for when probable and estimable as required under the Compensation - Nonretirement Postemployment Benefits topic of the ASC. In addition, when the decision to commit to a restructuring plan requires a long-lived asset and finite-lived intangible asset impairment review, Monsanto evaluates such impairment issues under the Property, Plant and Equipment topic of the ASC. The three and nine months ended May 31, 2017, and May 31, 2016, include the reversal of $34 million, $91 million, $8 million and $20 million, respectively, of previously recognized expense due to changes in estimates related to work force reductions. The following table summarizes the activities related to the company’s 2015 Restructuring Plan.
(2) The restructuring liability balance included $1 million that was recorded in long-term restructuring reserves in the Statement of Consolidated Financial Position as of May 31, 2017. |
CUSTOMER FINANCING PROGRAMS |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CUSTOMER FINANCING PROGRAMS [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CUSTOMER FINANCING PROGRAMS | CUSTOMER FINANCING PROGRAMS Monsanto participates in customer financing programs as follows:
The gross amounts of receivables sold under transactions that qualify for sales treatment were:
In addition to the arrangements in the above table, Monsanto also participates in a financing program in Brazil that allows Monsanto to transfer up to 350 million Brazilian reais (approximately $108 million as of May 31, 2017) for select customers in Brazil to a revolving financing program. Under the arrangement, a recourse provision requires Monsanto to cover the first credit losses within the program up to the amount of the company’s investment. Credit losses above Monsanto’s investment would be covered by senior interests in the entity by a reduction in the fair value of their mandatorily redeemable shares. The company evaluated its relationship with the entity under the guidance within the Consolidation topic of the ASC, and as a result, the entity has been consolidated. For further information on this topic, see Note 5 — Variable Interest Entities and Investments. There were no significant recourse or non-recourse liabilities for all programs as of May 31, 2017, and Aug. 31, 2016. There were no significant delinquent loans for all programs as of May 31, 2017, and Aug. 31, 2016. |
VARIABLE INTEREST ENTITIES |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 31, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Equity Method Investments and Joint Ventures [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||
VARIABLE INTEREST ENTITIES | VARIABLE INTEREST ENTITIES AND INVESTMENTS Variable Interest Entities On Oct. 19, 2016, Monsanto exited a financing program in Brazil that was recorded as a consolidated variable interest entity (“VIE”). On Nov. 4, 2016, Monsanto entered into a new financing program in Brazil that is recorded as a consolidated VIE. For the most part, the new and previous arrangements of the Brazil VIE consist of a revolving financing program that is funded by investments from the company and other third parties, primarily investment funds, and has been established to service Monsanto’s customer receivables. Under the new arrangement, third parties, primarily investment funds, hold senior interests of 88 percent, and Monsanto holds the remaining 12 percent in the entity as of May 31, 2017. Under the previous arrangement, as of Aug. 31, 2016, third parties, primarily investment funds, held senior interest of 89 percent, and Monsanto held the remaining 11 percent interest. Under the new arrangement, the senior interests held by third parties are mandatorily redeemable shares and are included in long-term debt in the Statement of Consolidated Financial Position as of May 31, 2017. Under the previous arrangement, the senior interests held by third parties were mandatorily redeemable shares and were included in short-term debt in the Statement of Consolidated Financial Position as of Aug. 31, 2016. Under the new arrangement, Monsanto is required to maintain an investment in the Brazil VIE of at least 11.1 percent and could be required to provide additional contributions to the Brazil VIE. Monsanto currently has no unfunded commitments to the Brazil VIE. Creditors have no recourse against Monsanto in the event of default by the Brazil VIE. The company’s financial or other support provided to the Brazil VIE is limited to its investment. Even though Monsanto holds a subordinate interest in the Brazil VIE, the Brazil VIE was established to service transactions involving the company, and the company determines the receivables that are included in the revolving financing program. Therefore, the determination is that Monsanto has the power to direct the activities most significant to the economic performance of the Brazil VIE. As a result, the company is the primary beneficiary of the Brazil VIE, and the Brazil VIE has been consolidated in Monsanto’s consolidated financial statements. The assets of the Brazil VIE may only be used to settle the obligations of the respective entity. Third-party investors in the Brazil VIE do not have recourse to the general assets of Monsanto. See Note 4 — Customer Financing Programs and Note 11 — Fair Value Measurements— for additional information. Monsanto has entered into an agreement with a third party to establish an entity to focus on research and development (“R&D”) related to agricultural fungicides for agricultural applications. This entity is recorded as a consolidated VIE of Monsanto. Under the arrangement, Monsanto holds a call option to acquire the majority of the equity interests in the R&D VIE from the third-party owner. Monsanto funds the operations of the R&D VIE in return for additional equity interests or to retain the call option. The funding is provided in separate research phases if research milestones are met. The R&D VIE was established to perform agricultural-based R&D activities for the benefit of Monsanto, and Monsanto provides all funding of the R&D VIE’s activities. Further, Monsanto has the power to direct the activities most significant to the R&D VIE. As a result, Monsanto is the primary beneficiary of the R&D VIE, and the R&D VIE is consolidated in Monsanto’s consolidated financial statements. The third-party owner of the R&D VIE do not have recourse to the general assets of Monsanto beyond Monsanto’s maximum exposure to loss at any given time relating to the R&D VIE. Monsanto enters into agreements with agents to distribute certain branded seed in the United States. Monsanto offers financing to agents that constitutes a variable interest as it exposes Monsanto to variability of the agent. Certain agents with these financing arrangements have been determined to be VIEs. Monsanto does not consolidate the agents as Monsanto is not the primary beneficiary, and any exposure to loss is limited to the amount of financing provided to the agent. The amount of Monsanto’s exposure varies based on the seasonality of the business and is not material as of May 31, 2017, and Aug. 31, 2016. Equity Method and Cost Basis Investments Monsanto has equity method and cost basis investments recorded in other assets in the Statements of Consolidated Financial Position. Due to the nature of the cost basis investments, the fair market value is not readily determinable. These investments are reviewed for impairment indicators on a quarterly basis. For such investments that were accounted for under the equity method and cost basis included in other assets in the Statements of Consolidated Financial Position, the amounts are summarized in the following table:
|
RECEIVABLES |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Receivables [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RECEIVABLES | RECEIVABLES Trade receivables in the Statements of Consolidated Financial Position are net of allowances of $116 million and $94 million as of May 31, 2017, and Aug. 31, 2016, respectively. The company has long-term customer financing receivables that relate to past due accounts which are not expected to be collected within the current year. The long-term customer receivables were $351 million and $260 million with a corresponding allowance for credit losses on these receivables of $234 million and $228 million as of May 31, 2017, and Aug. 31, 2016, respectively. These long-term customer receivable balances and the corresponding allowance are included in long-term receivables, net in the Statements of Consolidated Financial Position. For these long-term customer receivables, interest is no longer accrued when the receivable is determined to be delinquent and classified as long-term based on estimated timing of collection. The following table displays a roll forward of the allowance for credit losses related to long-term customer receivables.
(1)Includes reclassifications from the allowance for current receivables and foreign currency translation adjustments. On an ongoing basis, the company evaluates credit quality of its financing receivables utilizing aging of receivables, collection experience and write-offs, as well as evaluating existing economic conditions, to determine if an allowance is necessary. |
INVENTORY |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
INVENTORY | INVENTORY Components of inventory are:
|
GOODWILL AND OTHER INTANGIBLE ASSETS |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GOODWILL AND OTHER INTANGIBLE ASSETS | GOODWILL AND OTHER INTANGIBLE ASSETS Changes in the net carrying amount of goodwill for the first nine months of fiscal year 2017, by segment, are as follows:
The fiscal year 2017 annual goodwill impairment test was performed as of Mar. 1, 2017, and no goodwill impairment existed as of that date. There were no events or circumstances indicating that goodwill might be impaired as of May 31, 2017. Information regarding the company’s other intangible assets is as follows:
Total amortization expense of total other intangible assets was $36 million and $29 million for the three months ended May 31, 2017, and May 31, 2016, respectively, and $110 million and $88 million for the nine months ended May 31, 2017, and May 31, 2016, respectively. The estimated intangible asset amortization expense for fiscal year 2017 through fiscal year 2021 is as follows:
|
DEBT AND OTHER CREDIT ARRANGEMENTS |
9 Months Ended |
---|---|
May 31, 2017 | |
Debt Disclosure [Abstract] | |
DEBT AND OTHER CREDIT ARRANGEMENTS | DEBT AND OTHER CREDIT ARRANGEMENTS In April 2016, Monsanto filed a shelf registration with the Securities and Exchange Commission (“SEC”) (“2016 shelf registration”) that allows the company to issue a maximum aggregate amount of $6 billion of debt, equity and hybrid offerings. The 2016 shelf registration expires in April 2019. Monsanto has a $3 billion credit facility agreement that provides a senior unsecured revolving credit facility through Mar. 27, 2020. As of May 31, 2017, Monsanto was in compliance with all debt covenants, and there were no outstanding borrowings under this credit facility. Monsanto’s short-term debt instruments include commercial paper, the current portion of long-term debt, notes payable to banks and borrowings under the delayed draw term loan facility. As of May 31, 2017, Monsanto had commercial paper borrowings outstanding of $1,212 million which are included in short-term debt in the Statement of Consolidated Financial Position. As of Aug. 31, 2016, there was $500 million of commercial paper borrowings outstanding. Additionally, as of May 31, 2017, the mandatorily redeemable shares of the Brazil VIE were classified as long-term debt instruments. These instruments were classified as short-term debt as of Aug. 31, 2016. See Note 5 — Variable Interest Entities and Investments — for additional information. In October 2016, Monsanto closed a $1 billion delayed draw term loan facility that matures the earlier of October 2019 or the consummation of the Merger with Bayer. Borrowings under the facility were $500 million as of May 31, 2017. Proceeds were used for general corporate purposes. The fair value of total short-term debt was $2,621 million and $1,589 million as of May 31, 2017, and Aug. 31, 2016, respectively. The fair value of the total long-term debt was $7,483 million and $7,834 million as of May 31, 2017, and Aug. 31, 2016, respectively. See Note 11 — Fair Value Measurements — for additional information. |
FAIR VALUE MEASUREMENTS |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 31, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FAIR VALUE MEASUREMENTS | FAIR VALUE MEASUREMENTS Monsanto determines the fair market value of its financial assets and liabilities based on quoted market prices, estimates from brokers and other appropriate valuation techniques. The company uses the fair value hierarchy established in the Fair Value Measurements and Disclosures topic of the ASC, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The hierarchy contains three levels as follows, with Level 3 representing the lowest level of input. Level 1 — Values based on unadjusted quoted market prices in active markets that are accessible at the measurement date for identical assets and liabilities. Level 2 — Values based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, discounted cash flow models, or other model-based valuation techniques adjusted, as necessary, for credit risk. Level 3 — Values generated from model-based techniques that use significant assumptions not observable in the market. These unobservable assumptions would reflect our own estimates of assumptions that market participants would use in pricing the asset or liability. Valuation techniques could include use of option pricing models, discounted cash flow models and similar techniques. The following tables set forth by level Monsanto’s assets and liabilities disclosed at fair value on a recurring basis as of May 31, 2017, and Aug. 31, 2016. As required by the Fair Value Measurements and Disclosures topic of the ASC, assets and liabilities are classified in their entirety based on the lowest level of input that is a significant component of the fair value measurement. Monsanto’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the classification of fair value assets and liabilities within the fair value hierarchy levels.
The company’s derivative contracts are measured at fair value, including forward commodity purchase and sale contracts, exchange-traded commodity futures and option contracts and over-the-counter (“OTC”) instruments related primarily to agricultural commodities, energy and raw materials, interest rates and foreign currencies. Exchange-traded futures and options contracts are valued based on unadjusted quoted prices in active markets and are classified as Level 1. Fair value for forward commodity purchase and sale contracts is estimated based on exchange-quoted prices adjusted for differences in local markets. These differences are generally determined using inputs from broker or dealer quotations or market transactions in either the listed or OTC markets and are classified as Level 2. Interest rate contracts consist of interest rate swaps measured using broker or dealer quoted prices. When observable inputs are available for substantially the full term of the contract, it is classified as Level 2. Based on historical experience with the company’s suppliers and customers, the company’s own credit risk and knowledge of current market conditions, the company does not view nonperformance risk to be a significant input to the fair value for the majority of its forward commodity purchase and sale contracts. The effective portions of changes in the fair value of derivatives designated as cash flow hedges are recognized in the Statements of Consolidated Financial Position as a component of accumulated other comprehensive loss until the hedged items are recorded in earnings or it is probable the hedged transaction will no longer occur. Changes in the fair value of derivatives are recognized in the Statements of Consolidated Operations as a component of net sales, cost of goods sold and other expense (income), net. The company’s short-term investments consist of cash which is contractually restricted as to withdrawal or usage. The company’s equity securities consist of publicly traded equity investments. Publicly traded equity investments are valued using quoted market prices and are classified as Level 1. Contractually restricted cash may be held in an interest bearing account measured using prevailing interest rates and is classified as Level 1. Short-term debt instruments are classified as Level 2. The company’s long-term debt securities are classified as Level 2 and valued using broker or dealer quoted prices with a maturity greater than one year. Short-term debt instruments may consist of commercial paper, current portion of long-term debt, borrowings under the delayed draw term loan facility and notes payable to banks. Commercial paper, notes payable to banks and borrowings under the delayed draw term loan facility are recorded at amortized cost in the Statements of Consolidated Financial Position, which approximates fair value. Current portion of long-term debt is measured at fair value for disclosure purposes and determined based on current market yields for Monsanto’s debt traded in the secondary market. See Note 10 — Debt and Other Credit Arrangements — for additional disclosures. Long-term debt was measured at fair value for disclosure purposes and determined based on current market yields for Monsanto’s debt traded in the secondary market. Long-term debt includes mandatorily redeemable shares. Mandatorily redeemable shares are recorded in the Statements of Consolidated Financial Position at fair value, which represents the amount of cash the consolidated variable interest entity would pay if settlement occurred as of the respective reporting date. Fair value of the mandatorily redeemable shares of the variable interest entity is calculated using observable and unobservable inputs from an interest rate market in Brazil and stated contractual terms (a Level 3 measurement). See Note 10 — Debt and Other Credit Arrangements — for additional disclosures. Accretion expense is included in the Statements of Consolidated Operations as interest expense. For the nine months ended May 31, 2017, and May 31, 2016, the company had no transfers between Level 1, Level 2 and Level 3. Monsanto does not have any assets with fair value determined using Level 3 inputs as of May 31, 2017, and Aug. 31, 2016. The following table summarizes the change in fair value of the Level 3 long-term debt instrument for the nine months ended May 31, 2017.
The following table summarizes the change in fair value of the Level 3 short-term debt instrument for the nine months ended May 31, 2017.
There were no significant measurements of liabilities to their implied fair value on a nonrecurring basis during the three and nine months ended May 31, 2017, and May 31, 2016. Significant measurements during the three and nine months ended May 31, 2017, and May 31, 2016, of assets to their implied fair value on a nonrecurring basis were as follows: Property, Plant and Equipment, Net: During the three months ended May 31, 2017, property, plant and equipment within the Seeds and Genomics segment with a net book value of $6 million was written down to its implied fair value of less than $1 million, resulting in an impairment charge of $6 million, with $2 million included in cost of goods sold and $4 million included in restructuring charges in the Statement of Consolidated Operations. The implied fair value calculations were performed using a discounted cash flow model (a Level 3 measurement). See Note 3 — Restructuring — for additional disclosures. During the nine months ended May 31, 2017, property, plant and equipment within the Seeds and Genomics segment with a net book value of $24 million was written down to its implied fair value estimate of $7 million, resulting in an impairment charge of $17 million, with $6 million included in cost of goods sold and $11 million included in restructuring charges in the Statement of Consolidated Operations. The implied fair value calculations were performed using a discounted cash flow model (a Level 3 measurement). See Note 3 — Restructuring — for additional disclosures. During the three months ended May 31, 2016, property, plant and equipment within the Seeds and Genomics segment with a net book value of $21 million was written down to its implied fair value estimate of $12 million, resulting in an impairment charge of $9 million, with $9 million included in restructuring charges in the Statement of Consolidated Operations. The implied fair value calculations were performed using a discounted cash flow model (a Level 3 measurement). See Note 3 — Restructuring — for additional disclosures. During the nine months ended May 31, 2016, property, plant and equipment within the Seeds and Genomics segment with a net book value of $65 million was written down to its implied fair value estimate of $27 million, resulting in an impairment charge of $38 million, with $15 million included in cost of goods sold and $23 million included in restructuring charges in the Statement of Consolidated Operations. The implied fair value calculations were performed using a discounted cash flow model (a Level 3 measurement). See Note 3 — Restructuring — for additional disclosures. Other Intangible Assets, Net: During the three months ended May 31, 2016, other intangible assets within the Seeds and Genomics segment with a net book value of $3 million were written down to their implied fair value of less than $1 million, resulting in an impairment charge of $3 million, with $3 million included in restructuring charges in the Statement of Consolidated Operations. The implied fair value calculations were performed using a discounted cash flow model (a Level 3 measurement). See Note 3 — Restructuring — for additional disclosures. During the nine months ended May 31, 2016, other intangible assets within the Seeds and Genomics segment with a net book value of $19 million were written down to their implied fair value of less than $1 million, resulting in an impairment charge of $19 million, with $19 million included in restructuring charges in the Statement of Consolidated Operations. The implied fair value calculations were performed using a discounted cash flow model (a Level 3 measurement). See Note 3 — Restructuring — for additional disclosures. During the nine months ended May 31, 2016, other intangible assets within the Agricultural Productivity segment with a net book value of $20 million were written down to their implied fair value of less than $1 million, resulting in an impairment charge of $20 million, with $20 million included in restructuring charges in the Statement of Consolidated Operations. The implied fair value calculations were performed using a discounted cash flow model (a Level 3 measurement). See Note 3 — Restructuring — for additional disclosures. The recorded amounts of cash, trade receivables, miscellaneous receivables, third-party guarantees, accounts payable, grower production accruals, accrued marketing programs and miscellaneous short-term accruals approximate their fair values as of May 31, 2017, and Aug. 31, 2016. Management is ultimately responsible for all fair values presented in the company’s consolidated financial statements. The company performs analysis and review of the information and prices received from third parties to ensure that the prices represent a reasonable estimate of fair value. This process involves quantitative and qualitative analysis. As a result of the analysis, if the company determines there is a more appropriate fair value based upon the available market data, the price received from the third party is adjusted accordingly. |
FINANCIAL INSTRUMENTS |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FINANCIAL INSTRUMENTS | FINANCIAL INSTRUMENTS Cash Flow Hedges The company uses foreign currency options and foreign currency forward contracts as hedges of anticipated sales or purchases denominated in foreign currencies. The company enters into these contracts to protect itself against the risk that the eventual net cash flows will be adversely affected by changes in exchange rates. Monsanto’s commodity price risk management strategy is to use derivative instruments to minimize significant unanticipated earnings fluctuations that may arise from volatility in commodity prices. Price fluctuations in commodities, mainly in corn and soybeans, can cause the actual prices paid to production growers for corn and soybean seeds to differ from anticipated cash outlays. Monsanto generally uses commodity futures and options contracts to manage these risks. Monsanto’s energy and raw material risk management strategy is to use derivative instruments to minimize significant unanticipated manufacturing cost fluctuations that may arise from volatility in natural gas, diesel and ethylene prices. Monsanto’s interest rate risk management strategy is to use derivative instruments, such as forward-starting interest rate swaps and option contracts, to minimize significant unanticipated earnings fluctuations that may arise from volatility in interest rates of the company’s borrowings and to manage the interest rate sensitivity of its debt. For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of the gain or loss on the derivative is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the period or periods during which the hedged transaction affects earnings. Gains and losses on the derivative representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings. The maximum term over which the company is hedging exposures to the variability of cash flow (for all forecasted transactions) is 15 months for foreign currency hedges and 30 months for commodity hedges. During the next 12 months, a pretax net loss of approximately $20 million is expected to be reclassified from accumulated other comprehensive loss into earnings. A pretax loss of $37 million was reclassified into other expense (income), net as a result of the discontinuance of an interest rate hedge during the nine months ended May 31, 2017, because it was probable the original forecasted transaction would not occur by the end of the originally specified time period. A pretax loss of less than $1 million during the nine months ended May 31, 2017, was reclassified into cost of goods sold in the Statement of Consolidated Operations as a result of the discontinuance of foreign currency cash flow hedges because it was probable that the original forecasted transactions would not occur by the end of the originally specified time period. A pretax loss of less than $1 million during the nine months ended May 31, 2016, was reclassified into cost of goods sold in the Statement of Consolidated Operations as a result of the discontinuance of commodity cash flow hedges because it was probable that the original forecasted transaction would not occur by the end of the originally specified time period. No cash flow hedges were discontinued during the three months ended May 31, 2017, and May 31, 2016. Fair Value Hedges The company uses commodity futures, forwards and options contracts as fair value hedges to manage the value of its soybean inventory and other assets. For derivative instruments that are designated and qualify as fair value hedges, both the gain or loss on the derivative and the offsetting loss or gain on the hedged item attributable to the hedged risk are recognized in current earnings. No fair value hedges were discontinued during the three and nine months ended May 31, 2017, and May 31, 2016. Derivatives Not Designated as Hedging Instruments The company uses foreign currency contracts to hedge the effects of fluctuations in exchange rates on foreign currency denominated third-party and intercompany receivables and payables. Both the gain or loss on the derivative and the offsetting loss or gain on the hedged item attributable to the hedged risk are recognized in current earnings. The company uses commodity option contracts to hedge anticipated cash payments to growers in the United States, Mexico and Brazil, which can fluctuate with changes in commodity price. Because these option contracts do not meet the provisions specified by the Derivatives and Hedging topic of the ASC, they do not qualify for hedge accounting treatment. Accordingly, the gain or loss on these derivatives is recognized in current earnings. To reduce credit exposure in Latin America, Monsanto collects payments on certain customer accounts in grain. Such payments in grain are negotiated at or near the time Monsanto’s products are sold to the customers and are valued at the prevailing grain commodity prices. By entering into forward sales contracts related to grain, Monsanto mitigates the commodity price exposure from the time a contract is signed with a customer until the time a grain merchant collects the grain from the customer on Monsanto’s behalf. The forward sales contracts do not qualify for hedge accounting treatment under the Derivatives and Hedging topic of the ASC. Accordingly, the gain or loss on these derivatives is recognized in current earnings. Monsanto uses interest rate contracts to minimize the variability of forecasted cash flows arising from the company’s consolidated VIE in Brazil. The interest rate contracts do not qualify for hedge accounting treatment under the Derivatives and Hedging Topic of the ASC. Accordingly, the gain or loss on these derivatives is recognized in current earnings. Financial instruments are neither held nor issued by the company for trading purposes. The notional amounts of the company’s derivative instruments outstanding as of May 31, 2017, and Aug. 31, 2016, are as follows:
The net presentation of the company’s derivative instruments outstanding was as follows:
The gains and losses on the company’s derivative instruments were as follows:
Most of the company’s outstanding foreign currency derivatives are covered by International Swap and Derivatives Association (“ISDA”) Master Agreements with the counterparties. There are no requirements to post collateral under these agreements; however, should Monsanto’s credit rating fall below a specified rating immediately following the merger of the company with another entity, the counterparty may require all outstanding derivatives under the ISDA Master Agreement to be settled immediately at current market value, which equals carrying value. Foreign currency derivatives that are not covered by ISDA Master Agreements do not have credit-risk-related contingent provisions. Most of Monsanto’s outstanding commodity derivatives are listed commodity futures, and the company is required by the relevant commodity exchange to post collateral each day to cover the change in the fair value of these futures in the case of an unrealized loss position. Non-exchange-traded commodity derivatives and interest rate contracts may be covered by the aforementioned ISDA Master Agreements and would be subject to the same credit-risk-related contingent provisions. The aggregate fair value of all derivative instruments under ISDA Master Agreements that are in a liability position was $9 million and $63 million as of May 31, 2017, and Aug. 31, 2016, respectively, which is the amount that would be required for settlement if the credit-risk-related contingent provisions underlying these agreements were triggered. Credit Risk Management Monsanto invests excess cash in deposits with major banks or money market funds throughout the world in high-quality short-term debt instruments. Such investments are made only in instruments issued or enhanced by high-quality institutions. As of May 31, 2017, and Aug. 31, 2016, the company had no financial instruments that represented a significant concentration of credit risk. Limited amounts are invested in any single institution to minimize risk. The company has not incurred any credit risk losses related to those investments. The company sells a broad range of agricultural products to a diverse group of customers throughout the world. In the United States, the company makes substantial sales to relatively few large wholesale customers. The company’s business is highly seasonal and is subject to weather conditions that affect commodity prices and seed yields. Credit limits, ongoing credit evaluation and account monitoring procedures are used to minimize the risk of loss. Collateral is secured when it is deemed appropriate by the company. Monsanto regularly evaluates its business practices to minimize its credit risk and periodically engages multiple banks in the United States, Latin America and Europe in the development of customer financing options that involve direct bank financing of customer purchases. For further information on these programs, see Note 4 — Customer Financing Programs. |
POSTRETIREMENT BENEFITS - PENSIONS, HEALTH CARE AND OTHER |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Compensation and Retirement Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
POSTRETIREMENT BENEFITS-PENSIONS, HEALTH CARE AND OTHER | POSTRETIREMENT BENEFITS — PENSIONS, HEALTH CARE AND OTHER Monsanto maintains noncontributory pension plans for the benefit of its U.S. employees. Effective Jul. 8, 2012, the U.S. pension plans were closed to new entrants; there were no significant changes to these plans for eligible employees hired prior to that date. The company also provides certain postretirement health care and life insurance benefits for eligible retired employees and certain pension plan benefits outside the U.S. The company’s net periodic benefit cost for pension benefits and health care and other postretirement benefits include the following components:
|
STOCK BASED COMPENSATION PLANS STOCK BASED COMPENSATION PLANS |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCK BASED COMPENSATION PLANS | STOCK-BASED COMPENSATION PLANS The following table shows total stock-based compensation expense included in the Statements of Consolidated Operations for the three and nine months ended May 31, 2017, and May 31, 2016.
|
ACCUMULATED OTHER COMPREHENSIVE LOSS |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ACCUMULATED OTHER COMPREHENSIVE LOSS | ACCUMULATED OTHER COMPREHENSIVE LOSS The following table sets forth the after-tax components of accumulated other comprehensive loss and changes thereto:
The following table provides additional information regarding items reclassified out of accumulated other comprehensive loss into earnings.
|
EARNINGS PER SHARE |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EARNINGS PER SHARE | EARNINGS PER SHARE Basic earnings per share (“EPS”) was computed using the weighted-average number of common shares outstanding during the periods shown in the table below. The diluted EPS computation takes into account the effect of dilutive potential common shares when in a net income position. Potential common shares consist primarily of stock options, restricted stock units and directors’ deferred shares calculated using the treasury stock method and are excluded if their effect is antidilutive. Of those antidilutive options, certain options were excluded from the computations of dilutive potential common shares as their exercise prices were greater than the average market price of the common shares for the period.
|
SUPPLEMENTAL CASH FLOW INFORMATION |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Supplemental Cash Flow Information [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
SUPPLEMENTAL CASH FLOW INFORMATION | SUPPLEMENTAL CASH FLOW INFORMATION Cash payments for interest and taxes were as follows:
During the nine months ended May 31, 2017, and May 31, 2016, the company recorded the following noncash transactions:
|
COMMITMENTS AND CONTINGENCIES |
9 Months Ended |
---|---|
May 31, 2017 | |
Commitments and Contingencies Disclosure [Abstract] | |
COMMITMENTS AND CONTINGENCIES | COMMITMENTS AND CONTINGENCIES Environmental and Litigation Liabilities: Monsanto is involved in environmental remediation and legal proceedings to which Monsanto is party in its own name and proceedings to which its former parent, Pharmacia LLC (“Pharmacia”), or its former subsidiary, Solutia, Inc. (“Solutia”), is a party but that Monsanto manages and for which Monsanto is responsible pursuant to certain indemnification agreements. In addition, Monsanto has liabilities established for various product claims. With respect to certain of these proceedings, Monsanto has a liability recorded of $266 million and $545 million as of May 31, 2017, and Aug. 31, 2016, respectively, for the estimated contingent liabilities. Information regarding the environmental liabilities appears in Monsanto’s Report on Form 10-K for the fiscal year ended Aug. 31, 2016. Litigation: The above liability includes amounts related to certain third-party litigation with respect to Monsanto’s business, as well as tort litigation related to Pharmacia’s former chemical business, including lawsuits involving polychlorinated biphenyls (“PCBs”), dioxins, and other chemical and premises liability litigation. Additional matters that are not reflected in the liability may arise in the future, and Monsanto may manage, settle, or pay judgments or damages with respect thereto in order to mitigate contesting potential liability. Following is a description of one of the more significant litigation matters. As described in Monsanto’s Report on Form 10-K for the fiscal year ended Aug. 31, 2016, and our Reports on Form 10-Q for the quarterly periods ended Nov. 30, 2016, and Feb. 28, 2017, the company was named in approximately 30 personal injury lawsuits filed over several years on behalf of approximately 750 persons in state courts in St. Louis, Missouri and Los Angeles, California. Plaintiffs claimed they were injured by PCBs manufactured by Pharmacia’s chemical business over four decades ago and incorporated into products made, used and sometimes disposed of by others. In September 2016, the parties reached an agreement to settle these personal injury lawsuits pursuant to which the company is required to pay up to $280 million into a settlement fund, with the settlement and the final payment amount contingent upon the level of claimant participation. As of Aug. 31, 2016, $280 million was recorded in the Statement of Consolidated Financial Position within miscellaneous short-term accruals; the related expense was included in selling, general and administrative expenses in the Statement of Consolidated Operations. In November 2016 and December 2016, the first and second claimant participation levels were met, and the company paid $250 million and $25 million respectively, into the settlement fund. In February 2017 and June 2017, pro rata portions of the final claimant participation level were met, and payments totaling approximately $4 million were made. The company also has been named in lawsuits brought by various governmental entities claiming that Monsanto, Pharmacia and Solutia, collectively as a manufacturer of PCBs, should be responsible for a variety of damages due to PCBs in bodies of water, regardless of how PCBs came to be located there. The company believes that these novel claims are without merit and is vigorously defending the cases on legal and factual grounds. Including litigation reflected in the liability, Monsanto is involved in various legal proceedings that arise in the ordinary course of its business or pursuant to Monsanto’s indemnification obligations to Pharmacia, as well as proceedings that management has considered to be material under SEC regulations. Some of the lawsuits seek damages in very large amounts or seek to restrict the company’s business activities. Monsanto believes that it has meritorious legal arguments and will continue to represent its interests vigorously in all of the proceedings that it is defending or prosecuting. Management does not anticipate the ultimate liabilities resulting from such proceedings, or the proceedings reflected in the above liability, will have a material adverse effect on Monsanto’s consolidated results of operations, financial position, cash flows or liquidity. The company is defending lawsuits in various state and federal courts, in which approximately 1,400 plaintiffs claim to have been injured by exposure to glyphosate-based products manufactured by the company. The majority of plaintiffs have brought actions in state courts in Missouri, Delaware and California, while the remainder of plaintiffs’ cases were filed in many different federal courts. In October 2016, the Judicial Panel on Multi-District Litigation transferred to the Northern District of California all of the federal cases for pretrial purposes. The company believes that it has meritorious factual and legal defenses to these cases and is vigorously defending them. Legal actions have been filed in Brazil that raise various issues challenging the right to collect certain royalties for Roundup Ready soybeans, such as whether Brazilian pipeline patents have the duration of their corresponding U.S. patents (2014 for Roundup Ready soybeans) and whether Brazil’s Plant Variety Protection law affects the enforceability of patents. These issues are currently under judicial review in Brazil. Monsanto believes it has meritorious legal arguments and will continue to represent its interests vigorously in these proceedings. The current estimate of the company’s reasonably possible loss contingency is not material to consolidated results of operations, financial position, cash flows or liquidity. Guarantees: Disclosures regarding the guarantees Monsanto provides for certain customer loans in the United States, Latin America and Europe can be found in Note 4 — Customer Financing Programs — of this Form 10-Q. Except as described in that note, there have been no significant changes to guarantees made by Monsanto since Aug. 31, 2016. Disclosures regarding these guarantees made by Monsanto can be found in Note 24 — Commitments and Contingencies — of the notes to the consolidated financial statements contained in Monsanto’s Report on Form 10-K for the fiscal year ended Aug. 31, 2016. Off-Balance Sheet Arrangement: Monsanto is in the process of making a significant expansion of its Chesterfield, Missouri facility. In December 2013, Monsanto executed the first of a series of incentive agreements with the County of St. Louis, Missouri. Under these agreements Monsanto has transferred the Chesterfield, Missouri facility to St. Louis County and received Industrial Revenue Bonds in the amount of up to $470 million, which enables the company to reduce the cost of constructing and operating the expansion by reducing certain state and local tax expenditures. Monsanto immediately leased the facility from the County of St. Louis and has an option to purchase the facility upon tendering the Industrial Revenue Bonds received to the County. The payments due to the company in relation to the Industrial Revenue Bonds and owed by the company in relation to the lease of the facility qualify for the right of offset under ASC 210, Balance Sheet, in the Statements of Consolidated Financial Position. As such, neither the Industrial Revenue Bonds nor the lease obligation are recorded in the Statements of Consolidated Financial Position as an asset or liability, respectively. The Chesterfield facility and the expansion are being treated as being owned by Monsanto. |
SEGMENT AND GEOGRAPHIC DATA |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SEGMENT INFORMATION | SEGMENT INFORMATION Monsanto conducts its worldwide operations through global businesses, which are aggregated into reportable segments based on similarity of products, production processes, customers, distribution methods and economic characteristics. The operating segments are aggregated into two reportable segments: Seeds and Genomics and Agricultural Productivity. The Seeds and Genomics segment consists of the global seeds and related traits businesses, biotechnology platforms and digital agriculture. Within the Seeds and Genomics segment, Monsanto’s significant operating segments are corn seed and traits, soybean seed and traits, cotton seed and traits, vegetable seeds and all other crops seeds and traits. The Agricultural Productivity reportable segment consists of the Agricultural Productivity operating segment. EBIT is defined as earnings (loss) before interest and taxes and is an operating performance measure for the two reportable segments. EBIT is useful to management in demonstrating the operational profitability of the segments by excluding interest and taxes, which are generally accounted for across the entire company on a consolidated basis. Sales between segments were not significant. Certain selling, general and administrative expenses (“SG&A”) are allocated between segments based on the segment’s relative contribution to total Monsanto operations. Allocation percentages remain consistent for fiscal years 2016 and 2017. Data for the Seeds and Genomics and Agricultural Productivity reportable segments, as well as for Monsanto’s significant operating segments, is presented in the table as follows:
A reconciliation of EBIT to net income attributable to Monsanto Company for each period is as follows:
|
SUBSEQUENTS EVENTS |
9 Months Ended |
---|---|
May 31, 2017 | |
Subsequent Events [Abstract] | |
Subsequent Event | SUBSEQUENT EVENT On June 6, 2017, the Board of Directors declared a quarterly dividend on its common shares of 54 cents per share. The dividend is payable on July 28, 2017, to shareowners of record on July 7, 2017. |
INCOME TAXES |
9 Months Ended |
---|---|
May 31, 2017 | |
Income Tax Disclosure [Abstract] | |
INCOME TAXES | INCOME TAXES Monsanto recorded a discrete tax benefit of $50 million in the first nine months of fiscal 2017, primarily as a result of favorable adjustments to Monsanto’s tax returns filed during the year. Monsanto recorded a discrete tax expense of $146 million in the first nine months of fiscal 2016, primarily as a result of establishing a valuation allowance on Argentina’s deferred tax assets, offset by favorable adjustments to Monsanto’s tax returns filed during the year. |
RESTRUCTURING (Tables) |
9 Months Ended | 21 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 31, 2017 |
May 31, 2017 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring and Related Activities [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring and Related Costs | Restructuring charges were recorded in the Statements of Consolidated Operations as follows:
|
The following tables display the pretax charges incurred by segment under the 2015 Restructuring Plan.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Restructuring Reserve by Type of Cost | The following table summarizes the activities related to the company’s 2015 Restructuring Plan.
(2) The restructuring liability balance included $1 million that was recorded in long-term restructuring reserves in the Statement of Consolidated Financial Position as of May 31, 2017. |
CUSTOMER FINANCING PROGRAMS (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CUSTOMER FINANCING PROGRAMS [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Customer Financing Programs | Monsanto participates in customer financing programs as follows:
The gross amounts of receivables sold under transactions that qualify for sales treatment were:
|
VARIABLE INTEREST ENTITIES (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 31, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Equity Method Investments and Joint Ventures [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Equity Method Investments and Cost Method Investments | For such investments that were accounted for under the equity method and cost basis included in other assets in the Statements of Consolidated Financial Position, the amounts are summarized in the following table:
|
RECEIVABLES (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Receivables [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Allowance For Doubtful Long Term Receivables | The following table displays a roll forward of the allowance for credit losses related to long-term customer receivables.
(1)Includes reclassifications from the allowance for current receivables and foreign currency translation adjustments. |
INVENTORY (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Components of Inventory | Components of inventory are:
|
GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net Carrying Amount of Goodwill | Changes in the net carrying amount of goodwill for the first nine months of fiscal year 2017, by segment, are as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Intangible Assets Information | Information regarding the company’s other intangible assets is as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Intangible Assets Future Amortization Expense | The estimated intangible asset amortization expense for fiscal year 2017 through fiscal year 2021 is as follows:
|
FAIR VALUE MEASUREMENTS (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 31, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assets and Liabilities Measured at Fair Value on a Recurring Basis | The following tables set forth by level Monsanto’s assets and liabilities disclosed at fair value on a recurring basis as of May 31, 2017, and Aug. 31, 2016. As required by the Fair Value Measurements and Disclosures topic of the ASC, assets and liabilities are classified in their entirety based on the lowest level of input that is a significant component of the fair value measurement. Monsanto’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the classification of fair value assets and liabilities within the fair value hierarchy levels.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Level 3 Rollforward | The following table summarizes the change in fair value of the Level 3 long-term debt instrument for the nine months ended May 31, 2017.
The following table summarizes the change in fair value of the Level 3 short-term debt instrument for the nine months ended May 31, 2017.
|
FINANCIAL INSTRUMENTS (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Instruments (Notional Amounts) | The notional amounts of the company’s derivative instruments outstanding as of May 31, 2017, and Aug. 31, 2016, are as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Values of Derivative Instruments | The net presentation of the company’s derivative instruments outstanding was as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gains Losses of Derivative Instruments | The gains and losses on the company’s derivative instruments were as follows:
|
POSTRETIREMENT BENEFITS - PENSIONS, HEALTH CARE AND OTHER (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Compensation and Retirement Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Components of Net Periodic Benefit Cost |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net Periodic Cost Postretirement |
|
STOCK BASED COMPENSATION PLANS (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 31, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Components of Stock Based Compensation | The following table shows total stock-based compensation expense included in the Statements of Consolidated Operations for the three and nine months ended May 31, 2017, and May 31, 2016.
|
ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Components of Accumulated Other Comprehensive Income | The following table sets forth the after-tax components of accumulated other comprehensive loss and changes thereto:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] | The following table provides additional information regarding items reclassified out of accumulated other comprehensive loss into earnings.
|
EARNINGS PER SHARE (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Basic Earnings Per Share Table |
|
SUPPLEMENTAL CASH FLOW INFORMATION SUPPLEMENTAL CASH FLOW INFORMATION (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||
Supplemental Cash Flow Information [Abstract] | |||||||||||||||||||||||||||||||||||||||||||
Cash Payments For Interest And Taxes | Cash payments for interest and taxes were as follows:
|
SEGMENT AND GEOGRAPHIC DATA (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Operating Segment Information | Data for the Seeds and Genomics and Agricultural Productivity reportable segments, as well as for Monsanto’s significant operating segments, is presented in the table as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The reconciliation of EBIT to Net Income | A reconciliation of EBIT to net income attributable to Monsanto Company for each period is as follows:
|
BACKGROUND AND BASIS OF PRESENTATION (Details) $ in Millions |
9 Months Ended | ||||
---|---|---|---|---|---|
Oct. 01, 2008 |
May 31, 2017
USD ($)
segment
|
May 31, 2016
USD ($)
|
Aug. 31, 2016
USD ($)
|
Nov. 02, 2015
USD ($)
|
|
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Gain on disposal | $ 88 | $ 31 | |||
Number of Reportable Segments | segment | 2 | ||||
Earn-out period, length of time | 10 years | ||||
Precision Planting [Member] | Disposal Group, Held-for-sale, Not Discontinued Operations [Member] | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Consideration | $ 190 | ||||
Silthiofam [Member] | Disposal Group, Held-for-sale, Not Discontinued Operations [Member] | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Cash proceeds | $ 140 | ||||
Gain on disposal | 85 | ||||
Disposal Group, Not Discontinued Operation, Carrying Amount Of Assets Sold | 2 | ||||
Disposal Group, Not Discontinued Operation, Contingent Consideration, Liability | 55 | ||||
Other Current Assets [Member] | Precision Planting [Member] | Disposal Group, Held-for-sale, Not Discontinued Operations [Member] | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Assets | 171 | $ 172 | |||
Other Current Liabilities [Member] | Precision Planting [Member] | Disposal Group, Held-for-sale, Not Discontinued Operations [Member] | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Liabilities | $ 9 | $ 12 |
RESTRUCTURING - Schedule of restructuring charges recored in the statement of consolidated operations (Details) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | ||||||
---|---|---|---|---|---|---|---|---|
May 31, 2017 |
May 31, 2016 |
May 31, 2017 |
May 31, 2016 |
Aug. 31, 2016 |
||||
Restructuring Cost and Reserve [Line Items] | ||||||||
Restructuring charges | $ 17 | $ (15) | $ 30 | $ (290) | ||||
Restructuring charge reversal | 17 | 30 | ||||||
Long-Term Restructuring Reserves | 10 | 10 | $ 17 | |||||
Cost of Sales [Member] | ||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||
Restructuring charges | [1] | (14) | (1) | (21) | (53) | |||
Restructuring Charges [Member] | ||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||
Restructuring charges | [1] | 17 | (15) | 30 | (290) | |||
Income (Loss) from Continuing Operations before Income Taxes [Member] | ||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||
Restructuring charges | 3 | (16) | 9 | (343) | ||||
Income Tax (Expense) Benefit [Member] | ||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||
Restructuring charges | (3) | 7 | 2 | 118 | ||||
Net Income (Loss) [Member] | ||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||
Restructuring charges | 0 | (9) | 11 | (225) | ||||
Seeds And Genomics [Member] | ||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||
Restructuring charge reversal | 15 | 27 | ||||||
Seeds And Genomics [Member] | Cost of Sales [Member] | ||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||
Restructuring charges | (14) | (1) | (20) | (53) | ||||
Seeds And Genomics [Member] | Restructuring Charges [Member] | ||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||
Restructuring charges | (13) | (259) | ||||||
Agricultural Productivity [Member] | ||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||
Restructuring charge reversal | $ 2 | 3 | ||||||
Agricultural Productivity [Member] | Cost of Sales [Member] | ||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||
Restructuring charges | $ (1) | |||||||
Agricultural Productivity [Member] | Restructuring Charges [Member] | ||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||
Restructuring charges | $ (2) | $ (31) | ||||||
|
RESTRUCTURING - Pretax restructuring charges related to 2015 restructuring (Details) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | 12 Months Ended | 21 Months Ended | ||
---|---|---|---|---|---|---|
May 31, 2017 |
May 31, 2016 |
May 31, 2017 |
May 31, 2016 |
Aug. 31, 2016 |
May 31, 2017 |
|
Restructuring Cost and Reserve [Line Items] | ||||||
Restructuring charges | $ (17) | $ 15 | $ (30) | $ 290 | ||
Restructuring Plan 2015 [Member] | ||||||
Restructuring Cost and Reserve [Line Items] | ||||||
Restructuring charges | (3) | 16 | (9) | 343 | $ 364 | $ 848 |
Employee Severance [Member] | Restructuring Plan 2015 [Member] | ||||||
Restructuring Cost and Reserve [Line Items] | ||||||
Restructuring charges | (26) | (4) | (62) | 213 | 189 | 344 |
Facility Closing [Member] | Restructuring Plan 2015 [Member] | ||||||
Restructuring Cost and Reserve [Line Items] | ||||||
Restructuring charges | 3 | 5 | 14 | 11 | $ 28 | 42 |
Impairment in value of Property, Plant and Equipment [Member] | Restructuring Plan 2015 [Member] | ||||||
Restructuring Cost and Reserve [Line Items] | ||||||
Restructuring charges | 6 | 11 | 26 | 40 | 150 | |
Inventory Valuation and Obsolescence [Member] | Restructuring Plan 2015 [Member] | ||||||
Restructuring Cost and Reserve [Line Items] | ||||||
Restructuring charges | 10 | 1 | 10 | 38 | 103 | |
Goodwill and Other Assets [Member] | Restructuring Plan 2015 [Member] | ||||||
Restructuring Cost and Reserve [Line Items] | ||||||
Restructuring charges | 4 | 3 | 3 | 41 | 209 | |
Seeds And Genomics [Member] | Restructuring Plan 2015 [Member] | ||||||
Restructuring Cost and Reserve [Line Items] | ||||||
Restructuring charges | (1) | 14 | (7) | 312 | 800 | |
Seeds And Genomics [Member] | Employee Severance [Member] | Restructuring Plan 2015 [Member] | ||||||
Restructuring Cost and Reserve [Line Items] | ||||||
Restructuring charges | (24) | (4) | (58) | 204 | 325 | |
Seeds And Genomics [Member] | Facility Closing [Member] | Restructuring Plan 2015 [Member] | ||||||
Restructuring Cost and Reserve [Line Items] | ||||||
Restructuring charges | 3 | 5 | 13 | 11 | 36 | |
Seeds And Genomics [Member] | Impairment in value of Property, Plant and Equipment [Member] | Restructuring Plan 2015 [Member] | ||||||
Restructuring Cost and Reserve [Line Items] | ||||||
Restructuring charges | 6 | 9 | 25 | 38 | 147 | |
Seeds And Genomics [Member] | Inventory Valuation and Obsolescence [Member] | Restructuring Plan 2015 [Member] | ||||||
Restructuring Cost and Reserve [Line Items] | ||||||
Restructuring charges | 10 | 1 | 10 | 38 | 103 | |
Seeds And Genomics [Member] | Goodwill and Other Assets [Member] | Restructuring Plan 2015 [Member] | ||||||
Restructuring Cost and Reserve [Line Items] | ||||||
Restructuring charges | 4 | 3 | 3 | 21 | 189 | |
Agricultural Productivity [Member] | Restructuring Plan 2015 [Member] | ||||||
Restructuring Cost and Reserve [Line Items] | ||||||
Restructuring charges | (2) | 2 | (2) | 31 | 48 | |
Agricultural Productivity [Member] | Employee Severance [Member] | Restructuring Plan 2015 [Member] | ||||||
Restructuring Cost and Reserve [Line Items] | ||||||
Restructuring charges | (2) | 0 | (4) | 9 | 19 | |
Agricultural Productivity [Member] | Facility Closing [Member] | Restructuring Plan 2015 [Member] | ||||||
Restructuring Cost and Reserve [Line Items] | ||||||
Restructuring charges | 0 | 0 | 1 | 0 | 6 | |
Agricultural Productivity [Member] | Impairment in value of Property, Plant and Equipment [Member] | Restructuring Plan 2015 [Member] | ||||||
Restructuring Cost and Reserve [Line Items] | ||||||
Restructuring charges | 0 | 2 | 1 | 2 | 3 | |
Agricultural Productivity [Member] | Inventory Valuation and Obsolescence [Member] | Restructuring Plan 2015 [Member] | ||||||
Restructuring Cost and Reserve [Line Items] | ||||||
Restructuring charges | 0 | 0 | 0 | 0 | 0 | |
Agricultural Productivity [Member] | Goodwill and Other Assets [Member] | Restructuring Plan 2015 [Member] | ||||||
Restructuring Cost and Reserve [Line Items] | ||||||
Restructuring charges | $ 0 | $ 0 | $ 0 | $ 20 | $ 20 |
RESTRUCTURING - Restructuring Charges by Activity (Details) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | 12 Months Ended | 21 Months Ended | |||||
---|---|---|---|---|---|---|---|---|---|
May 31, 2017 |
May 31, 2016 |
May 31, 2017 |
May 31, 2016 |
Aug. 31, 2016 |
May 31, 2017 |
||||
Restructuring Reserve [Roll Forward] | |||||||||
Restructuring charges | $ (17) | $ 15 | $ (30) | $ 290 | |||||
Long-Term Restructuring Reserves | 10 | 10 | $ 17 | $ 10 | |||||
Restructuring Plan 2015 [Member] | |||||||||
Restructuring Reserve [Roll Forward] | |||||||||
Beginning balance | 244 | 217 | 217 | ||||||
Restructuring charges | (3) | 16 | (9) | 343 | 364 | 848 | |||
Cash Payments | (116) | (192) | |||||||
Asset impairments and write-offs | (39) | (147) | |||||||
Foreign Currency Impact | (2) | 2 | |||||||
Ending balance | 78 | 78 | 244 | 78 | |||||
Employee Severance [Member] | Restructuring Plan 2015 [Member] | |||||||||
Restructuring Reserve [Roll Forward] | |||||||||
Beginning balance | [1] | 244 | 217 | 217 | |||||
Restructuring charges | (26) | (4) | (62) | 213 | 189 | 344 | |||
Cash Payments | (105) | (164) | |||||||
Asset impairments and write-offs | 0 | 0 | |||||||
Foreign Currency Impact | (2) | 2 | |||||||
Ending balance | [1] | 75 | 75 | 244 | 75 | ||||
Long-Term Restructuring Reserves | 10 | 10 | 17 | 10 | |||||
Facility Closing [Member] | Restructuring Plan 2015 [Member] | |||||||||
Restructuring Reserve [Roll Forward] | |||||||||
Beginning balance | 0 | 0 | 0 | ||||||
Restructuring charges | 3 | $ 5 | 14 | 11 | 28 | 42 | |||
Cash Payments | (11) | (28) | |||||||
Asset impairments and write-offs | 0 | 0 | |||||||
Foreign Currency Impact | 0 | 0 | |||||||
Ending balance | 3 | 3 | 0 | 3 | |||||
Long-Term Restructuring Reserves | 1 | 1 | 1 | ||||||
Impairment Of Asset [Member] | Restructuring Plan 2015 [Member] | |||||||||
Restructuring Reserve [Roll Forward] | |||||||||
Beginning balance | 0 | $ 0 | 0 | ||||||
Restructuring charges | 39 | 147 | |||||||
Cash Payments | 0 | 0 | |||||||
Asset impairments and write-offs | (39) | (147) | |||||||
Foreign Currency Impact | 0 | 0 | |||||||
Ending balance | $ 0 | $ 0 | $ 0 | $ 0 | |||||
|
RESTRUCTURING - Narrative (Details) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | 12 Months Ended | 21 Months Ended | |||||
---|---|---|---|---|---|---|---|---|---|
May 31, 2017 |
May 31, 2016 |
May 31, 2017 |
May 31, 2016 |
Aug. 31, 2016 |
May 31, 2017 |
||||
Restructuring Cost and Reserve [Line Items] | |||||||||
Long-Term Restructuring Reserves | $ 10 | $ 10 | $ 17 | $ 10 | |||||
Restructuring charges | 17 | $ (15) | 30 | $ (290) | |||||
Restructuring charge reversal | 17 | 30 | |||||||
Cost of Sales [Member] | |||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||
Restructuring charges | [1] | (14) | (1) | (21) | (53) | ||||
Restructuring Charges [Member] | |||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||
Restructuring charges | [1] | 17 | (15) | 30 | (290) | ||||
Income (Loss) from Continuing Operations before Income Taxes [Member] | |||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||
Restructuring charges | 3 | (16) | 9 | (343) | |||||
Restructuring Plan 2015 [Member] | |||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||
Restructuring charges | 3 | (16) | 9 | (343) | (364) | (848) | |||
Employee Severance [Member] | Restructuring Plan 2015 [Member] | |||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||
Long-Term Restructuring Reserves | 10 | 10 | 17 | 10 | |||||
Restructuring charges | 26 | 4 | 62 | (213) | (189) | (344) | |||
Restructuring charge reversal | 34 | 8 | 91 | 20 | |||||
Facility Closing [Member] | Restructuring Plan 2015 [Member] | |||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||
Long-Term Restructuring Reserves | 1 | 1 | 1 | ||||||
Restructuring charges | (3) | (5) | (14) | (11) | (28) | (42) | |||
Impairment Of Asset [Member] | Restructuring Plan 2015 [Member] | |||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||
Restructuring charges | (39) | $ (147) | |||||||
Impairment in value of Property, Plant and Equipment [Member] | Restructuring Plan 2015 [Member] | |||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||
Restructuring charges | (6) | (11) | (26) | (40) | (150) | ||||
Inventory Valuation and Obsolescence [Member] | Restructuring Plan 2015 [Member] | |||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||
Restructuring charges | (10) | (1) | (10) | (38) | (103) | ||||
Minimum [Member] | Restructuring Plan 2015 [Member] | |||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||
Estimated restructuring charges | 925 | 925 | 925 | ||||||
Minimum [Member] | Employee Severance [Member] | Restructuring Plan 2015 [Member] | |||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||
Estimated restructuring charges | 350 | 350 | 350 | ||||||
Minimum [Member] | Facility Closing [Member] | Restructuring Plan 2015 [Member] | |||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||
Estimated restructuring charges | 95 | 95 | 95 | ||||||
Minimum [Member] | Impairment Of Asset [Member] | Restructuring Plan 2015 [Member] | |||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||
Estimated restructuring charges | 480 | 480 | 480 | ||||||
Maximum [Member] | Restructuring Plan 2015 [Member] | |||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||
Estimated restructuring charges | 1,000 | 1,000 | 1,000 | ||||||
Maximum [Member] | Employee Severance [Member] | Restructuring Plan 2015 [Member] | |||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||
Estimated restructuring charges | 370 | 370 | 370 | ||||||
Maximum [Member] | Facility Closing [Member] | Restructuring Plan 2015 [Member] | |||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||
Estimated restructuring charges | 115 | 115 | 115 | ||||||
Maximum [Member] | Impairment Of Asset [Member] | Restructuring Plan 2015 [Member] | |||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||
Estimated restructuring charges | 515 | 515 | 515 | ||||||
Seeds And Genomics [Member] | |||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||
Restructuring charge reversal | 15 | 27 | |||||||
Seeds And Genomics [Member] | Cost of Sales [Member] | |||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||
Restructuring charges | (14) | (1) | (20) | (53) | |||||
Seeds And Genomics [Member] | Restructuring Charges [Member] | |||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||
Restructuring charges | (13) | (259) | |||||||
Seeds And Genomics [Member] | Restructuring Plan 2015 [Member] | |||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||
Restructuring charges | 1 | (14) | 7 | (312) | (800) | ||||
Seeds And Genomics [Member] | Employee Severance [Member] | Restructuring Plan 2015 [Member] | |||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||
Restructuring charges | 24 | 4 | 58 | (204) | (325) | ||||
Seeds And Genomics [Member] | Facility Closing [Member] | Restructuring Plan 2015 [Member] | |||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||
Restructuring charges | (3) | (5) | (13) | (11) | (36) | ||||
Seeds And Genomics [Member] | Impairment in value of Property, Plant and Equipment [Member] | Restructuring Plan 2015 [Member] | |||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||
Restructuring charges | (6) | (9) | (25) | (38) | (147) | ||||
Seeds And Genomics [Member] | Inventory Valuation and Obsolescence [Member] | Restructuring Plan 2015 [Member] | |||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||
Restructuring charges | (10) | (1) | (10) | (38) | (103) | ||||
Agricultural Productivity [Member] | |||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||
Restructuring charge reversal | 2 | 3 | |||||||
Agricultural Productivity [Member] | Cost of Sales [Member] | |||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||
Restructuring charges | (1) | ||||||||
Agricultural Productivity [Member] | Restructuring Charges [Member] | |||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||
Restructuring charges | (2) | (31) | |||||||
Agricultural Productivity [Member] | Restructuring Plan 2015 [Member] | |||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||
Restructuring charges | 2 | (2) | 2 | (31) | (48) | ||||
Agricultural Productivity [Member] | Employee Severance [Member] | Restructuring Plan 2015 [Member] | |||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||
Restructuring charges | 2 | 0 | 4 | (9) | (19) | ||||
Agricultural Productivity [Member] | Facility Closing [Member] | Restructuring Plan 2015 [Member] | |||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||
Restructuring charges | 0 | 0 | (1) | 0 | (6) | ||||
Agricultural Productivity [Member] | Impairment in value of Property, Plant and Equipment [Member] | Restructuring Plan 2015 [Member] | |||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||
Restructuring charges | 0 | (2) | (1) | (2) | (3) | ||||
Agricultural Productivity [Member] | Inventory Valuation and Obsolescence [Member] | Restructuring Plan 2015 [Member] | |||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||
Restructuring charges | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 | ||||
|
CUSTOMER FINANCING PROGRAMS (Details) BRL in Millions, $ in Millions |
3 Months Ended | 9 Months Ended | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 31, 2017
USD ($)
|
May 31, 2016
USD ($)
|
May 31, 2017
USD ($)
|
May 31, 2017
BRL
|
May 31, 2016
USD ($)
|
Aug. 31, 2016
USD ($)
|
||||||||
US agreement to sell trade receivables [Member] | |||||||||||||
Customer Financing Programs [Line Items] | |||||||||||||
Outstanding balance | [1] | $ 171 | $ 171 | $ 511 | |||||||||
Maximum future payout under recourse provisions | [1] | 9 | 9 | 19 | |||||||||
Transactions that Qualify for Sales Treatment | [1] | 151 | $ 151 | 266 | $ 167 | ||||||||
Maximum Amount of Potential Sales of Receivables | 1,500 | ||||||||||||
Other agreements to sell trade receivables [Member] | |||||||||||||
Customer Financing Programs [Line Items] | |||||||||||||
Outstanding balance | [2] | 9 | 9 | 60 | |||||||||
Maximum future payout under recourse provisions | [2] | 3 | 3 | 35 | |||||||||
Transactions that Qualify for Sales Treatment | [2] | 1 | $ 6 | 12 | $ 38 | ||||||||
Agreements With Lenders [Member] | |||||||||||||
Customer Financing Programs [Line Items] | |||||||||||||
Outstanding balance | [3] | 95 | 95 | 73 | |||||||||
Maximum future payout under recourse provisions | [3] | $ 64 | 64 | $ 57 | |||||||||
Brazil Revolving Financing Program [Member] | |||||||||||||
Customer Financing Programs [Line Items] | |||||||||||||
Maximum Amount of Potential Sales of Receivables | $ 108 | BRL 350 | |||||||||||
|
VARIABLE INTEREST ENTITIES - Narrative (Details) |
9 Months Ended | 12 Months Ended |
---|---|---|
May 31, 2017 |
Aug. 31, 2016 |
|
Revolving Financing Programs [Line Items] | ||
Variable Interest Entity, Financial or Other Support, Percentage | 11.10% | |
Senior Interest [Member] | ||
Revolving Financing Programs [Line Items] | ||
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage | 88.00% | 89.00% |
Monsanto Interest [Member] | ||
Revolving Financing Programs [Line Items] | ||
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage | 12.00% | 11.00% |
VARIABLE INTEREST ENTITIES - Equity Method Investments and Cost Method Investments (Details) - USD ($) $ in Millions |
May 31, 2017 |
Aug. 31, 2016 |
---|---|---|
Equity Method Investments and Joint Ventures [Abstract] | ||
Equity Method Investments | $ 146 | $ 152 |
Cost Basis Investments | 100 | 94 |
Total | $ 246 | $ 246 |
RECEIVABLES (Details) - USD ($) $ in Millions |
9 Months Ended | 12 Months Ended | ||
---|---|---|---|---|
May 31, 2017 |
Aug. 31, 2016 |
|||
Allowance For Doubtful Accounts Current [Abstract] | ||||
Net allowances | $ 116 | $ 94 | ||
Allowance for Doubtful Accounts Receivable [Roll Forward] | ||||
Beginning Balance | 228 | 120 | ||
Incremental Provision | 17 | 78 | ||
Recoveries | (31) | (2) | ||
Write-offs | (1) | (4) | ||
Other | [1] | 21 | 36 | |
Ending Balance | 234 | 228 | ||
Long Term Receivables [Abstract] | ||||
Long term customer receivables, gross | $ 351 | $ 260 | ||
|
INVENTORY (Details) - USD ($) $ in Millions |
May 31, 2017 |
Aug. 31, 2016 |
---|---|---|
Inventory Disclosure [Abstract] | ||
Finished Goods | $ 1,564 | $ 1,404 |
Goods In Process | 1,316 | 1,489 |
Raw Materials and Supplies | 466 | 498 |
Inventory at FIFO Cost | 3,346 | 3,391 |
Excess of FIFO over LIFO Cost | (157) | (150) |
Total | $ 3,189 | $ 3,241 |
GOODWILL AND OTHER INTANGIBLE ASSETS Schedule of net carrying amount of goodwill (Details) $ in Millions |
9 Months Ended |
---|---|
May 31, 2017
USD ($)
| |
Goodwill [Roll Forward] | |
Balance as of Aug. 31, 2016 | $ 4,020 |
Effect of foreign currency translation and other adjustments | 12 |
Balance as of May 31, 2017 | 4,032 |
Seeds And Genomics [Member] | |
Goodwill [Roll Forward] | |
Balance as of Aug. 31, 2016 | 3,967 |
Effect of foreign currency translation and other adjustments | 14 |
Balance as of May 31, 2017 | 3,981 |
Agricultural Productivity [Member] | |
Goodwill [Roll Forward] | |
Balance as of Aug. 31, 2016 | 53 |
Effect of foreign currency translation and other adjustments | (2) |
Balance as of May 31, 2017 | $ 51 |
GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS Information of other intangible assets (Details) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | |||
---|---|---|---|---|---|
May 31, 2017 |
May 31, 2016 |
May 31, 2017 |
May 31, 2016 |
Aug. 31, 2016 |
|
Acquired Finite-Lived Intangible Assets [Line Items] | |||||
Carrying Amount | $ 2,831 | $ 2,831 | $ 2,812 | ||
Accumulated Amortization | (1,878) | (1,878) | (1,779) | ||
Net | 953 | 953 | 1,033 | ||
Total Other Intangible Assets, Carrying Amount | 2,923 | 2,923 | 2,904 | ||
Total Other Intangible Assets, net | 1,045 | 1,045 | 1,125 | ||
Amortization expense | 36 | $ 29 | 110 | $ 88 | |
Acquired Intellectual Property [Member] | |||||
Acquired Finite-Lived Intangible Assets [Line Items] | |||||
Carrying Amount | 1,073 | 1,073 | 1,042 | ||
Accumulated Amortization | (654) | (654) | (593) | ||
Net | 419 | 419 | 449 | ||
Acquired Germplasm [Member] | |||||
Acquired Finite-Lived Intangible Assets [Line Items] | |||||
Carrying Amount | 1,070 | 1,070 | 1,070 | ||
Accumulated Amortization | (801) | (801) | (778) | ||
Net | 269 | 269 | 292 | ||
Trademarks [Member] | |||||
Acquired Finite-Lived Intangible Assets [Line Items] | |||||
Carrying Amount | 334 | 334 | 334 | ||
Accumulated Amortization | (165) | (165) | (152) | ||
Net | 169 | 169 | 182 | ||
Customer Relationships [Member] | |||||
Acquired Finite-Lived Intangible Assets [Line Items] | |||||
Carrying Amount | 286 | 286 | 301 | ||
Accumulated Amortization | (220) | (220) | (223) | ||
Net | 66 | 66 | 78 | ||
Other Intangible Assets [Member] | |||||
Acquired Finite-Lived Intangible Assets [Line Items] | |||||
Carrying Amount | 68 | 68 | 65 | ||
Accumulated Amortization | (38) | (38) | (33) | ||
Net | 30 | 30 | 32 | ||
In Process Research and Development [Member] | |||||
Acquired Finite-Lived Intangible Assets [Line Items] | |||||
In Process Research & Development, Indefinite Lives | $ 92 | $ 92 | $ 92 |
GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS Schedule of estimated amortization expense (Details) $ in Millions |
May 31, 2017
USD ($)
|
---|---|
Goodwill and Intangible Assets Disclosure [Abstract] | |
2017 | $ 147 |
2018 | 120 |
2019 | 111 |
2020 | 108 |
2021 | $ 106 |
DEBT AND OTHER CREDIT ARRANGEMENTS (Details) - USD ($) |
May 31, 2017 |
Oct. 31, 2016 |
Aug. 31, 2016 |
Apr. 30, 2016 |
||||||
---|---|---|---|---|---|---|---|---|---|---|
Debt Instrument [Line Items] | ||||||||||
Shelf registration, maximum aggregate amount | $ 6,000,000,000 | |||||||||
Commercial paper outstanding | $ 1,212,000,000 | $ 500,000,000 | ||||||||
Short-term Debt, Fair Value | [1] | 2,621,000,000 | 1,589,000,000 | |||||||
Long-term Debt, Fair Value | 7,483,000,000 | [1] | $ 7,834,000,000 | [2] | ||||||
Line of Credit [Member] | Revolving Credit Facility [Member] | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Credit facility, maximum borrowing capacity | 3,000,000,000 | |||||||||
Line of Credit Facility, Fair Value of Amount Outstanding | 0 | |||||||||
Line of Credit [Member] | Term Loan Facility [Member] | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Credit facility, maximum borrowing capacity | $ 1,000,000,000 | |||||||||
Line of credit outstanding | $ 500,000,000 | |||||||||
|
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS Fair Value Hierarchy Levels (Details) - USD ($) $ in Millions |
9 Months Ended | ||||||||
---|---|---|---|---|---|---|---|---|---|
May 31, 2017 |
May 31, 2016 |
Aug. 31, 2016 |
|||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||||||||
Cash equivalents | $ 1,243 | $ 1,081 | |||||||
Short-term investments | 6 | 60 | |||||||
Equity securities | 10 | 13 | |||||||
Foreign currency contracts | 23 | 10 | |||||||
Commodity contracts | 31 | 18 | |||||||
Total Assets at Fair Value | 1,313 | 1,182 | |||||||
Foreign currency contracts | 9 | 15 | |||||||
Commodity contracts | 16 | 52 | |||||||
Short-term Debt, Fair Value | [1] | 2,621 | 1,589 | ||||||
Long-term Debt, Fair Value | 7,483 | [1] | 7,834 | [2] | |||||
Interest rate contracts | 41 | ||||||||
Total Liabilities Recorded and Not Recorded at Fair Value | 10,129 | 9,531 | |||||||
Liabilities, Fair Value Adjustment | 0 | $ 0 | |||||||
Fair Value, Inputs, Level 1 [Member] | |||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||||||||
Cash equivalents | 1,243 | 1,081 | |||||||
Short-term investments | 6 | 60 | |||||||
Equity securities | 10 | 13 | |||||||
Foreign currency contracts | 0 | 0 | |||||||
Commodity contracts | 27 | 9 | |||||||
Total Assets at Fair Value | 1,286 | 1,163 | |||||||
Foreign currency contracts | 0 | 0 | |||||||
Commodity contracts | 10 | 32 | |||||||
Short-term Debt, Fair Value | 0 | [1] | 0 | ||||||
Long-term Debt, Fair Value | 0 | [1] | 0 | [2] | |||||
Interest rate contracts | 0 | ||||||||
Total Liabilities Recorded and Not Recorded at Fair Value | 10 | 32 | |||||||
Fair Value, Inputs, Level 2 [Member] | |||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||||||||
Cash equivalents | 0 | 0 | |||||||
Short-term investments | 0 | 0 | |||||||
Equity securities | 0 | 0 | |||||||
Foreign currency contracts | 23 | 10 | |||||||
Commodity contracts | 4 | 9 | |||||||
Total Assets at Fair Value | 27 | 19 | |||||||
Foreign currency contracts | 9 | 15 | |||||||
Commodity contracts | 6 | 20 | |||||||
Short-term Debt, Fair Value | 2,621 | [1] | 1,476 | ||||||
Long-term Debt, Fair Value | 7,385 | [1] | 7,834 | [2] | |||||
Interest rate contracts | 41 | ||||||||
Total Liabilities Recorded and Not Recorded at Fair Value | 10,021 | 9,386 | |||||||
Fair Value, Inputs, Level 3 [Member] | |||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||||||||
Cash equivalents | 0 | 0 | |||||||
Short-term investments | 0 | 0 | |||||||
Equity securities | 0 | 0 | |||||||
Foreign currency contracts | 0 | 0 | |||||||
Commodity contracts | 0 | 0 | |||||||
Total Assets at Fair Value | 0 | 0 | |||||||
Foreign currency contracts | 0 | 0 | |||||||
Commodity contracts | 0 | 0 | |||||||
Short-term Debt, Fair Value | 0 | [1] | 113 | ||||||
Long-term Debt, Fair Value | 98 | [1] | 0 | [2] | |||||
Interest rate contracts | 0 | ||||||||
Total Liabilities Recorded and Not Recorded at Fair Value | $ 98 | $ 113 | |||||||
|
FAIR VALUE MEASUREMENTS Summary of the Change in Level 3 Liability (Details) $ / shares in Units, $ in Millions |
9 Months Ended | ||||||||
---|---|---|---|---|---|---|---|---|---|
May 31, 2017
USD ($)
$ / shares
shares
|
May 31, 2017
BRL / shares
shares
|
Aug. 31, 2016
$ / shares
shares
|
Aug. 31, 2016
BRL / shares
shares
|
||||||
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | |||||||||
Mandatorily Redeemable Shares Outstanding | shares | 315,000 | 315,000 | 350,000 | 350,000 | |||||
Mandatorily Redeemable Shares, Par Value | (per share) | $ 308 | BRL 1,000 | $ 309 | BRL 1,000 | |||||
Long-term Debt [Member] | |||||||||
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | |||||||||
Beginning Balance | [1] | $ 0 | |||||||
Reclassification | 93 | ||||||||
Accretion expense | 6 | ||||||||
Payments | (5) | ||||||||
Effect of foreign currency translation adjustments | 4 | ||||||||
Ending Balance | [1] | 98 | |||||||
Short-term Debt [Member] | |||||||||
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | |||||||||
Beginning Balance | 113 | ||||||||
Reclassification | (103) | ||||||||
Accretion expense | 2 | ||||||||
Payments | (7) | ||||||||
Effect of foreign currency translation adjustments | (5) | ||||||||
Ending Balance | [2] | $ 0 | |||||||
|
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS - Narrative (Details) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | 12 Months Ended | 21 Months Ended | ||||||
---|---|---|---|---|---|---|---|---|---|---|
May 31, 2017 |
May 31, 2016 |
May 31, 2017 |
May 31, 2016 |
Aug. 31, 2016 |
May 31, 2017 |
Feb. 29, 2016 |
||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Restructuring charges | $ 17 | $ (15) | $ 30 | $ (290) | ||||||
Restructuring charge reversal | 17 | 30 | ||||||||
Property, Plant and Equipment, Net | 5,500 | 5,500 | $ 5,231 | $ 5,500 | ||||||
Other Intangible Assets, Net | 1,045 | 1,045 | 1,125 | 1,045 | ||||||
Restructuring Charges [Member] | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Restructuring charges | [1] | 17 | (15) | 30 | (290) | |||||
Cost of Sales [Member] | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Restructuring charges | [1] | (14) | (1) | (21) | (53) | |||||
Seeds And Genomics [Member] | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Restructuring charge reversal | 15 | 27 | ||||||||
Seeds And Genomics [Member] | Impairment Of Asset [Member] | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Other Intangible Assets, Net | 3 | 3 | 19 | |||||||
Seeds And Genomics [Member] | Estimate of Fair Value Measurement [Member] | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Other Intangible Assets, Net | 1 | 1 | $ 1 | |||||||
Seeds And Genomics [Member] | Property, Plant and Equipment [Member] | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Asset Impairment Charges | 6 | 9 | 17 | 38 | ||||||
Seeds And Genomics [Member] | Other Intangible Assets [Member] | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Asset Impairment Charges | 3 | 19 | ||||||||
Seeds And Genomics [Member] | Cost of Goods Sold [Member] | Property, Plant and Equipment [Member] | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Asset Impairment Charges | 15 | |||||||||
Seeds And Genomics [Member] | Restructuring Charges [Member] | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Restructuring charges | (13) | (259) | ||||||||
Seeds And Genomics [Member] | Restructuring Charges [Member] | Property, Plant and Equipment [Member] | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Asset Impairment Charges | 4 | 9 | 11 | 23 | ||||||
Seeds And Genomics [Member] | Restructuring Charges [Member] | Other Intangible Assets [Member] | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Asset Impairment Charges | 3 | 19 | ||||||||
Seeds And Genomics [Member] | Cost of Sales [Member] | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Restructuring charges | (14) | (1) | (20) | (53) | ||||||
Seeds And Genomics [Member] | Cost of Sales [Member] | Property, Plant and Equipment [Member] | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Asset Impairment Charges | 2 | 6 | ||||||||
Agricultural Productivity [Member] | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Restructuring charge reversal | 2 | 3 | ||||||||
Agricultural Productivity [Member] | Impairment Of Asset [Member] | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Other Intangible Assets, Net | 20 | |||||||||
Agricultural Productivity [Member] | Estimate of Fair Value Measurement [Member] | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Other Intangible Assets, Net | 1 | |||||||||
Agricultural Productivity [Member] | Other Intangible Assets [Member] | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Asset Impairment Charges | 20 | |||||||||
Agricultural Productivity [Member] | Restructuring Charges [Member] | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Restructuring charges | (2) | (31) | ||||||||
Agricultural Productivity [Member] | Restructuring Charges [Member] | Other Intangible Assets [Member] | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Asset Impairment Charges | 20 | |||||||||
Agricultural Productivity [Member] | Cost of Sales [Member] | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Restructuring charges | (1) | |||||||||
Restructuring Plan 2015 [Member] | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Restructuring charges | 3 | (16) | 9 | (343) | (364) | (848) | ||||
Restructuring Plan 2015 [Member] | Seeds And Genomics [Member] | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Restructuring charges | 1 | (14) | 7 | (312) | (800) | |||||
Restructuring Plan 2015 [Member] | Agricultural Productivity [Member] | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Restructuring charges | 2 | (2) | 2 | (31) | (48) | |||||
Minimum [Member] | Restructuring Plan 2015 [Member] | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Estimated restructuring charges | 925 | 925 | 925 | |||||||
Maximum [Member] | Restructuring Plan 2015 [Member] | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Estimated restructuring charges | 1,000 | 1,000 | 1,000 | |||||||
Impaired Assets Identified In Current Year To Date | Seeds And Genomics [Member] | Impairment Of Asset [Member] | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Property, Plant and Equipment, Net | 24 | 24 | 24 | |||||||
Impaired Assets Identified In Current Year To Date | Seeds And Genomics [Member] | Estimate of Fair Value Measurement [Member] | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Property, Plant and Equipment, Net | 7 | 7 | 7 | |||||||
Impaired Assets Identified In Current Year To Date | Seeds And Genomics [Member] | Property, Plant and Equipment [Member] | Impairment Of Asset [Member] | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Property, Plant and Equipment, Net | 65 | |||||||||
Impaired Assets Identified In Current Year To Date | Seeds And Genomics [Member] | Property, Plant and Equipment [Member] | Estimate of Fair Value Measurement [Member] | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Property, Plant and Equipment, Net | $ 27 | |||||||||
Impaired Assets Identified In Current Quarter | Seeds And Genomics [Member] | Impairment Of Asset [Member] | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Property, Plant and Equipment, Net | 6 | 6 | 6 | |||||||
Impaired Assets Identified In Current Quarter | Seeds And Genomics [Member] | Estimate of Fair Value Measurement [Member] | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Property, Plant and Equipment, Net | $ 1 | $ 1 | $ 1 | |||||||
Impaired Assets Identified In Current Quarter | Seeds And Genomics [Member] | Property, Plant and Equipment [Member] | Impairment Of Asset [Member] | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Property, Plant and Equipment, Net | 21 | 21 | ||||||||
Impaired Assets Identified In Current Quarter | Seeds And Genomics [Member] | Property, Plant and Equipment [Member] | Estimate of Fair Value Measurement [Member] | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Property, Plant and Equipment, Net | $ 12 | $ 12 | ||||||||
|
FINANCIAL INSTRUMENTS Narrative (Details) - USD ($) |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
May 31, 2017 |
May 31, 2017 |
May 31, 2016 |
Aug. 31, 2016 |
|
Derivatives, Fair Value [Line Items] | ||||
Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months | $ (20,000,000) | |||
Loss on Discontinuation of Cash Flow Hedge Due to Forecasted Transaction Probable of Not Occurring | $ 1,000,000 | $ 1,000,000 | ||
Discontinuation of Cash Flow Hedge | 37,000,000 | |||
subject to master netting arrangement, or similar agreement [Member] | ||||
Derivatives, Fair Value [Line Items] | ||||
Derivative Liability Subject to Master Netting Arrangement, or Similar Agreement | $ 9,000,000 | $ 9,000,000 | $ 63,000,000 | |
Foreign Exchange Contract [Member] | ||||
Derivatives, Fair Value [Line Items] | ||||
Maximum Length of Time Hedged in Cash Flow Hedge | 15 months | |||
Commodity Contracts | ||||
Derivatives, Fair Value [Line Items] | ||||
Maximum Length of Time Hedged in Cash Flow Hedge | 30 months |
FINANCIAL INSTRUMENTS FINANCIAL INSTRUMENTS Notional Amounts of Derivative Instruments Outstanding (Details) - USD ($) $ in Millions |
May 31, 2017 |
Aug. 31, 2016 |
---|---|---|
Designated as Hedging Instrument | ||
Derivatives, Notional [Line Items] | ||
Total Derivatives | $ 871 | $ 1,022 |
Not Designated as Hedging Instrument | ||
Derivatives, Notional [Line Items] | ||
Total Derivatives | 1,848 | 1,435 |
Foreign Exchange Contract [Member] | Designated as Hedging Instrument | ||
Derivatives, Notional [Line Items] | ||
Total Derivatives | 218 | 388 |
Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument | ||
Derivatives, Notional [Line Items] | ||
Total Derivatives | 1,547 | 1,096 |
Commodity Contracts | Designated as Hedging Instrument | ||
Derivatives, Notional [Line Items] | ||
Total Derivatives | 653 | 484 |
Commodity Contracts | Not Designated as Hedging Instrument | ||
Derivatives, Notional [Line Items] | ||
Total Derivatives | 280 | 223 |
Interest Rate Contracts [Member] | Designated as Hedging Instrument | ||
Derivatives, Notional [Line Items] | ||
Total Derivatives | 0 | 150 |
Interest Rate Contracts [Member] | Not Designated as Hedging Instrument | ||
Derivatives, Notional [Line Items] | ||
Total Derivatives | $ 21 | $ 116 |
FINANCIAL INSTRUMENTS FINANCIAL INSTRUMENTS Fair Value of Derivatives Outstanding (Details) - USD ($) $ in Millions |
May 31, 2017 |
Aug. 31, 2016 |
|||||||
---|---|---|---|---|---|---|---|---|---|
Derivatives, Fair Value [Line Items] | |||||||||
Derivative Asset, Fair Value, Gross Asset | $ 54 | $ 28 | |||||||
Derivative Asset, Collateral, Obligation to Return Cash, Offset | (10) | (39) | |||||||
Derivative Asset, Fair Value, Amount Offset Against Collateral | 44 | (11) | |||||||
Derivative Asset, Fair Value of Collateral | 1 | 24 | |||||||
Derivative Asset | 45 | 13 | |||||||
Other Assets, Current | 231 | 227 | |||||||
Other Assets, Noncurrent | 512 | 489 | |||||||
Derivative Liability, Fair Value, Gross Liability | 25 | 108 | |||||||
Derivative Liability, Collateral, Right to Reclaim Cash, Offset | (10) | (39) | |||||||
Derivative Liability, Fair Value, Amount Offset Against Collateral | 15 | 69 | |||||||
Derivative Liability, Fair Value of Collateral | 0 | 0 | |||||||
Derivative Liability | 15 | 69 | |||||||
Miscellaneous short-term accruals | 813 | 1,004 | |||||||
Other Liabilities, Noncurrent | 321 | 318 | |||||||
Other Assets | |||||||||
Derivatives, Fair Value [Line Items] | |||||||||
Derivative Asset, Fair Value, Gross Asset | 0 | 0 | |||||||
Derivative Asset, Collateral, Obligation to Return Cash, Offset | (1) | (4) | |||||||
Derivative Asset, Fair Value, Amount Offset Against Collateral | (1) | (4) | |||||||
Derivative Asset, Fair Value of Collateral | 1 | 4 | |||||||
Derivative Asset | 0 | 0 | |||||||
Non-derivative Balances | 512 | 489 | |||||||
Derivative Liability, Fair Value, Gross Liability | 1 | 4 | |||||||
Derivative Liability, Collateral, Right to Reclaim Cash, Offset | (1) | (4) | |||||||
Derivative Liability, Fair Value, Amount Offset Against Collateral | 0 | 0 | |||||||
Derivative Liability, Fair Value of Collateral | 0 | 0 | |||||||
Derivative Liability | 0 | 0 | |||||||
Other current assets | |||||||||
Derivatives, Fair Value [Line Items] | |||||||||
Derivative Asset, Fair Value, Gross Asset | 54 | 28 | |||||||
Derivative Asset, Collateral, Obligation to Return Cash, Offset | (9) | (35) | |||||||
Derivative Asset, Fair Value, Amount Offset Against Collateral | 45 | (7) | |||||||
Derivative Asset, Fair Value of Collateral | 0 | 20 | |||||||
Derivative Asset | 45 | 13 | |||||||
Non-derivative Balances | 186 | 214 | |||||||
Derivative Liability, Fair Value, Gross Liability | 9 | 35 | |||||||
Derivative Liability, Collateral, Right to Reclaim Cash, Offset | (9) | (35) | |||||||
Derivative Liability, Fair Value, Amount Offset Against Collateral | 0 | 0 | |||||||
Derivative Liability, Fair Value of Collateral | 0 | 0 | |||||||
Derivative Liability | 0 | 0 | |||||||
Miscellaneous short term accruals | |||||||||
Derivatives, Fair Value [Line Items] | |||||||||
Non-derivative Balances | 798 | 937 | |||||||
Derivative Liability, Fair Value, Gross Liability | 15 | 67 | |||||||
Derivative Liability, Collateral, Right to Reclaim Cash, Offset | 0 | 0 | |||||||
Derivative Liability, Fair Value, Amount Offset Against Collateral | 15 | 67 | |||||||
Derivative Liability, Fair Value of Collateral | 0 | 0 | |||||||
Derivative Liability | 15 | 67 | |||||||
Other liabilities | |||||||||
Derivatives, Fair Value [Line Items] | |||||||||
Non-derivative Balances | 316 | ||||||||
Derivative Liability, Fair Value, Gross Liability | 2 | ||||||||
Derivative Liability, Collateral, Right to Reclaim Cash, Offset | 0 | ||||||||
Derivative Liability, Fair Value, Amount Offset Against Collateral | 2 | ||||||||
Derivative Liability, Fair Value of Collateral | 0 | ||||||||
Derivative Liability | 2 | ||||||||
Foreign Exchange Contract [Member] | Other current assets | Designated as Hedging Instrument | |||||||||
Derivatives, Fair Value [Line Items] | |||||||||
Derivative Asset, Fair Value, Gross Asset | 2 | 4 | |||||||
Derivative Asset, Collateral, Obligation to Return Cash, Offset | 0 | 0 | |||||||
Derivative Asset, Fair Value, Amount Offset Against Collateral | 2 | 4 | |||||||
Derivative Asset, Fair Value of Collateral | 0 | 0 | |||||||
Derivative Asset | 2 | 4 | |||||||
Foreign Exchange Contract [Member] | Other current assets | Not Designated as Hedging Instrument | |||||||||
Derivatives, Fair Value [Line Items] | |||||||||
Derivative Asset, Fair Value, Gross Asset | 21 | 6 | |||||||
Derivative Asset, Collateral, Obligation to Return Cash, Offset | 0 | 0 | |||||||
Derivative Asset, Fair Value, Amount Offset Against Collateral | 21 | 6 | |||||||
Derivative Asset, Fair Value of Collateral | 0 | 0 | |||||||
Derivative Asset | 21 | 6 | |||||||
Foreign Exchange Contract [Member] | Miscellaneous short term accruals | Designated as Hedging Instrument | |||||||||
Derivatives, Fair Value [Line Items] | |||||||||
Derivative Liability, Fair Value, Gross Liability | 8 | ||||||||
Derivative Liability, Collateral, Right to Reclaim Cash, Offset | 0 | ||||||||
Derivative Liability, Fair Value, Amount Offset Against Collateral | 8 | ||||||||
Derivative Liability, Fair Value of Collateral | 0 | ||||||||
Derivative Liability | 8 | ||||||||
Foreign Exchange Contract [Member] | Miscellaneous short term accruals | Not Designated as Hedging Instrument | |||||||||
Derivatives, Fair Value [Line Items] | |||||||||
Derivative Liability, Fair Value, Gross Liability | 9 | 7 | |||||||
Derivative Liability, Collateral, Right to Reclaim Cash, Offset | 0 | 0 | |||||||
Derivative Liability, Fair Value, Amount Offset Against Collateral | 9 | 7 | |||||||
Derivative Liability, Fair Value of Collateral | 0 | 0 | |||||||
Derivative Liability | 9 | 7 | |||||||
Commodity Contract [Member] | Other Assets | Designated as Hedging Instrument | |||||||||
Derivatives, Fair Value [Line Items] | |||||||||
Derivative Asset, Fair Value, Gross Asset | 0 | 0 | |||||||
Derivative Asset, Collateral, Obligation to Return Cash, Offset | (1) | (4) | |||||||
Derivative Asset, Fair Value, Amount Offset Against Collateral | (1) | (4) | |||||||
Derivative Asset, Fair Value of Collateral | 1 | 4 | |||||||
Derivative Asset | 0 | 0 | |||||||
Derivative Liability, Fair Value, Gross Liability | 1 | [1] | 4 | [2] | |||||
Derivative Liability, Collateral, Right to Reclaim Cash, Offset | (1) | [1] | (4) | [2] | |||||
Derivative Liability, Fair Value, Amount Offset Against Collateral | 0 | [1] | 0 | [2] | |||||
Derivative Liability, Fair Value of Collateral | 0 | [1] | 0 | [2] | |||||
Derivative Liability | 0 | [1] | 0 | [2] | |||||
Commodity Contract [Member] | Other current assets | Designated as Hedging Instrument | |||||||||
Derivatives, Fair Value [Line Items] | |||||||||
Derivative Asset, Fair Value, Gross Asset | 26 | [1] | 9 | [2] | |||||
Derivative Asset, Collateral, Obligation to Return Cash, Offset | (9) | [1] | (29) | [2] | |||||
Derivative Asset, Fair Value, Amount Offset Against Collateral | 17 | [1] | (20) | [2] | |||||
Derivative Asset, Fair Value of Collateral | 0 | [1] | 20 | [2] | |||||
Derivative Asset | 17 | [1] | 0 | [2] | |||||
Derivative Liability, Fair Value, Gross Liability | 9 | [1] | 29 | [2] | |||||
Derivative Liability, Collateral, Right to Reclaim Cash, Offset | (9) | [1] | (29) | [2] | |||||
Derivative Liability, Fair Value, Amount Offset Against Collateral | 0 | [1] | 0 | [2] | |||||
Derivative Liability, Fair Value of Collateral | 0 | [1] | 0 | [2] | |||||
Derivative Liability | 0 | [1] | 0 | [2] | |||||
Commodity Contract [Member] | Other current assets | Not Designated as Hedging Instrument | |||||||||
Derivatives, Fair Value [Line Items] | |||||||||
Derivative Asset, Fair Value, Gross Asset | 5 | [1] | 9 | [2] | |||||
Derivative Asset, Collateral, Obligation to Return Cash, Offset | 0 | [1] | (6) | [2] | |||||
Derivative Asset, Fair Value, Amount Offset Against Collateral | 5 | [1] | 3 | [2] | |||||
Derivative Asset, Fair Value of Collateral | 0 | [1] | 0 | [2] | |||||
Derivative Asset | 5 | [1] | 3 | [2] | |||||
Derivative Liability, Fair Value, Gross Liability | 6 | ||||||||
Derivative Liability, Collateral, Right to Reclaim Cash, Offset | (6) | ||||||||
Derivative Liability, Fair Value, Amount Offset Against Collateral | 0 | ||||||||
Derivative Liability, Fair Value of Collateral | 0 | ||||||||
Derivative Liability | 0 | ||||||||
Commodity Contract [Member] | Miscellaneous short term accruals | Designated as Hedging Instrument | |||||||||
Derivatives, Fair Value [Line Items] | |||||||||
Derivative Liability, Fair Value, Gross Liability | 5 | 11 | |||||||
Derivative Liability, Collateral, Right to Reclaim Cash, Offset | 0 | 0 | |||||||
Derivative Liability, Fair Value, Amount Offset Against Collateral | 5 | 11 | |||||||
Derivative Liability, Fair Value of Collateral | 0 | 0 | |||||||
Derivative Liability | 5 | 11 | |||||||
Commodity Contract [Member] | Miscellaneous short term accruals | Not Designated as Hedging Instrument | |||||||||
Derivatives, Fair Value [Line Items] | |||||||||
Derivative Liability, Fair Value, Gross Liability | [1] | 1 | |||||||
Derivative Liability, Collateral, Right to Reclaim Cash, Offset | [1] | 0 | |||||||
Derivative Liability, Fair Value, Amount Offset Against Collateral | [1] | 1 | |||||||
Derivative Liability, Fair Value of Collateral | [1] | 0 | |||||||
Derivative Liability | [1] | $ 1 | |||||||
Commodity Contract [Member] | Other liabilities | Designated as Hedging Instrument | |||||||||
Derivatives, Fair Value [Line Items] | |||||||||
Derivative Liability, Fair Value, Gross Liability | 2 | ||||||||
Derivative Liability, Collateral, Right to Reclaim Cash, Offset | 0 | ||||||||
Derivative Liability, Fair Value, Amount Offset Against Collateral | 2 | ||||||||
Derivative Liability, Fair Value of Collateral | 0 | ||||||||
Derivative Liability | 2 | ||||||||
Interest Rate Contracts [Member] | Miscellaneous short term accruals | Designated as Hedging Instrument | |||||||||
Derivatives, Fair Value [Line Items] | |||||||||
Derivative Liability, Fair Value, Gross Liability | 41 | ||||||||
Derivative Liability, Collateral, Right to Reclaim Cash, Offset | 0 | ||||||||
Derivative Liability, Fair Value, Amount Offset Against Collateral | 41 | ||||||||
Derivative Liability, Fair Value of Collateral | 0 | ||||||||
Derivative Liability | $ 41 | ||||||||
|
FINANCIAL INSTRUMENTS FINANCIAL INSTRUMENTS Gain (Loss) from Derivatives (Details) - USD ($) |
3 Months Ended | 9 Months Ended | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 31, 2017 |
May 31, 2016 |
May 31, 2017 |
May 31, 2016 |
||||||||||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||||||||||||
Amount of Gain (Loss) Recognized in AOCI (Effective Portion) | $ (19,000,000) | $ 48,000,000 | $ 40,000,000 | $ (4,000,000) | |||||||||||
Amount of Gain (Loss) Recognized in Income | 46,000,000 | (50,000,000) | (32,000,000) | (130,000,000) | |||||||||||
Gain (Loss) from Components Excluded from Assessment of Cash Flow Hedge Effectiveness, Net | 0 | 0 | 0 | 0 | |||||||||||
Discontinuation of Cash Flow Hedge | 37,000,000 | ||||||||||||||
Foreign Currency Transaction Gain (Loss) Realized | 31,000,000 | 19,000,000 | 13,000,000 | 169,000,000 | |||||||||||
Loss on Discontinuation of Cash Flow Hedge Due to Forecasted Transaction Probable of Not Occurring | 1,000,000 | 1,000,000 | |||||||||||||
Designated as Hedging Instrument | |||||||||||||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||||||||||||
Amount of Gain (Loss) Recognized in AOCI (Effective Portion) | (19,000,000) | 48,000,000 | 40,000,000 | (4,000,000) | |||||||||||
Amount of Gain (Loss) Recognized in Income | 24,000,000 | (49,000,000) | (34,000,000) | (107,000,000) | |||||||||||
Not Designated as Hedging Instrument | |||||||||||||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||||||||||||
Amount of Gain (Loss) Recognized in Income | 22,000,000 | (1,000,000) | 2,000,000 | (23,000,000) | |||||||||||
Commodity Contracts | Cost of Sales [Member] | Not Designated as Hedging Instrument | |||||||||||||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||||||||||||
Amount of Gain (Loss) Recognized in Income | 1,000,000 | 0 | 0 | 1,000,000 | |||||||||||
Commodity Contracts | Net Sales [Member] | Not Designated as Hedging Instrument | |||||||||||||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||||||||||||
Amount of Gain (Loss) Recognized in Income | 1,000,000 | 7,000,000 | 1,000,000 | 8,000,000 | |||||||||||
Foreign Exchange Contract [Member] | Other expense, net [Member] | Not Designated as Hedging Instrument | |||||||||||||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||||||||||||
Amount of Gain (Loss) Recognized in Income | [1] | 20,000,000 | (8,000,000) | 1,000,000 | (32,000,000) | ||||||||||
Fair Value Hedges | Commodity Contracts | Cost of Sales [Member] | Designated as Hedging Instrument | |||||||||||||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||||||||||||
Amount of Gain (Loss) Recognized in Income | [2] | 28,000,000 | (20,000,000) | 18,000,000 | (19,000,000) | ||||||||||
Fair Value Hedges | Commodity Contracts | Other expense, net [Member] | Designated as Hedging Instrument | |||||||||||||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||||||||||||
Amount of Gain (Loss) Recognized in Income | 0 | (1,000,000) | 0 | [2] | (1,000,000) | [2] | |||||||||
Cash Flow Hedging [Member] | Commodity Contracts | Cost of Sales [Member] | Designated as Hedging Instrument | |||||||||||||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||||||||||||
Amount of Gain (Loss) Recognized in AOCI (Effective Portion) | [3] | (17,000,000) | 57,000,000 | 12,000,000 | 20,000,000 | ||||||||||
Amount of Gain (Loss) Recognized in Income | [2],[4] | (2,000,000) | (34,000,000) | (17,000,000) | (106,000,000) | ||||||||||
Cash Flow Hedging [Member] | Foreign Exchange Contract [Member] | Cost of Sales [Member] | Designated as Hedging Instrument | |||||||||||||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||||||||||||
Amount of Gain (Loss) Recognized in AOCI (Effective Portion) | [3] | (2,000,000) | (1,000,000) | 5,000,000 | 3,000,000 | ||||||||||
Amount of Gain (Loss) Recognized in Income | [2],[4] | 3,000,000 | 6,000,000 | 5,000,000 | 19,000,000 | ||||||||||
Cash Flow Hedging [Member] | Foreign Exchange Contract [Member] | Net Sales [Member] | Designated as Hedging Instrument | |||||||||||||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||||||||||||
Amount of Gain (Loss) Recognized in AOCI (Effective Portion) | [3] | 0 | (9,000,000) | 20,000,000 | (4,000,000) | ||||||||||
Amount of Gain (Loss) Recognized in Income | [2],[4] | (2,000,000) | 3,000,000 | 8,000,000 | 11,000,000 | ||||||||||
Cash Flow Hedging [Member] | Interest Rate Contracts [Member] | Interest Expense [Member] | Designated as Hedging Instrument | |||||||||||||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||||||||||||
Amount of Gain (Loss) Recognized in AOCI (Effective Portion) | [3] | 0 | 1,000,000 | 3,000,000 | (23,000,000) | ||||||||||
Amount of Gain (Loss) Recognized in Income | [2],[4] | $ (3,000,000) | $ (3,000,000) | (11,000,000) | (11,000,000) | ||||||||||
Cash Flow Hedging [Member] | Interest Rate Contracts [Member] | Other expense, net [Member] | Designated as Hedging Instrument | |||||||||||||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||||||||||||
Amount of Gain (Loss) Recognized in AOCI (Effective Portion) | [2] | 0 | 0 | ||||||||||||
Amount of Gain (Loss) Recognized in Income | [2] | $ (37,000,000) | $ 0 | ||||||||||||
|
POSTRETIREMENT BENEFITS - PENSIONS, HEALTH CARE AND OTHER (Details) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
May 31, 2017 |
May 31, 2016 |
May 31, 2017 |
May 31, 2016 |
|
United States Pension Plans [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Service Cost for Benefits Earned During the Period | $ 16 | $ 19 | $ 46 | $ 51 |
Interest Cost on Benefit Obligation | 20 | 28 | 61 | 77 |
Assumed Return on Plan Assets | (43) | (46) | (128) | (125) |
Amortization of Unrecognized Net Loss (Gain) | 12 | 13 | 35 | 39 |
Defined Benefit Plan, Other Costs | 0 | 0 | ||
Defined Benefit Plan, Recognized Net Gain (Loss) Due to Settlements and Curtailments | 0 | 0 | 0 | 0 |
Defined Benefit Plan, Net Periodic Benefit Cost | 5 | 14 | 14 | 42 |
Foreign Pension Plans [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Service Cost for Benefits Earned During the Period | 3 | 3 | 9 | 9 |
Interest Cost on Benefit Obligation | 1 | 2 | 4 | 5 |
Assumed Return on Plan Assets | (2) | (2) | (6) | (6) |
Amortization of Unrecognized Net Loss (Gain) | 1 | 1 | 3 | 3 |
Defined Benefit Plan, Other Costs | 2 | 1 | ||
Defined Benefit Plan, Recognized Net Gain (Loss) Due to Settlements and Curtailments | 1 | 0 | 1 | 0 |
Defined Benefit Plan, Net Periodic Benefit Cost | 4 | 4 | 13 | 12 |
Pension Plan, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Service Cost for Benefits Earned During the Period | 19 | 22 | 55 | 60 |
Interest Cost on Benefit Obligation | 21 | 30 | 65 | 82 |
Assumed Return on Plan Assets | (45) | (48) | (134) | (131) |
Amortization of Unrecognized Net Loss (Gain) | 13 | 14 | 38 | 42 |
Defined Benefit Plan, Other Costs | 2 | 1 | ||
Defined Benefit Plan, Recognized Net Gain (Loss) Due to Settlements and Curtailments | 1 | 0 | 1 | 0 |
Defined Benefit Plan, Net Periodic Benefit Cost | 9 | 18 | 27 | 54 |
Postretirement and ESOP Liabilities [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Service Cost for Benefits Earned During the Period | 3 | 2 | 5 | 5 |
Interest Cost on Benefit Obligation | 1 | 1 | 4 | 5 |
Amortization of Unrecognized Net Loss (Gain) | 1 | (1) | 4 | (4) |
Defined Benefit Plan, Other Costs | 2 | 0 | ||
Defined Benefit Plan, Net Periodic Benefit Cost | $ 5 | $ 2 | $ 15 | $ 6 |
STOCK BASED COMPENSATION PLANS Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
May 31, 2017 |
May 31, 2016 |
May 31, 2017 |
May 31, 2016 |
|
Cost of Goods Sold [Member] | ||||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||||
Allocated Stock Based Compensation Expense | $ 3 | $ 4 | $ 10 | $ 11 |
Selling, General and Administrative Expenses [Member] | ||||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||||
Allocated Stock Based Compensation Expense | 19 | 11 | 64 | 57 |
Research and Development Expenses [Member] | ||||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||||
Allocated Stock Based Compensation Expense | 6 | 6 | 19 | 22 |
Restructuring Charges [Member] | ||||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||||
Allocated Stock Based Compensation Expense | 0 | 2 | 1 | 2 |
Pre-Tax Stock-Based Compensation Expense [Member] | ||||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||||
Allocated Stock Based Compensation Expense | 28 | 23 | 94 | 92 |
Income Tax Benefit [Member] | ||||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||||
Allocated Stock Based Compensation Expense | (9) | (7) | (32) | (30) |
Net Stock Based Compensation [Member] | ||||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||||
Allocated Stock Based Compensation Expense | $ 19 | $ 16 | $ 62 | $ 62 |
ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | 12 Months Ended | ||||
---|---|---|---|---|---|---|---|
May 31, 2017 |
May 31, 2016 |
May 31, 2017 |
May 31, 2016 |
Aug. 31, 2016 |
|||
Accumulated Other Comprehensive Income (Loss) [Roll Forward] | |||||||
Beginning balance | $ (2,808) | $ (2,801) | $ (2,801) | ||||
Other comprehensive (loss) income before reclassifications | 9 | (92) | |||||
Amounts reclassified from accumulated other comprehensive loss | $ 11 | $ 23 | 64 | 72 | 85 | ||
Total Other Comprehensive Income (Loss), Net of Tax | 82 | 192 | 73 | (58) | (7) | ||
Ending balance | (2,735) | (2,735) | (2,808) | ||||
Other comprehensive (income) loss, reclassification adjustment, available for sale securities, tax | 0 | 0 | (1) | 0 | |||
Realized net derivative (gains) losses, tax (expense) benefit | 2 | 13 | 21 | 39 | |||
Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Tax | (5) | (3) | (16) | (12) | |||
Available-for-sale Securities [Member] | |||||||
Accumulated Other Comprehensive Income (Loss) [Roll Forward] | |||||||
Beginning balance | 1 | 2 | 2 | ||||
Other comprehensive (loss) income before reclassifications | (2) | (2) | |||||
Amounts reclassified from accumulated other comprehensive loss | 0 | 0 | 1 | 0 | 1 | ||
Total Other Comprehensive Income (Loss), Net of Tax | (1) | (1) | |||||
Ending balance | 0 | 0 | 1 | ||||
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax | 0 | 0 | 2 | 0 | |||
Pension Plan, Defined Benefit [Member] | |||||||
Accumulated Other Comprehensive Income (Loss) [Roll Forward] | |||||||
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax | 14 | 11 | 48 | 36 | |||
Accumulated Translation Adjustment [Member] | |||||||
Accumulated Other Comprehensive Income (Loss) [Roll Forward] | |||||||
Beginning balance | (2,292) | (2,327) | (2,327) | ||||
Other comprehensive (loss) income before reclassifications | (15) | 35 | |||||
Amounts reclassified from accumulated other comprehensive loss | 0 | 0 | |||||
Total Other Comprehensive Income (Loss), Net of Tax | (15) | 35 | |||||
Ending balance | (2,307) | (2,307) | (2,292) | ||||
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] | |||||||
Accumulated Other Comprehensive Income (Loss) [Roll Forward] | |||||||
Beginning balance | (177) | (190) | (190) | ||||
Other comprehensive (loss) income before reclassifications | 26 | (42) | |||||
Amounts reclassified from accumulated other comprehensive loss | 2 | 15 | 31 | 48 | 55 | ||
Total Other Comprehensive Income (Loss), Net of Tax | 57 | 13 | |||||
Ending balance | (120) | (120) | (177) | ||||
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax | 4 | 28 | 52 | 87 | |||
Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] | |||||||
Accumulated Other Comprehensive Income (Loss) [Roll Forward] | |||||||
Beginning balance | (340) | (286) | (286) | ||||
Other comprehensive (loss) income before reclassifications | 0 | (83) | |||||
Amounts reclassified from accumulated other comprehensive loss | 9 | 8 | 32 | 24 | 29 | ||
Total Other Comprehensive Income (Loss), Net of Tax | 32 | (54) | |||||
Ending balance | (308) | (308) | $ (340) | ||||
Cost of Sales [Member] | Pension Plan, Defined Benefit [Member] | |||||||
Accumulated Other Comprehensive Income (Loss) [Roll Forward] | |||||||
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax | (3) | (2) | (14) | (12) | |||
Selling, General and Administrative Expenses [Member] | Pension Plan, Defined Benefit [Member] | |||||||
Accumulated Other Comprehensive Income (Loss) [Roll Forward] | |||||||
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax | 9 | 7 | 29 | 24 | |||
Restructuring Charges [Member] | Pension Plan, Defined Benefit [Member] | |||||||
Accumulated Other Comprehensive Income (Loss) [Roll Forward] | |||||||
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax | 0 | 0 | 4 | 0 | |||
Foreign Exchange Contract [Member] | Net Sales [Member] | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] | |||||||
Accumulated Other Comprehensive Income (Loss) [Roll Forward] | |||||||
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax | 2 | (3) | (8) | (11) | |||
Foreign Exchange Contract [Member] | Cost of Sales [Member] | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] | |||||||
Accumulated Other Comprehensive Income (Loss) [Roll Forward] | |||||||
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax | (3) | (6) | (5) | (19) | |||
Commodity Contract [Member] | Cost of Sales [Member] | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] | |||||||
Accumulated Other Comprehensive Income (Loss) [Roll Forward] | |||||||
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax | 2 | 34 | 17 | 106 | |||
Interest Rate Contracts [Member] | Other Expense [Member] | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] | |||||||
Accumulated Other Comprehensive Income (Loss) [Roll Forward] | |||||||
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax | 0 | 0 | 37 | 0 | |||
Interest Rate Contracts [Member] | Interest Expense [Member] | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] | |||||||
Accumulated Other Comprehensive Income (Loss) [Roll Forward] | |||||||
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax | 3 | 3 | 11 | 11 | |||
Inventory [Member] | Pension Plan, Defined Benefit [Member] | |||||||
Accumulated Other Comprehensive Income (Loss) [Roll Forward] | |||||||
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax | [1] | 5 | 4 | 15 | 12 | ||
Sale of Securities [Member] | Other Operating Income (Expense) [Member] | Available-for-sale Securities [Member] | |||||||
Accumulated Other Comprehensive Income (Loss) [Roll Forward] | |||||||
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax | $ 0 | $ 0 | $ 2 | $ 0 | |||
|
EARNINGS PER SHARE (Details) - shares shares in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
May 31, 2017 |
May 31, 2016 |
May 31, 2017 |
May 31, 2016 |
|
Earnings Per Share [Abstract] | ||||
Weighted-Average Number of Common Shares | 439.1 | 437.1 | 438.6 | 444.2 |
Dilutive Potential Common Shares | 4.3 | 3.2 | 4.4 | 4.0 |
Antidilutive Potential Common Shares | 0.3 | 5.3 | 2.1 | 4.9 |
Shares Excluded From Computation of Dilutive Potential Shares with Exercise Prices Greater than the Average Market Price of Common Shares for the Period | 0.3 | 3.2 | 1.7 | 3.2 |
SUPPLEMENTAL CASH FLOW INFORMATION (Details) - USD ($) $ in Millions |
9 Months Ended | |
---|---|---|
May 31, 2017 |
May 31, 2016 |
|
Supplemental Cash Flow Information [Abstract] | ||
Capital Expenditures Incurred but Not yet Paid | $ 136 | $ 84 |
Interest | 287 | 256 |
Taxes | $ 475 | $ 704 |
COMMITMENTS AND CONTINGENCIES ENVIRONMENTAL AND LITIGATION (Details) $ in Millions |
1 Months Ended | 5 Months Ended | 9 Months Ended | ||||
---|---|---|---|---|---|---|---|
Dec. 31, 2016
USD ($)
|
Nov. 30, 2016
USD ($)
|
Sep. 30, 2016
USD ($)
|
Jun. 30, 2017
USD ($)
|
May 31, 2017
USD ($)
plaintiff
|
May 31, 2016
plaintiff
|
Aug. 31, 2016
USD ($)
|
|
Accrual For Environmental And Litigation Loss Contingencies [Abstract] | |||||||
Accrual For Environmental And Litigation Loss Contingencies | $ 266 | $ 545 | |||||
Pending Litigation [Member] | Personal Injury Lawsuits [Member] | State Courts in St Louis, Missouri and Los Angeles, California [Member] | |||||||
Accrual For Environmental And Litigation Loss Contingencies [Abstract] | |||||||
Loss Contingency, Number of cases | plaintiff | 30 | ||||||
Loss Contingency, Number of Plaintiffs | plaintiff | 750 | ||||||
Pending Litigation [Member] | Personal Injury Lawsuits [Member] | Various State And Federal Courts [Member] | |||||||
Accrual For Environmental And Litigation Loss Contingencies [Abstract] | |||||||
Loss Contingency, Number of Plaintiffs | plaintiff | 1,400 | ||||||
Settled Litigation [Member] | Personal Injury Lawsuits [Member] | State Courts in St Louis, Missouri and Los Angeles, California [Member] | |||||||
Accrual For Environmental And Litigation Loss Contingencies [Abstract] | |||||||
Loss Contingency, Loss in Period | $ 250 | $ 4 | |||||
Settled Litigation [Member] | Personal Injury Lawsuits [Member] | Maximum [Member] | State Courts in St Louis, Missouri and Los Angeles, California [Member] | |||||||
Accrual For Environmental And Litigation Loss Contingencies [Abstract] | |||||||
Settlement received (paid) | $ (280) | ||||||
Settled Litigation [Member] | Personal Injury Lawsuits [Member] | Other Current Liabilities [Member] | State Courts in St Louis, Missouri and Los Angeles, California [Member] | |||||||
Accrual For Environmental And Litigation Loss Contingencies [Abstract] | |||||||
Accrual | $ 280 | ||||||
Loss Contingency, Loss in Period | $ 25 |
COMMITMENTS AND CONTINGENCIES OFF-BALANCE SHEET ARRANGEMENTS (Details) $ in Millions |
Dec. 31, 2013
USD ($)
|
---|---|
Bond [Member] | |
Off Balance Sheet Arrangement [Line Items] | |
Fair Value Disclosure, Off-balance Sheet Risks, Face Amount, Asset | $ 470 |
SEGMENT AND GEOGRAPHIC DATA (Details) $ in Millions |
3 Months Ended | 9 Months Ended | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 31, 2017
USD ($)
|
May 31, 2016
USD ($)
|
May 31, 2017
USD ($)
segment
|
May 31, 2016
USD ($)
|
|||||||||||||||
Segment Reporting Information [Line Items] | ||||||||||||||||||
Number of Reportable Segments | segment | 2 | |||||||||||||||||
Income from operations of discontinued business | $ 0 | $ 0 | $ 21 | $ 24 | ||||||||||||||
Net Sales | [1] | 4,230 | 4,189 | 11,954 | 10,940 | |||||||||||||
Gross Profit | 2,386 | 2,380 | 6,597 | 5,879 | ||||||||||||||
EBIT | [2],[3],[4] | 1,155 | 1,281 | 3,325 | 2,511 | |||||||||||||
Depreciation and Amortization Expense | 177 | 178 | 549 | 542 | ||||||||||||||
Net loss attributable to noncontrolling interest | 4 | (2) | 8 | (9) | ||||||||||||||
Reconciliation of EBIT to Net Income [Abstract] | ||||||||||||||||||
EBIT | [2],[3],[4] | 1,155 | 1,281 | 3,325 | 2,511 | |||||||||||||
Interest Expense — Net | 83 | 86 | 285 | 281 | ||||||||||||||
Income Tax Provision | [5] | 229 | 478 | 800 | 703 | |||||||||||||
Net Income Attributable to Monsanto Company | 843 | 717 | 2,240 | 1,527 | ||||||||||||||
Corn seed and traits [Member] | ||||||||||||||||||
Segment Reporting Information [Line Items] | ||||||||||||||||||
Net Sales | 1,491 | [1] | 1,592 | [1] | 5,342 | 5,024 | ||||||||||||
Gross Profit | 922 | 976 | 3,389 | 3,063 | ||||||||||||||
Soybean seed and traits [Member] | ||||||||||||||||||
Segment Reporting Information [Line Items] | ||||||||||||||||||
Net Sales | 896 | [1] | 693 | [1] | 2,358 | 1,913 | ||||||||||||
Gross Profit | 588 | 391 | 1,667 | 1,220 | ||||||||||||||
Cotton seed and traits [Member] | ||||||||||||||||||
Segment Reporting Information [Line Items] | ||||||||||||||||||
Net Sales | 338 | [1] | 285 | [1] | 562 | 370 | ||||||||||||
Gross Profit | 268 | 205 | 418 | 248 | ||||||||||||||
Vegetable seeds [Member] | ||||||||||||||||||
Segment Reporting Information [Line Items] | ||||||||||||||||||
Net Sales | 199 | [1] | 196 | [1] | 523 | 526 | ||||||||||||
Gross Profit | 99 | 108 | 267 | 244 | ||||||||||||||
All other crops seeds and traits [Member] | ||||||||||||||||||
Segment Reporting Information [Line Items] | ||||||||||||||||||
Net Sales | 208 | [1] | 441 | [1] | 381 | 590 | ||||||||||||
Gross Profit | 138 | 369 | 191 | 430 | ||||||||||||||
Total Seeds and Genomics [Member] | ||||||||||||||||||
Segment Reporting Information [Line Items] | ||||||||||||||||||
Net Sales | 3,132 | [1] | 3,207 | [1] | 9,166 | 8,423 | ||||||||||||
Gross Profit | 2,015 | 2,049 | 5,932 | 5,205 | ||||||||||||||
EBIT | 995 | [2],[3] | 1,094 | [2],[3] | 3,033 | 2,258 | ||||||||||||
Depreciation and Amortization Expense | 137 | 144 | 422 | 444 | ||||||||||||||
Net loss attributable to noncontrolling interest | 5 | 2 | 11 | 10 | ||||||||||||||
Reconciliation of EBIT to Net Income [Abstract] | ||||||||||||||||||
EBIT | 995 | [2],[3] | 1,094 | [2],[3] | 3,033 | 2,258 | ||||||||||||
Agricultural Productivity [Member] | ||||||||||||||||||
Segment Reporting Information [Line Items] | ||||||||||||||||||
Net Sales | 1,098 | [1] | 982 | [1] | 2,788 | 2,517 | ||||||||||||
Gross Profit | 371 | 331 | 665 | 674 | ||||||||||||||
Net loss attributable to noncontrolling interest | 1 | 1 | 1 | |||||||||||||||
Total Agricultural Productivity [Member] | ||||||||||||||||||
Segment Reporting Information [Line Items] | ||||||||||||||||||
Income from operations of discontinued business | 21 | 24 | ||||||||||||||||
Net Sales | 1,098 | [1] | 982 | [1] | 2,788 | 2,517 | ||||||||||||
Gross Profit | 371 | 331 | 665 | 674 | ||||||||||||||
EBIT | 160 | [2],[3] | 187 | [2],[3] | 292 | 253 | [2],[3] | |||||||||||
Depreciation and Amortization Expense | 40 | 34 | 127 | 98 | ||||||||||||||
Net loss attributable to noncontrolling interest | 1 | |||||||||||||||||
Reconciliation of EBIT to Net Income [Abstract] | ||||||||||||||||||
EBIT | $ 160 | [2],[3] | $ 187 | [2],[3] | $ 292 | $ 253 | [2],[3] | |||||||||||
|
SUBSEQUENT EVENTS (Details) - USD ($) $ / shares in Units, $ in Millions |
3 Months Ended | 9 Months Ended | 12 Months Ended | |||
---|---|---|---|---|---|---|
Jun. 06, 2017 |
May 31, 2017 |
May 31, 2016 |
May 31, 2017 |
May 31, 2016 |
Aug. 31, 2016 |
|
Subsequent Event [Line Items] | ||||||
Dividends Declared per Share | $ 0 | $ 0 | $ 1.08 | $ 1.08 | $ 2.16 | |
Gain on disposal | $ 88 | $ 31 | ||||
Subsequent Event [Member] | ||||||
Subsequent Event [Line Items] | ||||||
Dividends Declared per Share | $ 0.54 |
INCOME TAXES (Details) - USD ($) $ in Millions |
9 Months Ended | |
---|---|---|
May 31, 2017 |
May 31, 2016 |
|
Income Tax Disclosure [Abstract] | ||
Discrete tax expense | $ 50 | $ 146 |
Q?RU
M@+^9S 23Z.9C=J)J&:0BE9B65]L1E6]>QYV;=O9JK!-G&:'"G-T,5)7GF7
M@;WE\4W^A$_3_E781G:.G(W'EXW]KXWQ@%)V5SA"+7ZPQ5!0^W#\C&<[C=ED
M>-///X@MW[CX#5!+ P04 " !'=MU*.A.2S+,! #4 P &0 'AL+W=O
M
>9>!?>3I37Z'3]/^6;A6&D\N
M-N#+IOXWU@9 *;L;'*$./]AB*&A"/-[CV4UC-AG!]O,/8LLW+G\!4$L#!!0
M ( $=VW4J&",7=M $ -(# 9 >&PO=V]R:W-H965T
]$>.+MGOO>%,$96Q'OO'CKO>><7VY3=@Y$4\QAC.&+F+<(YMGG
M%'PMQ8'_ ^?K\&1581+AR3N%_R'8K1+L(L'NTQ+78I(/2=BBIPI,':?)D@)[
M'2=YX9T']H;'-WD+'Z?]AS!UJRTYH?,O&_M?(3KP4C87?H0:_\%F0T+EPO'*
MG\TX9J/AL)M^$)N_&PO=V]R:W-H965TYDRIS>3&\'^"DD+X(P=3O(W Y%7B'WQ,O?=L9ER!E/K(6OH'Y
M/IZ4C:.*2XT
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MV